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1. INTRODUCTION 
1.1. The blood-brain barrier: overview and culture models 
The microvessels of the brain differ fundamentally from peripheral vasculature. In 
humans, the estimated total length of cerebral capillaries is about 650 km and the total surface 
area is between 12 and 18 m2 (Nag and Begley, 2005). The microvessels together with neurons 
and glial cells form the neurovascular unit, which is involved in cerebral activity dependent 
regulation of the cerebral blood flow, cerebral angiogenesis, neurogenesis, development and 
maintenance of brain homeostasis (Neuwelt et al., 2011). Brain capillaries constitute the blood-
brain barrier (BBB) as a functional unit. (Pardridge, 2002; Cecchelli et al., 2007).  
Cerebral endothelial cells were identified as the anatomical basis of the BBB (Abbott et 
al., 2006). They have a dynamic interaction with the other neighboring cells, such as astroglia, 
pericytes, perivascular microglia, and neurons (Fig. 1). The cross-talk between these cells induces 
a unique phenotype in endothelial cells including (i) a morphological barrier based on 
interendothelial junctions that markedly limit paracellular permeability, (ii) a unique pattern of 
receptors, transporters and drug efflux pumps, and (iii) enzymatic and metabolic barriers (Abbott 
et al., 2010).  
 
Figure 1. Drawing on the structure of the neurovascular unit. Brain endothelial cells and the tight junctions (TJ) 
between them constitute the anatomical basis of the blood-brain barrier (Tóth et al., 2011, Annex II.) 
 
The three major functions of the BBB are the creation and maintenance of ionic 
homeostasis for neuronal functions, supply of the central nervous system (CNS) with nutrients, 
and protection from toxic insults (Abbott et al., 2006). The tightness of the paracellular barrier, 
regulated by tight junctions (TJs) and adherens junctions (AJs), is a fundamental property of BBB 
(Zlokovic, 2008). TJs prevents hydrophilic molecules and even ions and water to enter freely the 
CNS. They are multiprotein complexes situated in lipid rafts and composed of integral proteins 
that associate with cytoplasmic linker proteins. Integral membrane proteins, such as occludin and 
claudins mediate cell-cell adhesion. Among the claudins, the endothelial cell-specific claudin-5 is 
expressed at the highest level at the BBB (Abbott et al., 2010). Linkers, like zonula occludens 
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proteins (ZO-1, -2, -3) and β-catenin, connect integral membrane junctional proteins to the 
cytoskeleton. ZOs interact with occludins, claudins and junctional adhesion molecules and also 
participate in cell signaling (Krizbai and Deli, 2003). In AJs the cytoplasmic tail of vascular 
endothelial cadherin (VE-cadherin) is attached to the actin cytoskeleton by β-catenin. Besides its 
role as a cytoskeletal linker, β-catenin is an important signaling and transcriptional factor at the 
BBB regulating its tightness (Liebner and Plate, 2010). Absence of fenestration and low number 
of pinocytotic vesicles are also important elements of the physiological barrier (Abbott et al., 
2010). The resistance of brain parenchymal microvessels reflecting paracellular tightness in vivo 
exceeds 1000 Ω×cm2 (Butt et al., 1990). The polarized expression of transporters, receptors and 
enzymes at either the luminal or abluminal cell surface is a crucial aspect of the BBB. Saturable, 
bidirectional transport systems exist for nutrients, vitamins and minerals at the BBB (Abbott et 
al., 2010; Deli, 2011). About 40 members of the solute carrier (SLC) transporter family were 
identified in brain microvessels (Enerson et al., 2006). The most important SLC carriers supply 
the CNS with glucose, ketons or amino acids, like glucose transporter 1, monocarboxylic acid 
transporter 1, large neutral amino acid transporter 1. Efflux pumps protect the brain from 
xenobiotics, but they are also responsible for restricting the penetration of many therapeutic 
molecules to brain. The primary efflux pumps at the BBB, P-glycoprotein (P-gp) and breast 
cancer resistance protein belong to the ATP-binding cassette  transporter family (Terasaki and 
Ohtsuki, 2005). The elements of the metabolic barrier include alkaline phosphatase, γ-glutamyl 
transpeptidase, monoamine oxidases or cytochrome P450 enzymes (Deli, 2011). 
Cell culture-based models proved to be one of the most versatile tools in basic BBB 
research and also in testing CNS drug penetration (Annex II.). All models should show some 
elements of general endothelial and specific BBB properties (Veszelka et al., 2011). Adjacent 
cells should possess endothelial morphology, like growing in monolayer and having TJs between 
overlapping plasma membranes. One of the most direct methods to determine the tightness of a 
model is the measurement of transendothelial electrical resistance (TEER) (Deli et al., 2005) An 
in vitro BBB models should reach a tightness of at least 150-200 Ω×cm2 to study the 
permeability or transport of molecules (Table 1). Another way to assess the integrity of the 
paracellular barrier is the measurement of passive flux of small hydrophilic tracers across 
monolayers. The endothelial or apparent permeability coefficients (Pe or Papp) are important 
parameters of the quality of BBB models (Gaillard and Boer, 2000). Furthermore, an ideal in 
vitro model should not only show BBB characteristics, it also needs to be simple to use, 
reproducible, cost-effective and applicable for medium or high throughput screening. 
Unfortunately, none of the available model fulfills all the above mentioned criteria, but models 
expressing the most critical features of the BBB can provide valuable information on BBB 
permeability and be useful tools in CNS drug discovery (Annex II.). 
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BBB model name Cell types BBB quality parameters Pat. 
Monolayers 
Immortalized brain 
endothelial line 
Immortalized bovine brain endothelial cell 
    line (TBMEC) Pe sucrose: 26x10
-6 cm/s 1 
BBB model tightened by 
Wnt/β-catenin signaling 
Mouse primary or immortalized endothelial  
    cells (H5V) ND 2 
Human BBB model Immortalized human brain endothelial cell      line (hCMEC/D3) 
TEER: 40 Ωxcm2 
Pe sucrose: 27.6x10-6 cm/s 
Pe fluorescein: 6x10-6 cm/s 
3 
Co-culture: 2 cell types 
BBB model tightened by 
cAMP signaling 
 Primary endothelial cells  
 Primary brain astrocytes TEER > 200 Ωxcm
2 4 
Co-culture of 
conditionally immortalized 
cell lines (TR-BBB) 
Temperature sensitive immortalized rat   
   brain endothelial cell line 
Temperature sensitive immortalized rat   
   astrocyte cell line  
TEER: 106 Ωxcm2 5 
Dynamic BBB model Endothelial cells  Astrocytes ND 6 
Multicellular BBB model 
Primary brain or embryonic stem cell  
   derived endothelial cells  
Neuronal progenitor cells 
TEER: 100-250 Ωxcm2 7 
Co-culture: 3 cell types 
Triple co-culture, 
mimicking the anatomical 
structure of the BBB 
Primary brain endothelial cells 
Primary brain astrocytes 
Primary brain pericytes 
TEER: 350-600 Ωxcm2 
Pe sucrose: 1.1x10-6 cm/s 
Pe fluorescein: 2.5x10-6 cm/s 
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Table 1. Patented in vitro BBB models and their parameters. Abbreviations: ND, no data; TEER, transendothelial 
electrical resistance; Pe, endothelial permeability coefficient; Pat., patent number (see at the end of Reference 
section). Table is modified from Tóth et al., 2011 (Annex II.) 
 
1.2. The blood-brain barrier under pathological conditions 
The morphology and functions of BBB are changed under pathological conditions, like 
neurodegenerative diseases, stroke, epilepsy, brain tumors, traumatic injuries of the central 
nervous system, brain infection, sepsis and metabolic disease (Deli, 2005; Zlokovic, 2008; 
Neuwelt et al., 2011). Alterations at the BBB in diseases include downregulation of TJ proteins, 
upregulation of vesicular transport in brain endothelium and decrease in nutrient transport. 
Pharmacoresistance due to upregulation of efflux pumps at the neurovascular unit in epilepsy and 
brain tumors makes clinical treatment very difficult (Neuwelt et al., 2011). Disturbances of CNS 
homeostasis as a result of barrier deficiencies could contribute to secondary neuronal loss and 
exacerbate the neuropathology (Deli, 2005; Zlokovic, 2008; Neuwelt et al., 2011). 
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1.2.1. The blood-brain barrier in Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common type of dementia which affects 36 million 
individuals worldwide (http://www.alz.co.uk/research/world-report). AD presents with symptoms 
of memory loss and cognitive impairment late in life. Because of the growing aged population 
future AD prevalence is expected to increase to an extent that it may threaten the sustainability of 
healthcare systems worldwide (Erickson and Banks, 2013). This necessitates to better understand 
AD, with the goal of identifying biomarkers for early diagnostic tests and developing treatments 
that can prevent or slow AD progression (Olah et al., 2012). As AD is a multifactorial disease 
there are several mechnisms to explain the cause and the development of the disease (Carreiras et 
al., 2013), like amyloid cascade and cholinergic (Pákáski and Kálmán, 2008), tau (Medina and 
Avila, 2014) oxidative stress (Padurariu et al., 2013), and neurovascular (Zlokovic, 2005) 
hypotheses. 
Recent clinical data indicate that vascular changes play an important role early in AD 
pathogenesis. Cerebral blood flow and cerebral glucose uptake reductions were demonstrated in the 
early stages of AD and both low cerebral blood flow and reduced brain glucose uptake may precede 
neurodegeneration and contribute to the progression of dementia prior to cerebral atrophy (Bell and 
Zlokovic, 2009). Positive links and overlap exist between cerebrovascular disorders and AD. Severe 
atherosclerosis increases threefold the risk of developing AD or vascular dementia (van Oijen et al., 
2007).  
Pathological amyloid-β (Aβ) fibrils are deposited both in brain parenchyma and around brain 
vessels in AD (Grammas et al., 2002; Bell and Zlokovic, 2009). The major component of deposits 
are Aβ peptides, cleaved from amyloid precursor protein by secretases (Forman et al., 2004). Aβ 
peptides can form soluble monomers, dimers, oligomers, protofibrils and insoluble fibrils (DeMager 
et al., 2002). The cerebrovascular amyloidosis or cerebral amyloid angiopathy is a hallmark of the 
disease, it is present in more than 80 % of AD patients and causally involved in the development of 
neurodegeneration in Alzheimer’s disease (Grammas et al., 2002; Bell and Zlokovic, 2009). 
Accumulation of Aβ in the wall of cerebral blood vessels and in the brain parenchyma in AD is due 
to imbalance between its production and clearance from the brain (Bell and Zlokovic, 2009). Several 
transporters were identified to participate in the transport of Aβ across the BBB, including receptor 
for advanced glycation end products (RAGE) (Deane et al., 2003; Giri et al., 200), low-density 
lipoprotein receptor related protein 1 (Shibata et al., 2000; Deane et al., 2004) and 2 (Calero et al., 
1999), P-glycoprotein (P-gp) (Cirrito et al., 2005), breast cancer resistance protein (Zlokovic, 2008) 
and multidrug resistance protein-1 (Pahnke et al., 2014) 
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Figure 2. A model of microvascular damage in Alzheimer’s disease. Abbreviations: ROS, reactive oxygen species; 
NFT, neurofibrillary tangles; ISF, interstitial fluid; p-tau, hyperphosphorylated tau (Zlokovic, 2011) 
 
Morphological abnormalities in the cerebral microvasculature in AD were also demonstrated 
during the disease progression in AD (Kalaria and Hedera, 1995). Small pial and intracerebral 
arteries with amyloid deposits develop a hypercontractile phenotype and cause dysregulated cerebral 
blood flow. With time pathological alterations in the vessel wall lead to muscle layer atrophy and 
rupture of the vessels resulting in microbleeds. Amyloid angiopathy can be observed parallelly with 
the appearance of cognitive decline (Zlokovic, 2011). At the level of capillaries due to faulty Aβ 
clearance Aβ oligomers accumulate in the interstitial fluid (Fig. 2). Microhaemorrhages occur and 
blood-derived molecules like thrombin, fibrin, albumin exert toxic effects on neurons. In a later 
phase microvascular degeneration leads to increased deposition of basement membrane proteins and 
perivascular amyloid formation, which obstruct capillary blood flow (Zlokovic, 2011). 
Hypoperfusion increases the dysfunction of efflux pumps and the accumulation of metabolic waste 
products, alters pH and electrolyte composition and all these changes aggravate neuronal 
dysfunction. Ischaemic injury, rising Aβ levels, neuroinflammation induced by activated microglia 
and astrocytes contribute to neuronal damage and accumulation of neurofibrillary tangles. The 
morphological changes are accompanied by functional alterations (Zlokovic, 2011). Enhancing Aβ 
clearance across the BBB, as well as protection of the BBB from injury are among the proposed new 
strategies for the therapy of AD (Zlokovic et al., 2000). 
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1.2.2. The blood-brain barrier and methylglyoxal 
Methylglyoxal (2-oxopropanal) is a highly reactive α-oxoaldehyde (Fig. 3A) with strong 
oxidant and glycation properties (Turk, 2010). Methylglyoxal is an endogenous metabolite, 
which is formed by elimination of phosphate from glyceraldehyde 3-phosphate and 
dihydroxyacetone phosphate, or by the oxidation of hydroxyacetone and aminoacetone (Sousa 
Silva et al., 2013). As it is a highly reactive molecule, its immediate elimination by detoxification 
systems is crucial. Methylglyoxal is oxidized by the glyoxalase pathway to D-lactate, and 
metabolized reductively to acetol (Német et al., 2006). Accumulated methylglyoxal triggers 
carbonyl stress by reacting with proteins, DNA and other biomolecules (Stitt et al., 2002), and the 
end products of these reactions are insoluble protease-resistant polymers, advanced glycated end 
products (AGE) (Lo et al., 1994). The cellular effects of methylglyoxal include inhibition of 
enzyme activity (Murata-Kamiya et al. 2001), transcriptional activation of genes (Yao et al., 
2006) and apoptosis (Thornalley et al., 1996). Methylglyoxal causes complications in several 
conditions and diseases, like diabetes mellitus (Lapolla et al., 2003; Vander Jagt et al. 2003), 
cardiovascular diseases (Uchida 2000; Rabbani et al., 2011), metabolic syndrome (Liu et al. 
2011), obesity (Matafome et al. 2013), aging (Beeri et al., 2011; Srikanth et al., 2013) dementias 
(Dukic-Stefanovic et al., 2001) and other neurodegenerative diseases, like AD (Münch et al., 
2012).  
 
    
 
Figure 3. Formation and detoxification of methylglyoxal (MG) (A; Sousa Silva et al., 2013). Role of MG and MG-
derived advanced glycated endptoducts (AGEs) in Alzheimers disease (B; Angeloni et al., 2014). Abbreviations: 
APP, amyloid-β protein precursor; ERK, extracellular-signal-regulated kinases; GSH, glutathione; GSK, glycogen 
synthase kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen activated protein kinase; NADPH, nicotinamide 
adenine dinucleotide phosphate; NFTs, neurofibrillary tangles; PP, protein phosphatase.  
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For the pathological alterations in AD not just Aβ but other factors are also responsible, 
including methylglyoxal. The polymerization of Aβ is enhanced by this reactive ketoaldehyde 
which level is doubled in the liquor of AD patients (Kuhla et al., 2005). Methylglyoxal reacts 
with the amino groups of Aβ peptide. Glycation destroys irreversibly the structure of the protein 
and induces Aβ aggregation (Fig. 3B). The byproducts of this reaction are AGE and their 
accumulation leads to enhanced production of amyloid precursor protein (Ko et al., 2010), further 
protein deposits and amyloidosis (Münch et al., 1999). Methylglyoxal have serious impact on 
neurons, too. It triggers the formation neurofibrillary tangles (Ledesma et al., 1994) and 
contribute to the production of harmful agents like reactive oxygen species (ROS) and nitrogen 
monoxide (Loske et al., 1998). In cerebral endothelial cells Aβ and AGE has a common influx 
receptor, RAGE. This receptor is responsible for the regulation of Aβ and AGE level among 
brain, blood and liquor (Srikanth et al., 2011). The expression level of RAGE is low in healthy 
brain, but is increased in AD (Miller et al., 2008). 
Carbonyl stress induced by high level of methylglyoxal is responsible for the diabetes 
related vascular complications (Mukohda et al., 2012), which can partly explain the higher 
incidence of stroke, dementia and Alzheimer’s disease in diabetes mellitus (Whitmer, 2007; 
Bruno et al., 2010). Therefore, considerable attention has been paid to the effects of MG on 
cerebral blood vessels recently. Methylglyoxal activates a series of inflammatory responses 
leading to accelerated vascular endothelial damage (Yamawaki et al., 2008; Okouchi et al., 2009; 
Sena et al., 2012). In human brain endothelial cells, methylglyoxal induced mitochondrial 
apoptotic signaling: decreased mitochondrial membrane potential, activated caspases and 
perturbed the cellular glutathione redox status (Okouchi et al., 2009), In another study, 
methylglyoxal caused barrier dysfunction. It glycated the TJ protein, occludin and disturbed the 
architectural organization of ZO-1 in cultured endothelial cells, and in brain microvessels of 
diabetic rats (Li et al., 2013b). These findings indicate that methylglyoxal-induced carbonyl and 
oxidative stress may play an important role in neurovascular pathology, and brain endothelium 
can be an early and significant target site of methylglyoxal.  
 
1.3. The blood-brain barrier as a therapeutical target 
The BBB is indispensable for creating and maintaining the homeostasis of the CNS, and 
even minor functional changes at the BBB without morphological alterations can lead to severe 
and lasting neurological dysfunction (Deli, 2005; Zlokovic, 2008). Therefore, the BBB is 
increasingly considered as a target of new therapeutical approaches in neurodegenerative 
disorders (Vangilder et al., 2011). There are several groups of potentially protective molecules 
acting on brain endothelial cells, including anti-inflammatory drugs, lipids, natural compounds, 
and neuropeptides (Heneka et al., 2011; Ishrat et al., 2012; Pintér et al., 2014). For brain 
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endothelial protection experiments only a limited number of anti-inflammatory molecules were 
selected with proved efficacy on other cell types and in clinical studies. From the three different 
compounds tested, pentosan polysulfate and edaravone are already used in clinical therapy for 
other indications, while docosahexaenoic acid is widely used as a dietary supplement.  
 
1.3.1. Pentosan polysulfate 
Pentosan polysulfate (PPS) is a semisynthetic polysaccharide obtained from beech tree 
(Fagus silvatica) shavings. It is a highly sulphated polyanion (average mw: 3-6 kDa) structurally 
related to the mammalian glycosaminoglycans (Fig. 4A). The high sulfation rate and charge 
density enables PPS to compete more effectively than other polyanions, i.e. heparin, with 
endogenous glycosaminoglycans (Ghosh, 1999). Glycosaminoglycans are important regulators in 
many biologically diverse processes, therefore PPS has also diverse molecular activities 
(Maffrand et al., 1991; Ghosh, 1999). PPS can inhibit protein kinase A and C, tyrosine protein 
kinases, serine proteases, matrix metalloproteinases, lysosomal enzymes, coagulation factors, 
complement factors, cytokines. It stimulates the release of tissue-type plasminogen activator, 
superoxide dismutase, and lipase in different cells and tissues (Ghosh, 1999). In clinical practice 
pentosan was used as an anti-coagulant (Maffrand et al., 1991) and as a treatment for inflamed 
varicose veins and for interstitial cystitis (Nordling, 2004). The FDA approved the drug under the 
brand name Elmiron (http://www.rxlist.com). In Hungary it is sold in form of tablets, injection 
and gel named SP 54 (Fig. 4B; http://www.pharmindex-online.hu). PPS is also used in the 
prevention and therapy of human prion diseases, which belong to the family of protein 
conformational diseases, similarly to AD (Panegyres and Armari, 2013). 
 
 
Figure 4. The structure of pentosan polysulfate (A). Form of the drug SP 54 (B).  
 
PPS can favorably regulate BBB phenotype (Deli et al., 2000), and protect against 
lipopolysaccharide-induced toxicity in brain endothelial cells (Veszelka et al., 2007). Damage 
induced by prion peptide treatment in brain endothelial cells was also attenuated by PPS (Deli et 
A B 
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al., 2000b). Importantly, prion peptide forms insoluble aggregates and plays a central role in 
prion diseases, similarly to Aβ in AD. PPS can inhibit the binding of endogenous 
glycosaminoglycans to Aβ and this effect was suggested as a potentially effective therapeutical 
approach to prevent or slow amyloidogenesis in AD (Leveugle et al., 1994). However, pentosan 
was not tested on brain endothelial cells treated with Aβ peptides. 
 
1.3.2. Docosahexaenoic acid 
Docosahexaenoic acid (DHA) is the end product of long-chain polyunsaturated ω-3 fatty 
acids (n-3 PUFAs) synthesis (Fig. 5A). It is an essential fatty acid, because the human body 
synthesizes it only in a small amount (Voss et al., 2011). The majority of DHA comes from 
nutrition. The richest sources of DHA are marine fishes and algae. Commercially available DHA 
nutritional supplements (Fig. 5B) are produced by microalgae such as Crypthecodinium cohnii 
and Schizochytrium species (Rapoport et al., 2007; Innis, 2007). 
DHA is vital for brain maturation and plays a primary role in neurotransmission as an 
important membrane component of neurons. It protects developing cholinergic neurons against 
glutamate cytotoxicity (Hőgyes et al., 2003). DHA has a hypotriglyceridemic and anti-
inflammatory effects. Classically, n-3 PUFAs antagonize n-6 PUFA arachidonic acid-induced 
proinflammatory prostaglandin E formation (De Caterina et al., 2000). Another well-known 
mechanism by which n-3 PUFAs exert their anti-inflammatory effects is via reduction of nuclear 
factor-κB activation. This transcription factor is a potent inducer of pro-inflammatory cytokine, 
e.g. interleukin-6 and tumor necrosis factor-α, production (Siriwardhana et al., 2012a). DHA can 
also inhibit the attachment of monocytes to endothelium (De Caterina et al., 2000). The anti-
apoptotic effect of DHA is mediated through the upregulation of Bcl-2 genes or inhibition of their 
phosphorylation (Marszalek et al., 2005).  
 
 
Figure 5. The structure of docosahexaenoic acid (A) and a nutritional supplement containing this fatty acid (B).  
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The dietary intake of DHA is beneficial in cardiovascular diseases, metabolic disorders, 
cancer, depression, arthritis, pregnancy and aging (Siriwardhana et al., 2012b). Epidemiological 
observations suggest that high unsaturated fatty acid intake is associated with decreased risk of 
dementia (Lopez et al., 2011). The absence of DHA could lead to reduced neuronal survival 
(McNamara et al., 2007), and cell death accompanied with declining cognitive functions (Serhan 
et al., 2004). The level of DHA is reduced in AD patients (Tully et al., 2003) and in AD post-
mortem brains (Söderberg et al., 1991) compared with age-matched healthy controls. DHA 
reduces amyloid-β 1-42 (Aβ42) peptide production in animal models of AD (Lim et al., 2005; 
Oksman et al., 2006) and chronic DHA treatment improves cognition in a transgenic mouse 
model of AD (Arsenault et al., 2011). DHA inhibits aggregation of amyloid and tau proteins 
(Lim et al., 2005; Hashimoto et al., 2005). Although, clinical studies found only minor effect of 
DHA on the improvement of cognitive functions in the very early stage of AD (Freund-Levi et 
al., 2006; Quinn et al., 2010). 
Based on these data DHA can be potentially important in the prevention of AD, however 
there are no data on its effect on the cells of the neurovascular unit, except neurons (Grimm et al., 
2011). Therefore our aim was to test the effect of DHA not only on neurons, but also on other 
important elements of the neurovascular unit, such as brain endothelial cells.  
 
1.3.3. Edaravone 
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, MCI-186) is a neuroprotective free 
radical scavenger (Fig. 6A). It is the active substance of the Japanese medicine Radicut (Fig. 6B), 
which helps neurological recovery following acute cerebral ischemia and subsequent cerebral 
infarct (Watanabe et al., 1994).  
 
 
 
Figure 6. The structure of edaravone (A) and an edaravone containing drug to treat ischemic stroke (B).  
A 
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The free radical scavenger edaravone exerts anti-oxidant effects by inhibiting hydroxyl 
radical-dependent and independent lipid peroxidation (Watanabe et al., 2004). Edaravone also 
suppresses increased hydroxyl and superoxide anion radical levels in models of ischemia-
reperfusion (Okatani et al., 2003). In addition to its free radical scavenging property, edaravone 
showed anti-apoptotic, anti-necrotic and anti-cytokine effects in animal models of various 
diseases (Kikuchi et al., 2012). To further reveal the mechanism of protection, brain microvessels 
(Yamashita et al., 2009) and the blood-brain barrier (Lukic-Panin et al., 2010) were investigated 
as potential pharmaceutical targets of edaravone in animal models of stroke. The effect of 
edaravone alone has been described on barrier function; it promoted tight junction formation via 
activation of sphingosin-1-phospate signaling pathway (Omori et al., 2007) and down-regulation 
of interleukin-1β induced monocyte chemoattractant protein-1 secretion (Onodera et al., 2013). 
In a recent study, edaravone pre-treatment protected human microvascular endothelial 
cells from methylglyoxal-induced injury by inhibiting AGEs/RAGE/oxidative stress (Li et al., 
2013b). However, it remained unanswered whether edaravone can also protect against 
methylglyoxal-induced barrier dysfunction of brain endothelial monolayers.  
 
1.4. Aims  
The role of the BBB to protect the brain in physiological and pathological conditions is 
increasingly emphasized. Protective strategies at the level of BBB are in the focus of new studies. 
We have selected Aβ42 and methylglyoxal, two major pathological factors in AD causing BBB 
dysfunction, to study potential protective molecules using in vitro BBB models. Three 
compounds were used in our studies based on previous results from our group and literature data.  
 
Therefore the main aims of our studies were the following:  
 
1. to examine the effects of Aβ42 on morphology and barrier properties using rat co-
culture based in vitro BBB models and to reveal the underlying mechanisms 
 
2. to test the protective action of PPS on Aβ42-induced changes on a BBB model 
 
3. to reveal the protective action of DHA on Aβ42-induced changes in brain 
endothelial cells 
 
4. to study the effects of methylglyoxal on barrier properties of human brain 
endothelial monolayers  
 
5. to evaluate the barrier protective effects of edaravone on methylglyoxal-induced 
changes 
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2. MATERIALS AND METHODS 
2.1. Materials 
All reagents were purchased from Sigma-Aldrich Ltd., Hungary, unless otherwise 
indicated. 
Aβ and scrambled peptides were synthesized at the Department of Medical Chemistry, 
University of Szeged. The synthesis of Aβ42 (mw: 4514 Da) and scrambled peptides and their 
dissolution in buffers were previously described (Zarándi et al., 2007; Annex I). 
Oligomerization of the peptides was checked by transmission electron microscope according 
to a standard protocol (Hetényi et al., 2008). Samples contained globulomers with a diameter 
of 5-7 nm either alone or in chain-like or annular assemblies, but not classical protofibrillar 
aggregates, which are 50-200 nm long (Fig. 7). 
 
Figure 7. Transmission electron microscope image of Aβ42 peptide dissolved in PBS to a concentration of 
75 µM, containing a mixture of oligomers and small protofibrillar structures. Scale: 100 nm. 
 
The iso-amyloid-β 1-42 (isoAβ42; mw: 4515 Da) was prepared according to the 
protocol of Bozsó et al. (for details see: Bozsó et al., 2009; Annex III) At physiological 
conditions (37 °C and pH 7.4) isoAβ42 in situ forms oligomeric Aβ42 via an O-N acyl-transfer 
reaction. The aggregates were visualized by transmission electron microscopy. IsoAβ42 forms 
round shaped oligomers, which can be characterized with a bimodal size-distribution: the 
small aggregates have an average diameter of 5.3 ± 1.0 nm, the large spherical aggregates 
have 7.9 ± 3.3 nm. The oligomers applied in 15 µM concentration aggregate slowly in vitro 
after 24 h of incubation. At this time point protofibrillar assemblies having a length of 30-
100 nm with an average diameter of 8.4 ± 2.1 nm are present together with spherical 
oligomers. 
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2.2. Cell cultures 
Monoculture, double or triple co-culture of primary rat brain endothelial cells (Fig. 8) 
and human hCMEC/D3 brain endothelial cell line (Weksler et al., 2013) under passage 
number 35 were used in the experiments.  
 
 
 
Figure 8. In vitro BBB models: monoculture, double and triple co-culture of brain endothelial cells. 
 
2.2.1. Primary rat brain endothelial cell cultures and BBB models 
Primary cultures of cerebral endothelial cells were prepared from 2-week-old rats. 
Forebrains were collected in ice-cold sterile PBS; meninges were removed, gray matter was 
minced by scalpels to 1 mm3 pieces and digested with collagenase CLS2 (1 mg/ml; 
Worthington, USA) in Dulbecco’s modified Eagle medium (DMEM) for 1.5 h at 37 ˚C. 
Microvessels were separated by centrifugation in 20 % bovine serum albumin (BSA)-DMEM 
(1000 × g, 20 min) from myelin containing elements, and further digested with collagenase–
dispase (1 mg/ml; Roche) in DMEM for 1 h. Microvascular endothelial cell clusters were 
separated on a 33 % continuous Percoll gradient (1000 × g, 10 min), collected, and washed 
twice in DMEM before plating on collagen type IV and fibronectin coated dishes (Falcon, 
Becton Dickinson). Cultures were maintained in DMEM/F12 supplemented with 15 % 
plasma-derived bovine serum (First Link, UK), gentamicin (50 µg/ml), basic fibroblast 
growth factor (1 ng/ml; Roche), insulin (5 µg/ml), transferrin (5 µg/ml), sodium selenite 
(5 ng/ml), and heparin (100 µg/ml). In the first 3 days, culture medium contained puromycin 
(4 µg/ml) to selectively remove P-glycoprotein negative contaminating cells (Perrière et al., 
2005). The endothelial cell cultures were immunopositive for von Willebrand factor and 
negative for the astroglia cell marker glial fibrillary acidic protein and α-smooth muscle actin 
in accordance with earlier published results (Perrière et al., 2005; Nakagawa et al., 2007). 
When the cultures reached 80 % confluency (fourth day in vitro), the purified endothelial cells 
were passaged to multiwell plates or Transwell filter inserts by a brief treatment with trypsin-
EDTA (w/v %: 0.05 and 0.02) solution, and used for experiments. To induce BBB 
characteristics, brain endothelial cells were treated with glia- and pericyte-conditioned 
medium or co-cultured with rat primary glial cells and with rat primary pericytes (Nakagawa 
et al., 2009). Preparation of primary rat glial and cerebral pericyte cultures were prepared as 
described in Annex I and III.  
For co-culture, brain endothelial cells were placed on cell culture inserts into 
multiwells containing astroglia at the bottom of the wells with endothelial culture medium in 
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both compartments. When brain endothelial cells became almost confluent hydrocortisone 
(550 nM) was added to the culture medium (Deli et al., 2005). To construct the three cell type 
BBB model, first pericytes were seeded on the bottom side of the inserts and finally 
endothelial cells were passaged to the upper side of the inserts coated with fibronectin and 
collagen type IV with endothelial culture medium in both compartments (Nakagawa et al., 
2009). 
 
2.2.2. Human hCMEC/D3 brain endothelial cell line 
Human brain endothelial cells were plated on rat tail collagen-coated culture dishes 
(Orange Scientific, Braine-l’Alleud, Belgium) and cultured at 37 ºC, 5 % CO2 in EBM-2 
medium (Lonza, Basel, Switzerland) containing 5 % fetal bovine serum (FBS), 
hydrocortisone (1.4 µM), Hepes (10 mM), gentamicin (50 µg/ml), ascorbic acid (5 µg/ml), 
chemically defined lipid concentrate (v/w: 1 %) and basic fibroblast growth factor (1 ng/ml; 
Roche, Basel, Switzerland). Cells were seeded in culture dishes at a density of 2.5 × 104 
cells/cm2 and the medium was changed every 3 days. At the first change of medium, 10 mM 
lithium chloride supplement was added to the cells (Paolinelli et al., 2013). When cells 
reached approximately 80-90 % of confluence in the dish, they were subcultured with 0.05 % 
trypsin-EDTA solution and used for experiments.  
 
2.3. Treatments 
All stock solutions were prepared freshly and separately, and added to the cells 
consecutively. The cell viability and ROS-detection experiments were done in 96-well format, 
where the abluminal surface was not available, therefore the cultures were treated only 
luminally. In all other experiments where endothelial cells were cultured on the membrane of 
the inserts treatment solutions were added both luminally and abluminally. Incubations of 
brain endothelial cells with the agents were performed in endothelial culture medium. 
Treatment of cells varied between 0-48 h, as described in the text and figure legends.  
Aβ42 peptides were tested at 0-200 µg/ml (0-45 µM) concentrations. IsoAβ42 was 
investigated at 0-30 µM (0-135 µg/ml) concentrations. The 75 µM stock solution of isoAβ42 
was freshly prepared in PBS and further diluted in cell culture medium for cell treatment. 
Methylglyoxal treatment solutions were made in the 100-1000 µM concentration range in 
EBM-2 medium containing 10 % FBS, Hepes (10 mM) and gentamicin (50 µg/ml). 
The stock solutions of protective agents were prepared in sterile distilled water and 
further diluted in culture medium, unless otherwise indicated. The concentration of PPS 
(Cartrophen, Biopharm Australia Pty Ltd.) varied between 1.6 and 166.6 µM ( 1-100 µg/ml) , 
as described in previous studies (Deli et al., 2000a; Veszelka et al., 2007). DHA stock 
solution (300 mM) was prepared in ethanol and further diluted in culture medium (1-300 µM) 
to treat the cells. Edaravone was used in the 600-3000 µM. Aminoguanidine, a well-known 
antiglycation agent, was tested at 600-2000 µM concentration and applied as a positive 
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control against the effect of methylglyoxal (Edelstein et al., 1992). Triton X-100 detergent 
was used at 10 mg/ml concentration in viability assays as a reference compound to cause cell 
death. Control conditions were similar to other treatment conditions except they did not 
contain any of the investigated agents. The medium for the controls was also diluted with the 
vehicle (PBS) in the appropriate proportion.  
 
2.4. Viability and cytotoxicity assays  
For colorimetric dye reduction assays cells were cultured in 96-well culture plates 
(Orange Scientific, Braine-l’Alleud, Belgium). For real-time cell electronic sensing 96-well 
plates with gold electrodes (E-plate 96, ACEA Biosciences, San Diego, USA) were used.  
 
2.4.1. Dye reduction cell viability assay 
Living cells convert the yellow dye 3-(4,5-dimethyltiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to purple, insoluble formazan crystals. Decrease in dye 
conversion reflects cellular damage. Endothelial cells grown to confluency were treated, then 
the medium was removed and the cells were incubated with MTT solution (0.5 mg/ml) in 
DMEM for 3 h in CO2 incubator. The amount of formazan crystals was dissolved in dimethyl-
sulfoxide and determined by measuring absorbance at 570 nm wavelength with a microplate 
reader (Fluostar Optima, BMG Labtechnologies, Germany). The control group was 
considered as 100 % viable. 
Lactate dehydrogenase (LDH) release is the indicator of cell membrane damage, 
which was determined from culture supernatants by a commercially available kit 
(Cytotoxicity detection kit LDH, Roche, Basel, Switzerland). After the treatment 50 µl 
samples from culture supernatants were removed and incubated with equal amounts of 
reaction mixture for 15 minutes. The enzyme reaction was stopped by 0.1 M HCl. Absorbance 
was measured at a wavelength of 492 nm with a microplate reader (Fluostar Optima, BMG 
Labtechnologies, Ortenberg, Germany). Cell death was calculated as percentage of the total 
LDH release from cells treated by 10 mg/ml Triton X-100 detergent.  
 
2.4.2. Real-time monitoring of impedance 
Impedance-based cell electronic sensing is a label-free technique for dynamic 
monitoring of living cells. The Real Time Cell Analyser Single Plate instrument (RTCA-SP; 
ACEA Biosciences Inc., USA) utilizes an automatic and continuous impedance measurement 
to non-invasively quantify adherent cell proliferation and viability in real-time. This method 
has been successfully used to measure number, adherence, growth and health of cells in 
control and treatment conditions (Ózsvári et al., 2010; Kiss et al., 2013). E-plates were coated 
with rat tail collagen at room temperature and dried for 40 minutes under UV and air-flow. 
Culture medium (50 µl) was added to each well for background readings, then 50 µL of cell 
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suspension was dispensed at the density of 1.6 × 104 cells/well. The cells were kept in 
incubator at 37 °C for 5 days until reaching confluence. Impedance was monitored every 2 
minutes. The cell index at each time point was defined as (Rn-Rb)/15, where Rn is the cell-
electrode impedance of the well when it contains cells and Rb is the background impedance of 
the well with the medium alone.  
 
2.5. Investigation of cell morphology 
2.5.1. Electron microscopy 
Cells grown on the membrane of culture inserts were fixed with 3 % paraformaldehyde 
in cacodylate buffer (pH 7.5) for 30 minutes at 4 °C. After washing with cacodylate buffer 
several times, the membranes of the culture inserts with the cells were removed from their 
support and placed into 24-well chamber slide and were postfixed in 1 % OsO4 for 30 
minutes. Following washing with distilled water, the cells on the membrane were dehydrated 
in graded ethanol, block-stained with 2 % uranyl acetate in 70 % ethanol for 1 h and 
embedded in Taab 812 (Taab; Aldermaston, Berks, UK). Ultrathin sections were cut 
perpendicularly for the membrane using a Leica UCT ultramicrotome (Leica Microsystems, 
Milton Keynes, UK) and examined using a Hitachi 7100 transmission electron microscope 
(Hitachi Ltd., Tokyo, Japan). Electron micrographs were made by Megaview II (lower 
resolution, Soft Imaging System, Münster, Germany). Brightness and contrast were adjusted 
if necessary using Adobe Photoshop CS3 (San Jose, CA, USA). 
 
2.5.2. Phase contrast microscopy 
Cultures grown in plastic dishes with or without treatment were examined by a Nikon 
Eclipse TE 2000 U phase contrast microscope (Nikon, Japan) and photographed by a Spot RT 
digital camera (Diagnostic Instruments, USA).  
 
2.5.3. Holographic phase contrast microscopy 
Digital holographic images were taken with a Holo-Monitor M3 instrument (Phase 
Holographic Imaging AB, Phiab, Sweden). Endothelial cells were cultured on collagen coated 
culture dishes with borosilicate glass bottom (MatTek, Ashland, MA, USA). Holographic 
images of the same culture area were captured before and during treatments. Cell 
morphological changes were analysed by the Holostudio 2.4 software provided with the 
microscope (Phase Holographic Imaging AB, Phiab, Sweden). Each point in the box plot 
reflects the data obtained on a single cell (Alm et al., 2013; Madácsi et al., 2013). 
 
2.6. Evaluation of the barrier integrity 
Transendothelial electrical resistance (TEER) reflects the permeability of intercellular 
tight junctions for ions. TEER was measured by an EVOM resistance meter using STX-2 
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electrodes (World Precision Instruments Inc., Sarasota, FL, USA) and expressed relative to 
the surface area (Ω × cm2). TEER values of cell-free inserts were subtracted from the 
measured data. Resistance measurements were carried out before and after treatments to 
check the barrier integrity. The TEER values are presented as percent of non treated control 
groups. 
To measure the flux of permeability marker molecules sodium fluorescein (mw: 
376 Da) or fluorescein isothiocyanate labeled dextran (FITC-dextran, mw: 4.4 kDa) and 
Evans blue-labeled albumin (EBA; mw: 67 kDa) across endothelial cell layers, cells were 
seeded onto Transwell inserts. Inserts with confluent layers were transferred to 12-well plates 
containing 1.5 ml Ringer–Hepes solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 
1.2 mM MgSO4, 5.5 mM D-glucose, 20 mM Hepes, pH 7.4), which was the abluminal (lower) 
compartment in the permeability experiments. In the upper chambers (luminal compartment) 
culture medium was replaced by 500 µl of Ringer-Hepes buffer containing sodium fluorescein 
or FITC-dextran solution (both 10 µg/ml) and Evans blue bound to 0.1 % BSA (165 µg/ml). 
The plates were kept in incubator at 37 °C with 5 % CO2 on a horizontal shaker (100 rpm). 
The inserts were transferred at 20, 40 and 60 minutes to a new well containing Ringer-Hepes 
solution. After incubation the concentrations of the marker molecules in samples from the 
luminal (upper) and abluminal (lower) compartments were determined by a fluorescent 
microplate reader (Fluostar Optima; emission wavelength: 485 nm, excitation wavelength: 
520 nm). Flux across cell-free inserts was also measured. The endothelial permability 
coefficient (Pe; in 10-6 cm/s) or the apparent coefficient (Papp, in 10-6 cm/s) was calculated, as 
described in the literature (Youdim et al., 2003).  
Pe is calculated from the concentration (C) of the tracer in the abluminal and luminal 
compartments and the volume (V) of the abluminal compartment (0.5 ml) by the following 
equation: 
 
The average cleared volume was plotted vs. time, and permeability  surface area product 
value for endothelial monolayer (PSe) was calculated by the following formula: 
 
 
PSe divided by the surface area (1 cm2 for Transwell-12) generated the endothelial 
permability coefficient (Pe; in 10-6 cm/s).  
The apparent permeability coefficient (Papp) was calculated from the concentration 
difference of the tracer in the abluminal compartments (Δ[C]A) after 1 hour and luminal 
luminal
abluminalabluminal
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compartments at 0 hour ([C]L), the volume of the abluminal compartment (VA; 1.5 ml) and the 
surface area available for permeability (A; 1.1 cm2) by the following equation. The Papp values 
were presented as percent of non treated control groups. 
 
  ΔtCA
VCΔ=)(P
L
AA

cm/sapp  
 
2.7. Immunohistochemistry  
Cell-cell connections and morphology of primary rat brain endothelial cells were 
confirmed by immunostaining for tight junctional proteins ZO-1, occludin and claudin-5. 
Cells were cultured on fibronectin- and collagen-coated glass coverslips and treated with Aβ42 
peptides in the absence or presence of PPS. The cultures were washed in PBS and fixed with 
ethanol-acetic acid (95:5 v %) for 10 minutes at -20 °C (ZO-1), with ethanol for 30 minutes at 
4 °C (claudin-5) with paraformaldehyde (4 %) for 30 min at 4 °C (occludin). Cells were 
blocked with 3 % BSA and incubated with primary antibodies anti-ZO-1, anti-claudin-5 and 
anti-occludin (all from Zymed, USA), for 1 h and 30 minutes. Incubation with secondary 
antibody Cy3-labelled anti-rabbit IgG lasted for 1 h. Between incubations cells were washed 
three times with PBS.  
The human hCMEC/D3 cells were investigated for junctional proteins β-catenin and 
claudin-5. D3 cells were cultured on rat tail collagen coated Transwell inserts. After 
treatments, cells were washed in PBS and fixed with acetone-methanol (1:1) for β-catenin and 
with ethanol-acetic acid (95:5 v %) for claudin-5 at -20 °C for 10 minutes. After rehydrating 
with PBS containing 1% FBS and washing with PBS cells were blocked with 3 % BSA in 
PBS at room temperature for 30 min. Samples were incubated overnight at 4 °C with anti-β-
catenin primary antibody (Invitrogen, Life Technologies Corp., Carlsbad, USA; 1:200) and 
with anti-claudin-5 primary antibody. Incubation with Cy3-labeled or Alexa Fluoro 488-
labeled anti-rabbit IgG secondary antibodies and bis-benzimide (Hoechst dye 33342) to stain 
cell nuclei was performed for 1 h.  
Between and after incubations cells were washed three times with PBS. Coverslips and 
inserts were mounted in Gel Mount (Biomeda, USA) and staining was examined by 
NikonEclipse TE2000 fluorescent microscope (Nikon, Japan), Olympus Fluoview FV1000 
(Olympus, Japan) or Leica SP5 confocal laser scanning microscopes (Leica Microsystems 
GmbH, Wetzlar, Germany). 
 
2.8. Detection of reactive oxygen species 
To measure ROS, we used a fluorometric detection probe, chloromethyl-dichloro-
dihydro-fluorescein diacetate (DCFDA; Molecular Probes, Life Technologies Corp., 
Carlsbad, USA). This indicator penetrates the cells by diffusion and becomes deacetylated by 
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intracellular esterases. Oxidation of DCFDA by reactive oxygen species yields a fluorescent 
molecule. Confluent brain endothelial cell layers cultured in 96-well plates were pretreated, 
then washed, and incubated with Ringer–Hepes buffer containing 2 µM DCFDA and 1,5 µM 
pluronic acid (Life Technologies, USA) for 1 h at 37 °C. Hydrogen peroxide pretreatment 
(100 µM, 30 min) served as a positive control in the ROS assay. The plates were measured by 
Fluostar Optima fluorescent plate reader (BMG Labtechnologies, Germany) at 485 nm 
excitation and 520 nm emission wavelengths. The fluorescent values were presented as 
percent of the control group after 1 h incubation with DCFDA indicator.  
 
2.9. Functional assay for P-glycoprotein 
P-gp efflux pump activity was determined by the measurement of cellular 
accumulation of rhodamine 123 (Fontaine et al., 1996). Endothelial monolayers pretreated 
with isoAβ42 (15 µM) and/or DHA (30 µM) for 24 h in 24-well plates were washed, and 
incubated with Ringer–Hepes buffer containing 10 µM rhodamine 123 for 1 h at 37 °C. The 
solution was quickly removed; endothelial cells were washed three times with ice-cold PBS, 
and solubilized in 0.2 M NaOH. Rhodamine 123 content was determined by Fluostra Optima 
(BMG Labtechnologies, Germany) at excitation at 485 nm, emission at 520 nm wavelengths. 
Verapamil (2 mM, 30 min preincubation) was used as a reference P-gp inhibitor. 
 
2.10. Protein modification experiment 
Bovine serum albumin (50 mg/ml) was incubated with methylglyoxal (2 mM) in the 
presence or absence of protective agents in PBS (pH 7.4) in 1 ml total volume, at 37 °C for 7 
days. Each solution was kept in a capped tube in the dark, and incubation was carried out in 
triplicate tubes. The formation of modified albumin was assessed by the characteristic 
fluorescence excitation wavelength at 360 nm and emission wavelength at 460 nm with a 
fluorescent microplate reader (Fluostar Optima, BMG Labtechnologies, Germany). 
 
2.11. Statistical Analysis 
All data presented are means ± SD or SEM as indicated in the text. The values were 
compared using the analysis of variance followed by Dunnett or Bonferroni posthoc tests 
using GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, CA, USA). Changes 
were considered statistically significant at p < 0.05. All experiments were repeated at least 
three times, the number of parallel wells or inserts for each treatment and time point varied 
between 3 and 16. 
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3. RESULTS 
3.1. Effect of pathological factors on brain endothelial cells 
3.1.1. Effect of Aβ peptides on viability of brain endothelial cells 
The direct effect of Aβ42 peptide on primary rat brain endothelial cell viability was 
examined by two colorimetric assays. Cell viability in control group measured by MTT assay, 
was reflected in the high absorbance values (0.98 ± 0.04 OD, mean ± SEM; Fig. 9A), and was 
considered as 100%. Treatment with Aβ42 for 48 h significantly decreased the viability of 
endothelial cells, whereas that with scrambled peptide did not. 
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Figure 9. The effect of Aβ42 peptide fragments on rat brain endothelial cells after 48 h treatment measured by 
MTT reduction assay (A) and LDH release assay (B). All values presented are means ± SEM, n ═ 8. Statistical 
analysis: one-way ANOVA followed by Dunnett test. Statistically significant differences (p < 0.05) from the 
control group are (#) indicated.  
 
In LDH toxicity assay no enzyme leakage was seen in the control group. Significant 
release of LDH from brain endothelial cells, indicating membrane damage, was induced by 
Aβ42 at 100 µM (9.2 ± 1.4%) and 200 µM (19.5 ± 2.6%) concentrations (Fig. 9B). Lower 
concentrations of Aβ42 did not exert toxic effect on brain endothelial cells in this test. 
Likewise, a peptide with scrambled amino acid sequence had no effect on endothelial cells in 
these viability tests, proving the specificity of the Aβ42 peptide treatment. 
Human D3 cell line
C Aβ MG Aβ+MG Tx0
50
100
###### ### ###
**
ns
v
ia
bi
lit
y (
%
 
o
f c
o
n
tro
l)
Primary endothelial cells
0 1 10 15 20 30
0
50
100
### ### ### ###
concentration (µM)
v
ia
bi
lit
y 
(%
 
o
f c
o
n
tr
o
l)
A B
 
Figure 10. Concentration dependent toxic effect of isoAβ42 (Aβ) on primary rat brain endothelial cell cultures 
(A); and modulating effect of methylglyoxal (MG; 600 µM) on isoAβ42-induced (10 µM) changes in human D3 
brain endothelial cell line (B) measured by MTT assay. Values presented are means ± SEM, n = 8. Statistical 
analysis: one-way ANOVA followed by Dunnett or Bonferroni test. Statistically significant differences 
(p < 0.05) compared to the control (C) groups (#) and to Aβ+MG treated group (*) are indicated. 
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 The effect of isoAβ42 on the viability of primary rat brain endothelial cells was also 
examined by MTT viability assay. The isoAβ42 treatment caused a concentration-dependent 
decrease in viability (Fig. 10A). At concentrations of 10-30 µM it significantly decreased the 
viability of endothelial cells at 24 h timepoint (10 µM, 51.3 ± 7.6 %; 15 µM, 45.7 ± 3.6 % of 
the control). When isoAβ42 (10 µM) was co-administered with methylglyoxal (600 µM) 
significantly reduced viability was measured as compared to control or isoAβ42 treatment 
(Fig. 10B). This indicates that methylglyoxal aggravated the toxicity of the amyloid peptide.  
 
3.1.2. Effect of Aβ42 on the morphology of brain endothelial cells 
To visualize the Aβ42 caused changes cerebral endothelial cells were investigated by 
phase contrast and electron microscopy (Fig. 11). Large assemblies of peptide oligomers 
adhered to the surface of treated endothelial cells, making it difficult to assess the shape of 
cells by phase contrast microscopy. The most prominent change in Aβ42-treated cells was 
vacuolization, which could be observed around the nucleus in the cell cytoplasm, indicated by 
asterisks (Fig.  11B), not present in control cells.  
By electron microscopy endothelial cells show smooth oval nuclei with uneven 
distribution of chromatin substance and several caveolae and caveolae-like invaginations on 
the luminal side (Fig. 11C). In the cytoplasm of control cells every organelle is bordered by 
clearly visibly membrane. In Aβ42-treated cells the shape of nuclei is less regular; the 
chromatin substance is more uniform. No caveolae-like invaginations but vacuoles can be 
observed. The cytoplasm is dense and ribosomes are indistinguishable (Fig. 11D).  
Elaborate intercellular junctions could be seen in brain endothelial cells. A long 
overlapping part of two cell processes is shown on Fig. 3E. Points of attachment, “kissing 
points” are indicated by arrows. The dense material at the kissing points demonstrates tight 
intercellular junctions. In contrast, the connection between two Aβ42-treated endothelial cells 
is not tight, the processes do not lie on each other but one process is circled by the other one 
(Fig. 11F). Pale kissing points (arrows) can be observed. The process on the left hand side is 
full with vacuoles.  
Although some regular TJs can be found in the Aβ42-treated cells too, the irregular 
contacts, junctions with less kissing points were more typical. Vacuolisation of processes and 
cell bodies (shown by asterisks) and decreased number of caveolae were common.  
In control cells well-developed Golgi, mitochondria, and small dots of ribosomes are 
visible (Fig. 11G). Cytoplasm of the Aβ42-treated endothelial cell is more dense than the 
control one and several mitochondria can be seen (Fig. 11H). The structure of mitochondria in 
Aβ42-treated cells shows less space between the outer and inner membranes but there is some 
separation from the cytoplasm. In Aβ42-treated cells less, if any, well preserved Golgi, more 
vacuoles and organelles unidentifiable by morphology were found compared with the control 
ones.  
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Figure 11. The effect of Aβ42 peptide on the morphology of cultured rat brain endothelial cells. Phase contrast 
(A-B) and transmission electron microscopy (C-H) images of brain endothelial cells grown on the filter 
membrane of Transwell inserts. Typical details of control (A,C,E,G) and Aβ42 treated (B,D,F,H) endothelial 
cells. Bar for phase contrast microscopy (A-B): 100 µm; Bar for electron microscopy (C-H): 400 nm. Asterisks 
show cytoplasmic vacuoles and arrows indicate the kissing points of the interendothelial junctions. N: nucleus, 
M: mitochondria. 
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3.1.3. Effect of methylglyoxal on viability of human brain endothelial cells 
Methylglyoxal showed concentration- and time-dependent toxicity in hCMEC/D3 
endothelial cells measured by RTCA-SP instrument (Fig. 12). The highest concentrations of 
methylglyoxal (300-1000 µM) caused a very quick and significant decrease of cell index 
values compared to control. However, this initial impedance drop was compensated with time 
depending on the amount of methylglyoxal. In case of cells treated with 100-400 µM 
methylglyoxal no effect on cell index was measured from 3 to 24 h. A significant toxicity of 
methylglyoxal was seen in concentrations of 500-1000 µM. Irreversible cell damage was 
observed at 800 and 1000 µM. To validate our data, 600 µM methylglyoxal concentration was 
tested using MTT assay at 8 h time point. The cell viability values after methylglyoxal 
treatment, measured by MTT test, decreased to 56.7 ± 4.6% (mean ± SD, n = 50) in good 
agreement with the decrease of cell index at the same concentration of methylglyoxal at the 
same time point (58.2 ± 5.8%, mean ± SD, n = 10). The 600 µM concentration of 
methylglyoxal causing approximately 50 % toxicity was selected for further tests. 
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Figure 12. Effect of methylglyoxal (100–1000 µM) on human hCMEC/D3 endothelial cells measured by real-
time cell electronic sensing method. Cell index is expressed as an arbitrary unit and calculated from impedance 
measurements between cells and sensors. Data are presented as mean ± SD, n = 10. Triton X-100 was used at 
10 mg/ml concentration. Statistical analysis: two-way ANOVA followed by Bonferroni test. Statistically 
significant differences (p < 0.05) from the control group (#) are indicated.  
 
3.1.4. Effect of methylglyoxal on morphology of human brain endothelial cells 
Holographic phase contrast microscopic analysis was performed to visualize the 
morphological changes caused by methylglyoxal (Fig. 13). This novel technology enabled us 
to follow living cells in a label-free and non-invasive way. Endothelial cells show a flat, 
elongated shape and grow next to each other. Treatment with methylglyoxal caused drastic 
changes in cell morphology; growth of cell height was especially prominent as indicated by 
the color-scale.  
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Figure 13. Holographic phase contrast images of morphological alterations induced in hCMEC/D3 human brain 
endothelial cells by treatment with methylglyoxal (MG; 600 µM) for 4 h. Color scale bar correspond to the 
height of single cells. Data were analysed by HoloStudio 2.4 software. Red circles indicate cells with drastical 
changes in cell morphology. Bar =100 µm 
 
The analysis of morphological data is shown on Fig. 14. During treatment with 
methylglyoxal the area of the cells significantly decreased (63.1 ± 33.7%) and their optical 
thickness increased by 1.8 fold (176.2 ± 36.1%) compared to the values at the beginning of 
treatment. These data indicate that endothelial cells treated with methylglyoxal contracted and 
rounded up which is also shown on Fig. 14. The volume of the cells was unchanged (data not 
shown).  
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Figure 14. Morphological alterations induced in human brain endothelial cells (hCMEC/D3) by treatment with 
methylglyoxal at 600 µM (A-B) for 4 h. Surface area (A) and average optical thickness (B) were calculated 
before and during treatments. Box represents 25 and 75 percentiles. Horizontal line represent the median. 
Whiskers show minimum and maximum values. n = 12. Statistical analysis: ANOVA followed by Dunnett test. 
Statistically significant differences (p < 0.05) from 0 h time point (#) are indicated.  
 
3. 2. Protection of brain endothelial cells by pentosan polysulfate 
3.2.1. Pentosan protects against Aβ42-induced toxicity 
In the MTT viability assay PPS could significantly inhibit the Aβ42 (25 µM; 48h) 
induced decrease in cell metabolism at the highest, 100 µg/ml concentration (Fig.  15A). 
Lower concentrations of PPS (0.1-10 µg/ml) had no protecting effect against Aβ42 toxicity. 
Pentosan alone, even at high concentration, did not change MTT reduction. Similarly to MTT 
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assay, PPS at 100 µg/ml concentration could effectively block the LDH release after amyloid 
exposure (Fig. 15B). 
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Figure 15. The effect of pentosan (PPS) on Aβ42-induced (25 µM) toxicity in rat brain endothelial cells 
measured by MTT viability (A) and LDH toxicity (B) assays after 48 h treatment. All values presented are 
means ± SEM, n ═ 8. Statistical analysis: one-way ANOVA followed by Dunnett test. Statistically significant 
differences (p < 0.05) from the Aβ42-treated group are (*) indicated.  
 
3.2.2. Pentosan protects against Aβ42-induced permeability increase 
The Aβ42 peptide induced TEER decrease in brain endothelial cells at both 24 h and 
48 h timepoints. Co-administration of PPS (100 µg/ml) could attenuate this effect of Aβ42 
(Annex I). In accordance with TEER data, Aβ42 treatment (48 h) induced increases in the 
BBB permeability for markers (Fig. 16). The Pe values for albumin were lower with one order 
of magnitude than the values for fluorescein, in agreement with the literature (Deli et al., 
2005) Co-administration of PPS significantly tightened the barrier and decreased permeability 
for both markers (Fig. 16). However, PPS treatment alone had no effect on the resistance or 
permeability of the barrier (Annex I, Fig. 16).  
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Figure 16. Changes in transendothelial permeability (Pe) for permeability markers fluorescein (A) and Evans 
blue labeled albumin (B) in rat brain endothelial cell monolayers treated with Aβ42 peptide (25 µM) and pentosan 
polysulfate (PPS, 100 µg/ml) for 48 h. All values presented are means ± SEM, n ═ 4. Statistical analysis: one-
way ANOVA followed by Bonferroni test. Statistically significant differences (p < 0.05) from control (#) and 
from the Aβ42-treated group are (*) indicated.  
26 
3.2.3. Pentosan protects against Aβ42-induced changes in TJ morphology  
To further investigate the effect of Aβ42 on the morphology of interendothelial 
junctions of brain endothelial cells immunostaining for junctional proteins was also 
performed. In control monolayers ZO-1, occludin and claudin-5 staining localized to the cell 
border and the tightly apposed, elongated endothelial cells were well delineated (Fig. 17). The 
pattern of immunostaining dramatically changed in Aβ42-treated (25 µM, 48 h) cells, 
fluorescent staining intensity decreased, fragmentation or loss of the continuous cortical 
staining pattern, and appearance of intercellular gaps were visible in rat brain endothelial 
cells. Co-administration of PPS inhibited these changes, the monolayer integrity was better 
preserved and the immunostaining pattern resembled to the control ones. The visualization of 
Aβ42 aggregates attached to the cells as cloudy patches by the anti-claudin-5 antibody 
(Fig. 17) is most probably due to non-specific binding of the antibody to the aggregates. 
 
 
Figure 17. Effect of Aβ42 peptide (25 µM) and pentosan polysulfate (PPS, 100 µg/ml) for 48h on 
immunostaining for junctional proteins ZO-1, occludin, and claudin-5 in rat brain endothelial cells. Arrows show 
holes formed between endothelial cells, fragmentation or loss of junctional immunostaining. Bar: 25 µm. 
 
The effect of Aβ42 on brain endothelial tight junctions was also evident on the electron 
microscopy pictures, the connection between cells became looser, processes did not lie on 
each other (Fig. 18C). PPS treatment ameliorated the ultrastructural changes induced by Aβ42 
(Fig. 18D), long overlapping processes of endothelial cell with dense material at the kissing 
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points demonstrating tight intercellular junctions were visible. PPS treatment did not change 
the morphology of brain endothelial cells (Fig. 18B) as compared to control (Fig. 18A). 
 
Figure 18. The effect of amyloid β peptide fragments on the morphology of intercellular junctions of rat brain 
endothelial cells by transmission electron microscopy. Typical details of control (A), pentosan (B), Aβ42 peptide 
(C), Aβ42 and pentosan (D) treated endothelial cells. Bar: 400 nm. The squares indicate the starting and the 
ending point, arrows the kissing points of the interendothelial junctions. Asterisks show cytoplasmic vacuoles. 
 
3.3. Protection of brain endothelial cells by docosahexaenoic acid 
3.3.1. DHA protects against isoAβ42-induced toxicity  
 Based on the results of the toxicity assay (Fig. 10) the 15 µM concentration of isoAβ42 
was selected to be optimal to reproducibly induce damages in brain endothelial cell cultures. 
The 30 µM concentration of DHA, causing no harm, was chosen to be tested as a protective 
agent against isoAβ42 toxicity. This concentration of DHA significantly attenuated the toxic 
effect of isoAβ42 measured by MTT viability assay in both rat primary endothelial cells 
(Fig. 19A) and human D3 cell line (Fig. 19B). D3 endothelial cells treated with both isoAβ42 
and methylglyoxal, but not with methylglyoxal alone, were also protected (Fig. 19B). 
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Figure 19. The effect of docosahexaenoic acid (DHA; 30 µM) on isoAβ42 (Aβ; 15 µM) and methylglyoxal (MG; 
600 µM) induced toxicity in rat primary (A) and human D3 brain endothelial cells (B). Values presented are 
means ± SEM, n = 8. Statistical analysis: one-way ANOVA followed by Bonferroni test. Statistically significant 
differences (p < 0.05) compared to the control (C) groups (#), and to isoAβ42 treated groups (*) are indicated. 
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3.3.2. DHA protects against isoAβ42-induced morphological changes 
 Treatment with isoAβ42 resulted in big intercellular gaps in the confluent monolayers 
of brain endothelial cells and floating apoptotic cells in the culture medium (Fig. 20B). Such 
gaps and damage of the monolayers were also visible after Aβ42 treatment (Fig. 17). At higher 
magnification cytoplasmic vacuolization could be observed, similarly to Aβ42-treated cells 
(Fig. 11). DHA inhibited the changes caused by isoAβ42; the monolayer integrity was better 
preserved and resembled to the control ones (Fig. 20C).  
 
Figure 20. The effect of docosahexaenoic acid (30 µM) on isoAβ42 (15 µM) induced toxicity on the morphology 
of rat brain endothelial cell cultures examined by phase contrast microscopy. Asterisks show holes in endothelial 
monolayers. Control (A), Aβ42 (B), Aβ42 and docosahexaenoic acid (C). Bar: 50 µm. 
 
3.3.3. DHA protects against isoAβ42-induced permeability increase  
 Treatment of endothelial cell monolayers with isoAβ42 (15 µM) reduced the TEER by 
70 % of the control after 24 h (Annex III). The flux of the paracellular marker fluorescein was 
4.6 fold higher in isoAβ42 treated monolayers as compared to the control group (Fig. 21A). 
The Pe values for albumin were lower with one order of magnitude than the values for 
fluorescein, in agreement with data presented on Fig. 16. The permeability for albumin was 
elevated by 5.9 fold in monolayers treated with isoAβ42 (Fig. 21B). The flux of permeability 
markers through endothelial monolayers was significantly decreased by co-administration of 
DHA, while DHA alone had no effect on permeability. 
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Figure 21. Effect of docosahexaenoic acid (DHA, 30 µM) on isoAβ42 (Aβ, 15 µM) induced changes in the 
permeability of primary brain endothelial cells for fluorescein (A) and Evans blue labeled albumin (B). Values 
presented are means ± SEM, n = 6. Statistical analysis: one-way ANOVA followed by Bonferroni test. 
Statistically significant differences (p < 0.05) compared to control (C) groups (#), and to isoAβ42 treated groups 
(*) are indicated. 
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3.3.4. DHA protects against isoAβ42-induced brain endothelial dysfunction 
IsoAβ42 treatment (15 µM, 24 h) significantly enhanced (1.4 fold) the production of 
ROS in brain endothelial cells measured by DCFDA assay (Fig. 22A). DHA (30 µM) caused 
no change alone, but effectively inhibited the isoAβ42-induced elevation in ROS production. 
Hydrogen peroxide treatment (100 µM, 15 min), a positive control in the ROS assay, elevated 
the amount of ROS measured by 3.4 fold in brain endothelial cells.  
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Figure 22. Effect of docosahexaenoic acid (DHA, 30 µM) on isoAβ42 (15 µM) induced changes in ROS 
production (A) and P-glycoprotein (P-gp) efflux pump activity (B) of primary rat brain endothelial cells. Values 
presented are means ± SEM., n = 5. Statistical analysis: one-way ANOVA followed by Bonferroni test. 
Statistically significant differences (p < 0.05) compared to control groups (#), and to isoAβ42 treated groups (*) 
are indicated. 
 
To examine the function of P-glycoprotein efflux pump rhodamine 123 uptake assay 
was used (Fig. 22B). Pre-treatment with isoAβ42 (15 µM, 24 h) significantly decreased efflux 
pump activity in rat brain endothelial cells as indicated by the increased level of rhodamine 
123 accumulation. Co-administration of DHA prevented the inhibition of P-gp. DHA-
treatment alone did not change the function of the efflux pump. Verapamil, an inhibitor of    
P-gp, was used as a reference blocker (Fig. 22B). 
 
3. 4. Protection of brain endothelial cells by edaravone 
3.4.1. Edaravone protects against methylglyoxal-induced toxicity 
To investigate the protective effects of edaravone on methylglyoxal-induced cell 
injury human brain endothelial cells were co-treated with different concentrations of 
edaravone and with a fixed concentration of methylglyoxal (600 µM). Edaravone protected 
cells at 1-3 mM concentrations and reversed or attenuated the drop in cell index caused by 
methylglyoxal in a concentration- and time-dependent way (Fig. 23). Edaravone at 1 mM had 
a short term (0.5-2 h) but significant effect. The 1.5 and 2 mM concentrations of edaravone 
could protect the endothelial cells for 6 and 8 h, respectively. Long lasting protection of 
hCMEC/D3 cells could be observed at 2.5 and 3 mM concentrations of edaravone. The 
reference drug aminoguanidine (2 mM) showed a complete protection against methylglyoxal-
induced cellular toxicity.  
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To determine the effect of protective agents alone, cells were incubated with different 
concentrations of edaravone (600-3000 µM) and aminoguanidine (600-2000 µM). There was no 
decrease in cell viability measured by MTT assay and impedance monitoring in cells treated with 
edaravone or aminoguanidine alone (Annex IV S1). Edaravone at 3 mM concentration slightly 
but statistically significantly increased both the impedance of the endothelial layers and the 
metabolic activity measured by MTT assay (121.8 ± 5.9 %). Based on these results, the 3 mM 
concentration of edaravone, which protected brain endothelial cells the most efficiently, was 
selected for other investigations. 
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Figure 23. Effect of co-treatment with methylglyoxal (600 µM) and different concentrations of edaravone (MG+E; 
600–3000 µM) or aminoguanidine (MG+AG; 2 mM). Cell index is expressed as an arbitrary unit and calculated from 
impedance measurements between cells and sensors. Data are presented as mean ± SD, n = 10. Triton X-100 was 
used at 10 mg/mL concentration. Statistical analysis: two-way ANOVA followed by Bonferroni test. Statistically 
significant differences (p < 0.05) from the methylglyoxal treated group (*) are indicated. 
 
3.4.2. Edaravone protects against methylglyoxal-induced morphological changes 
Morphological changes caused by methylglyoxal and the protective effect of edaravone 
were visualized by holographic phase contrast microscopy (Fig. 24). Methylglyoxal weakened 
cell-cell and cell-basal membrane connections and cells were rounded up (Fig. 13,14). In 
endothelial cells co-treated with edaravone (3 mM) and methylglyoxal (600 µM) there was no 
change in cell morphology during the treatment period (4 h). Accordingly, cell area and optical 
thickness did not change significantly in endothelial cells co-treated with edaravone (Annex IV.).  
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Figure 24. Holographic phase contrast images of morphological alterations induced in hCMEC/D3 human brain 
endothelial cells by treatment with methylglyoxal (MG; 600 µM) and co-treatment with 3 mM edaravone (MG+E) 
for 4 h. Color scale bar correspond to the height of single cells. Data were analyzed by means of HoloStudio 2.4 
software. Red circles indicate cells with drastical changes in cell morphology. Yellow circles indicate cells without 
any morphological changes. Bar=100 µm 
 
3.4.3. Edaravone protects against methylglyoxal-induced permeability increase 
The direct effect of methylglyoxal on the permeability of brain endothelial monolayers 
was determined by TEER and permeability measurement. Treatment of endothelial cell 
monolayers with methylglyoxal at 600 µM concentrations significantly decreased TEER to 
90.6 ± 2.5 % compared to control (Annex IV) and increased the permeability for both markers in 
hCMEC/D3 endothelial cells (Fig. 25). The flux of FITC-dextran (4.4 kDa) was elevated by 1.5 
fold as compared to the control group (Fig. 25A). The permeability coefficient values for albumin 
(65 kDa) were one sixth of the values for FITC-dextran (0.6 ± 0.03 x 106 cm/s vs. 
3.6 ± 0.8 x 106 cm/s), as published previously (Deli et al., 2005). The permeability for albumin 
was doubled after incubation with methylglyoxal (Fig. 25B). Edaravone (3 mM) completely 
protected brain endothelial monolayers from the damaging effects of methylglyoxal and kept 
TEER and the permeability at the level of the control group for both markers (Annex IV, Fig. 25). 
The same effect was seen by the co-administration of aminoguanidine (Fig. 25B). 
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Figure 25. Changes in transendothelial permeability (Papp) for permeability markers FITC-dextran (A) and Evans 
blue labeled albumin (B) in human brain endothelial cell monolayers treated with methylglyoxal (MG; 600 µM) and 
edaravone (E, 3 mM) or aminoguanidine (AG) for 4 h. All values presented are means ± SD, n ═ 4. Statistical 
analysis: one-way ANOVA followed by Bonferroni test. Statistically significant differences (p < 0.05) from the 
control group (*) and from methylglyoxal-treated group are (*) indicated.  
 
3.4.4. Edaravone protects against methylglyoxal-induced changes in junctional morphology 
The effect of methylglyoxal on cell-cell adhesion was investigated by staining of cell 
nuclei and immunostaining for β-catenin, a cytoplasmic adherens junction protein, and claudin-5, 
a transmembrane tight junction protein (Fig. 26).  
 
Figure 26. Immunostaining for adherens junction protein β-catenin (A-D) and integral tight junction membrane 
protein claudin-5 (E-H) in human hCMEC/D3 brain endothelial cells. Control (A and E), 4 h treatment with 
methylglyoxal (600 µM; B and F), co-treatment with edaravone (3 mM; C and G) or aminoguanidine (2 mM; D and 
H). Blue color: bis-benzimide staining of cell nuclei; red color: immunostaining for β-cathenin; green color: 
immunostaining for claudin-5. Bar=20 µm. 
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In control monolayers β-catenin staining was localized to the cell border and the tightly 
apposed, elongated endothelial cells were well delineated (Fig. 26A). Claudin-5 localization at 
the interendothelial junctions was less stringent than for β-catenin but clearly visible in part of the 
cell borders (Fig. 26E) and resembled the immunostaining shown in the paper describing this cell 
line (Weksler et. al., 2005). The pattern of the staining was dramatically changed in 
methylglyoxal (600 µM, 4 h) treated cells. Treatment with methylglyoxal resulted in decreased 
immunostaining intensity, fragmentation or loss of the continuous cortical staining pattern, the 
appearance of intercellular gaps (Fig. 26B and 26F) and apoptotic cells (Fig. 26F). Co-
administration of protective agents, edaravone (Fig. 26C and 26G) and aminoguanidine (Fig. 26D 
and 26H) attenuated these changes; The monolayer integrity was better preserved and the 
immunostaining pattern resembled to the control ones. 
 
3.4.5. Edaravone protects against methylglyoxal-induced changes:  
 ROS production and protein modification 
As methylglyoxal generates carbonyl and oxidative stress (Kalapos, 2008), ROS 
production and protein modification were measured (Fig. 27). 
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Figure 27. Effect of co-treatment with 600 µM methylglyoxal and 3 mM edaravone (MG+E) or 2 mM 
aminoguanidine (MG+AG). ROS production of human brain endothelial cells after 4 h treatment (A). Fluorescent 
intensity of ROS expressed as a percentage of control (C). Modification of BSA by methylglyoxal and its inhibition 
by protective agents (B). Fluorescent intensity was expressed as a percentage of methylglyoxal (MG). Values 
presented are means ± SD, n = 9. Statistical analysis: ANOVA followed by Bonferroni test. Statistically significant 
differences (p < 0.05) from the control group (#) and from the methylglyoxal-treated group (*) are indicated.  
 
In cells treated with methylglyoxal (600 µM; 4 h), ROS production was significantly 
enhanced (120.9 ± 7.3%). Edaravone (3 mM) completely inhibited the methylglyoxal-induced 
increase in ROS production bringing back to the level of control (97.2 ± 1.7%). Co-
administration of aminoguanidine (2 mM) also decreased ROS production (89.1 ± 2.1%). In 
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contrast to edaravone, which had no effect alone (102.5 ± 1.7%), treatment with aminoguanidine 
alone decreased the amount of ROS in endothelial cells below the level of the control group 
(87.4 ± 1.3%). Hydrogen peroxide treatment (100 µM, 15 min), a positive control in the ROS 
assay, doubled the amount of ROS. (Fig.  27A). 
Incubation of BSA with methylglyoxal (2 mM; 0-7 days) resulted in significant elevation of 
modified BSA’s fluorescence at the wavelength pair of 360 and 460 nm (Fig 19B). The 
fluorescence of BSA by methylglyoxal treated samples was considered as 100%. Edaravone 
(1 mM) and aminoguanidine (2 mM) reduced the BSA’s fluorescence indicating almost complete 
inhibition of protein modification for 7 days (Fig. 27B).  
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4. DISCUSSION 
4.1 Effect of pathological factors on brain endothelial cells 
4.1.1. Amyloid-β induced changes in brain endothelial cells 
In our study, Aβ42 peptide induced remarkable ultrastructural alterations in primary rat 
brain endothelial cells, which have not been described in the literature earlier. In agreement with 
Aβ-induced changes in brain microvessel morphology in pathological samples and animal studies 
(Erickson and Banks, 2013; Kalaria and Hedera, 1995) degeneration of the cells, namely dark 
cytoplasm, pronounced vacuolization, decreased number of caveolae and Golgi, and shrunken 
mitochondria could be observed after peptide treatment. Irregular interendothelial contacts and 
junctions with less kissing points were especially notable, indicating an increased paracellular 
pathway. Cytoplasmic vacuolization could be seen by both electron and phase contrast 
microscopy. These toxic effects were also confirmed by reduced MTT dye reduction, and 
increased LDH release indicating plasma membrane damage. Our results are in agreement with 
experimental data from other laboratories showing the damaging effects of Aβ on cultured 
endothelial cells. Aβ peptides inhibited the proliferation of brain endothelial cells (Grammas et 
al., 2002). In addition, Aβ peptides exerted toxic effects on both peripheral and cerebral 
microvessel endothelial cells (Blanc et al., 1997; Preston et al., 1998). Furthermore aggregates of 
various Aβ
 
peptides decreased viability on cultured human cerebrovascular endothelial cells 
obtained from the brain of a victim of AD (Eisenhauer et al., 2000). The Akt (Yin et al., 2005), 
and protein kinase C (Pákáski et al., 2002) signalling pathways, RAGE (Baiguera et al., 2009) 
and the activation of caspase-8 (Folin et al., 2006) can participate in the decrease of cell viability 
and apoptotic cascade induced by Aβ in endothelial cells. 
The effect of Aβ42 was also studied on several aspects of the barrier function of rat 
primary brain endothelial cells, in which barrier properties were induced by glial cells and/or 
pericytes. Aβ42 decreased the resistance and increased the permeability for markers fluorescein 
and albumin. Since the paracellular barrier at the BBB is regulated by TJ proteins, 
immunostaining for these proteins was investigated after Aβ treatment in brain endothelial cells. 
Aβ42 led to fragmentation and loss of junctional immunostaining for occludin, claudin-5 and ZO-
1 in our model. These data are in accordance with previous observations, where Aβ42 altered 
occludin, claudin-5 and ZO-2 TJ protein distribution and expression (Marco and Skaper et al., 
2006). Interestingly, a specific decrease of occludin but not of claudin-5 and ZO-1 was described 
in an immortalized human brain endothelial cell line (Tai et al., 2010). 
In AD, the accumulation of Aβ42 increases the production of reactive oxygen species. In the 
present study ROS production was elevated by isoAβ42 in primary brain endothelial cells, in 
agreement with data obtained on an endothelial cell line (Carrano et al., 2011). P-gp in brain 
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endothelial cells participates in Aβ peptide efflux transport (Candela et al., 2010). In our 
experiments isoAβ42 pretreatment inhibited the activity of P-gp on brain endothelial cells, in 
concordance with other observations (Kuhnke et al., 2007; Kania et al., 2011). The relevance of 
these results is emphasized by a recent clinical observation providing the first direct evidence that 
P-glycoprotein transporter at the BBB is compromised in AD (van Assema et al., 2012).  
Cell-free aggregation experiments and a culture study on neurons indicated, that 
methylglyoxal can conribute to the harmful effect of Aβ peptides (Angeloni et al., 2014). This 
recent study, which investigated the difference between authentic and glycated Aβ (Aβ-AGE) 
treatment in embryonic hippocampal neurons found that Aβ-AGE was more toxic, than Aβ alone. 
In neurons Aβ-AGE decreased viability, increased apoptosis, induced tau hyperphosphorylation, 
and reduced synaptic proteins significantly compaired with authentic Aβ-treatment (Li XH et al., 
2013). Co-treatment with methylglyoxal and Aβ has not been investigated on endothelial cells 
previously. We found, that brain endothelial damage induced by isoAβ42 was more pronounced in 
the presence of methylglyoxal. Our data support the link between methylglyoxal and AD 
(Angeloni et al., 2014). 
 
4.1.2. Methylglyoxal induced changes in brain endothelial cells 
A direct toxic effect of methylglyoxal on brain microvessels was proposed in a recent 
paper (Li et al. 2013b). In the present study we further supported the fact that methylglyoxal 
alone could induce damage to brain endothelial cells. Methylglyoxal exerted a time- and 
concentration-dependent toxicity on cultured human brain endothelial cells; it significantly 
reduced the integrity of the barrier measured by both functional and morphological experiments. 
This is the first observation on the kinetics of methylglyoxal toxicity by impedance-based cell 
electronic sensing. The two different cell viability assays we used were in complete agreement on 
the direct cellular damaging effect of methylglyoxal. Impedance data reflecting changes in cell 
adhesion, shape and number were confirmed by MTT tests measuring the metabolic activity of 
cells. Our data lend support to and expand previous findings on the effect of methylglyoxal on 
human brain endothelial cells (Okouchi et al., 2009; Li et al., 2013a; Li et al., 2013b; Li et al., 
2013c). We selected the human hCMEC/D3 cell line as a simplified model of the BBB. This cell 
line is widely used in different experiments, including pharmacological and drug studies 
(Weksler et al., 2013). To support the relevance of our data on hCMEC/D3 endothelial cell line, 
the effect of methylglyoxal was also tested on primary cultures of rat brain endothelial cells 
(Annex IV. Fig. S2 and S3). The results were in agreement with our observations on the human 
cell line, indicating a similar sensitivity of primary endothelial cells and hCMEC/D3 endothelial 
cell line for the toxic effects of methylglyoxal. We found no data on primary brain endothelial 
cells related to methylglyoxal in the literature, therefore the present study is the first to include 
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primary brain endothelial cells in this setting. The relevance of our findings on endothelial cells is 
limited by the use of high concentrations of methylglyoxal to induce barrier damage, a common 
concern in cell culture studies. However, in four recent and independent papers both the time 
needed to measure methylglyoxal-induced injury in cultured endothelial cells and the 
concentrations used were in similar range as in our study (Okouchi et al., 2009; Li et al., 2013a; 
Li et al., 2013b; Li et al., 2013c). 
Damage by methylglyoxal is mediated not only via carbonyl, but also by oxidative stress 
(Yim et al., 1995; Kalapos 2008). ROS are generated as by-products of protein glycation (Lee et 
al., 1998). Furthermore, methylglyoxal increases glycation of selected mitochondrial proteins 
resulting in increased formation of superoxide (Rabbani et al., 2008). Elevated level of ROS 
weakens the barrier integrity (Pun et al., 2009), however the contribution of methylglyoxal-
triggered ROS production in the increased endothelial permeability is controversial (Li et al., 
2013b). In the present study we confirmed that methylglyoxal treatment promotes oxidative stress 
in brain endothelial cells, similarly to previous results on endothelial cells (Li et al., 2013b; Li et 
al., 2013c) and other cellular systems (Desai and Wu, 2008). The kinetics of ROS production 
helped to determine the optimal time point for protection assays and other experiments: the 4 h 
time point, where ROS formation was still elevated, was purposefully selected.  
In good agreement with data from toxicity measurements methylglyoxal increased the 
permeability of human and rat brain endothelial monolayers. The effect was concentration-
dependent, with only high concentrations of methylglyoxal causing significant damage to barrier 
integrity. These data are in accordance with previous findings showing that methylglyoxal 
induced an increase in the permeability of brain endothelial cells (Li et al., 2013b). In that study 
decreased TEER and increased dextran flux were coupled with glycation of occludin and 
disturbed localization of ZO-1 TJ proteins. We found the redistribution of two other junctional 
proteins important for the regulation of brain endothelial permeability, namely the TJ protein 
claudin-5 and AJ protein β-catenin in methylglyoxal treated brain endothelial cells. Decreased 
expression, delocalization or redistribution of claudin-5 and β-catenin in brain endothelial cells 
are linked to permeability increase in many pathologies (Liebner and Plate, 2010). We 
demonstrated for the first time, that treatment with methylglyoxal resulted in fragmentation and 
loss of the continuous cortical pattern of β-catenin in brain endothelial cells, confirming the 
importance of β-catenin in the regulation of barrier tightness. 
For the maintenance of the integrity of the BBB permeability the attachment of 
endothelial cells to the basement membrane is crucial (Del Zoppo et al., 2006). Damage to the 
basal lamina weakens microvascular wall structures and results in increase of brain vessel 
permeability in vivo (Wang et al., 2007). Our data confirmed these observations and visualized 
for the first time the kinetics of morphological changes caused by methylglyoxal using a novel 
technique, holographic phase contrast microscopy in living cells (Alm et al., 2013; Madácsi et 
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al., 2013). Methylglyoxal changed drastically the shape of brain endothelial cells by time: the 
area of cells decreased, their optical height significantly increased indicating cell-cell and cell-
basal lamina detachment. Similar observation was made in case of peripheral endothelial cells, 
where modification of basement membrane by methylglyoxal caused cell detachment, anoikis 
and inhibition of angiogenesis (Dobler et al., 2006).  
 
4.2. Protection against brain endothelial dysfunction 
Brain endothelial dysfunction initiates and contributes to the disease process in AD (Deli, 
2005; Zlokovic, 2011), therefore in addition to neurons, brain endothelial cells and other 
elements of the neurovascular unit are increasingly recognized as therapeutical targets in AD 
(Neuwelt et al., 2011). Since previous therapeutic attempts of AD were focused on the prevention 
of neuronal death, there are a great number of experimental data on the protection of neurons 
against the toxic effects of Aβ. In contrast, only few studies examined protective molecules in 
brain endothelial cells (Zlokovic, 2011).  
The prevention of methylglyoxal-induced injury is in the focus of current research (Desai 
and Wu, 2007). Aminoguanidine was the first drug extensively studied, and attenuated the 
development of a range of diabetic vascular complications both in vitro and in vivo. However, 
due to toxic side effects at high doses, it failed in clinical trials. This compound is considered as a 
prototype for antiglycation agents and used as a reference molecule in experiments (Thornalley, 
2003). 
 
4.2.1. Protection by pentosan polysulfate 
PPS, a drug of plant origin used clinically for a long time, protected primary mouse 
cerebral endothelial cells against prion peptide toxicity (Deli et al., 2000b) and attenuated both 
the permeability barrier impairment and inhibition of P-gp in lipopolysaccharide-exposed 
primary rat brain endothelial cells (Veszelka et al., 2007) in our previous experiments. We have 
demonstrated that PPS successfully attenuates the toxic effects of Aβ peptides and protects the 
barrier integrity of endothelial monolayers treated with Aβ, however it does not change BBB 
parameters of TEER, permeability, or morphology in cultured brain endothelial cells. Because 
PPS does not cross the BBB, endothelial cells of the blood-nerve and blood-brain barriers may be 
among the cellular targets of PPS (Leveugle et al., 1998). 
The exact mode of action of PPS at the BBB has not been elucidated yet. In other cell 
types PPS inhibits a wide range of enzymes and biological modulators, like protein kinases in 
smooth muscle cells (Maffrand et al., 1991), serine proteases, matrix metalloproteinases, 
lysosomal enzymes, coagulation factors, complement factors and pro-inflammatory cytokines in 
chondrocytes. In peripheral endothelial cells PPS stimulates the release of anti-coagulant tissue-
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type plasminogen activator and anti-oxidant superoxide dismutase contributing to its efficacy in 
arthritis (Ghosh, 1999). The inhibition of serine proteases, matrix metalloproteinases and 
cytokines or increased levels of superoxide dismutase (Ghosh, 1999) could also contribute to the 
protection of the BBB; however other actions of PPS could be also important. 
Surface plasmon resonance and atomic force microscopy data indicate for the first time 
that PPS can directly interact with Aβ42, and may have a physicochemical effect resulting in 
fewer adherences to the examined surfaces (Annex I). This is in agreement with the only study 
that examined the effect of PPS on the binding of heparan sulfate glycosaminoglycans to Aβ. PPS 
was the most effective to displace heparan sulfate glycosaminoglycans bound to Aβ. Since 
heparan sulfate glycosaminoglycans are involved in Aβ aggregation in vivo, sulfated polyanions, 
like PPS, can be useful against amyloid deposition in AD brain (Leveugle et al., 1994). Pentosan 
may exert multiple effects (Fig. 28); some of these could be cellular while others could be related 
to its direct interaction with Aβ. The present results support pentosan’s dual mode of action and 
the endothelial protective properties.  
 
 
Figure 28. Effect of amyloid-β 1-42 peptide and pentosan or docosahexaenoic acid on brain endothelial cells. 
Abbreviations: Aβ: amyloid-β 1-42 peptide; DHA: docosahexaenoic acid; P-gp: P-glycoprotein; PPS: pentosan 
polysulfate; RAGE: receptor for advanced glycated endproducts; ROS: reactive oxygen species; ZO-1: zonula 
occludens protein-1. 
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4.2.2. Protection by docosahexaenoic acid 
The beneficial effect of DHA was investigated in several models of AD, but these were 
focused on neurons (Oksman et al., 2006; Grimm et al., 2011). In our study DHA was not only 
protective against oligomeric Aβ42 toxicity in primary neurons, but also on acute hippocampal 
slices, a more complex ex vivo model (Annex III.) Importantly, DHA readily crosses the BBB by 
diffusion (Ouellet et al., 2009) and can easily reach glial cells and neurons. Our main results 
indicate for the first time that DHA can protect not only neurons, but also the other elements of 
the neurovascular unit, like brain endothelial cells, from the toxic effects of isoAβ42 (Fig. 28). 
DHA was effective in toxicity tests and improved the morphological changes after Aβ42 
treatment, indicating a more extensive and diverse protective effect than previously supposed. 
The permeability of cerebral endothelial monolayers was increased by isoAβ42 similarly to our 
another study (Annex I), and was attenuated by DHA.  
The decrease in P-gp activity induced by isoAβ42 treatment was also prevented by DHA in 
our experiments. Since decreased P-gp function is involved in the pathogenesis of AD (Candela 
et al., 2010), our novel finding strengthens the therapeutical potential of DHA. The effect of Aβ42 
on P-gp is mediated via Wnt/β-catenin signaling (Kania et al., 2011), which activation increases 
BBB functions (Liebner et al., 2008). It is tempting to speculate that DHA may also act through 
this pathway.  
The mechanism of the DHA action is not fully understood. RAGE is both a gate for Aβ 
peptides toward the brain (Candela et al., 2010), and a receptor for the methylglyoxal derived 
AGE (Srikanth et al., 2011). The expression level of RAGE in brain endothelial cells is low in 
healthy brain, however it is increased in AD, because this receptor is up-regulated by its ligands 
(Zlokovic, 2004). Aβ is not able to enter from the blood toward the brain in RAGE knock-out 
mice which highlights the importance of RAGE in AD (Deane et al., 2003). While there are no 
data on how DHA may affect RAGE, it was recently demonstrated in cultured brain endothelial 
cells that Aβ accumulation is lipid raft and caveolae dependent and involves RAGE (András et 
al., 2012). Disruption of lipid rafts by pretreatment with β-methyl-cyclodextrin protected against 
Aβ accumulation in this model. DHA is a well known inducer of membrane fluidity (Yang et al., 
2011) and by reducing cholesterol (Grimm et al., 2011). It destabilizes rafts and decreases the 
docking of Aβ (Hashimoto et al., 2011) that may influence RAGE activity and contribute to the 
protective effect of DHA.  
In AD the accumulation of Aβ42 increases the production of ROS, resulting in increased 
lipid peroxidation in the brain (Floyd and Hensley, 2002). Oxidative damage and formation of 
oxidized lipids and proteins have been observed in the brains of patients with AD during 
postmortem analysis (Choi et al., 2004). Lipid peroxide levels are significantly lower in DHA-
administered rats indicating that dietary DHA contributes to the antioxidant defense, decreases 
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oxidative stress, and protects against memory loss (Morley and Banks, 2010). The levels of ROS 
in the cerebral cortex and hippocampus increase significantly after the infusion of Aβ42 into the 
cerebral ventricle of rats, but then decrease significantly after the dietary administration of DHA 
(Hashimoto et al., 2005). In our experiments, similarly to cytotoxicity and BBB dysfunction, 
ROS production elevated by oligomeric Aβ42 could be also inhibited by DHA in primary brain 
endothelial cells. Aβ-induced oxidative stress-mediated BBB changes were observed on a brain 
endothelial cell line in concordance with our results (Carrano et al., 2011). These observations 
suggest that DHA increases the antioxidant defense in the brain, including the BBB, and its mode 
of action may be related to direct scavenging of ROS or to the induction of antioxidant enzymes.  
Methylglyoxal is also a strong inducer of oxidative stress and this phenomenon is thought 
to be one of the links between AD and carbonyl stress (Angeloni et al., 2014). The beneficial 
effects of DHA on brain endothelial cells were also visible during isoAβ42 and methylglyoxal co- 
treatment. DHA attenuated the combined toxic effect of the two agents in human brain 
endothelial cell; however no complete protection was achieved. There may be several reasons to 
explain this observation. Methylglyoxal enhances Aβ-toxicity via several ways. It induces 
oxidative stress, partly through RAGE signaling pathway, and modifies proteins such as Aβ and 
tau. DHA has antioxidant effect and supposedly may influence RAGE activity, but has no anti-
glycation effect and cannot protect against protein modification as proved in our experiments 
(data of BSA modification experiments are not shown). Based on these data, DHA could be a 
promising molecule for the prevention of BBB dysfunction. However, to fully prevent the 
damages caused by carbonyl stress in AD in addition to DHA other agents, like edaravone, may 
be needed.  
 
4.2.3. Protection by edaravone 
Edaravone was reported to protect the neurovascular unit and the BBB after ischemic 
stroke (Yamashita et al., 2009; Lukic-Panin et al., 2010). In a recent study, edaravone reduced 
cell injury in oxygen-glucose deprivation in vitro model. Edaravone pretreatment attenuated 
methylglyoxal-induced decrease in cell viability of brain endothelial cells (Li et al. 2013c). In our 
study co-treatment with edaravone provided a complete protection against the toxic effect of 
methylglyoxal (Fig. 29). We could see a concentration- and time-dependent effect based on 
kinetic data from impedance measurements. Our data are in agreement with viability studies on 
the effect of edaravone pretreatment against methylglyoxal-induced toxicity (Li et al., 2013c). 
Edaravone treatment alone increased the metabolic activity and impedance of the endothelial 
layers. A beneficial effect of edaravone on human endothelial cells was also found previously by 
resistance measurement and proteomic assay (Omori et al., 2007; Onodera et al., 2013). The used 
edaravone concentrations were in the millimolar range similarly to another independent work on 
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cultured human brain endothelial cells (Onodera et al., 2013). For long-lasting protection 
suprapharmacological concentration of edaravone (Kaste et al., 2013) was needed in our culture 
study. However, the applied methylglyoxal levels were also comparably high, as in other in vitro 
methylglyoxal studies (Okouchi et al., 2009; Li et al. 2013a; Li et al., 2013b; Li et al., 2013c). 
Although we used higher concentrations in cultured cells, importantly, the ratio of the 
methylglyoxal to edaravone used in our study was the same as the ratio of the pathological 
plasma methylglyoxal concentrations (Kalapos, 2013) to clinical concentrations of edaravone 
(Kaste et al., 2013).  
 
 
Figure 29. Effect of methylglyoxal and edaravone on brain endothelial cells. Abbreviations: AGE: advanced 
glycated end-products; ECM: extracellular matrix; MG: methylglyoxal; RAGE: receptor for AGE; ROS: reactive 
oxygen species; ZO-1: zonula occludens protein-1. 
 
Originally, edaravone was a drug to promote neuronal rehabilitation after ischemic stroke 
by protecting against oxidative stress (Watanabe et al., 1994). Its antioxidant effect was observed 
in our experiment, too. In a recent independent study edaravone suppressed methyglyoxal-
induced ROS production in human brain endothelial cells by two possible mechanisms (Li et al., 
2013c). Pre-treatment with edaravone decreased methylglyoxal-induced AGE accumulation and 
activation of its receptor RAGE (Li XH et al., 2013), and the subsequent production of ROS 
(Mangalmurti et al., 2010; Rouhiainen et al., 2013). Furthermore, as in our experiments, 
edaravone inhibited protein-modification of BSA by methylglyoxal, therefore it decreased ROS 
generated as by-products during protein glycation (Lee et al., 1998). All these results together 
indicate that the antioxidant mechanisms induced by edaravone contribute to its protective effect 
against methylglyoxal-induced oxidative stress. 
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Prior work described, that edaravone protects from methylglyoxal-induced injury by 
inhibiting AGEs/RAGE/oxidative stress in human brain microvascular endothelial cells (Li et al., 
2013c). However, it remained unanswered whether edaravone can also protect against methyl-
glyoxal-induced barrier dysfunction in brain endothelial monolayers. Therefore, this study 
focused on the protective effect of edaravone against methylglyoxal-induced barrier damage. We 
found that co-treatment with edaravone restored barrier properties of endothelial cells and 
protected against methylglyoxal-induced decrease of resistance and increase in permeability for 
paracellular and transcellular markers. Moreover, we also demonstrated that edaravone treatment 
alone tightened the brain endothelial barrier. Our data expand and further support previous 
observations on barrier enhancing effect of edaravone (Omori et al., 2007; Onodera et al., 2013).  
Increased endothelial permeability was coupled with disturbed localization of junctional 
proteins claudin-5 and β-catenin after incubation with methylglyoxal, while co-treatment with 
edaravone restored distribution of both proteins along the cell borders. Similar observation was 
made in a previous study, where edaravone treatment enhanced β-catenin at cell-cell contact area 
and the cortical arrangement for its linked protein, actin on half confluent peripheral endothelial 
monolayer (Omori et al., 2007). Our holographic phase contrast microscopic data are in 
accordance with these observations; edaravone completely prevented methylglyoxal-induced 
changes in cell morphology, no sign of detachment and cellular morphological alteration was 
observed, indicating no cytoskeletal rearrangement.  
 
4.3. Conclusion and perspectives 
Because of the increasing prevalence of CNS disorders there is a large number of new 
centrally active drug candidates, especially biomolecules, under development. Reliable BBB 
models that present physiologically realistic cell architecture and other attributes of in vivo BBB 
phenotype are needed as testing and screening tools. The primary brain endothelial cell-based co-
culture models used in our studies involve also other elements of the neurovascular unit, 
especially glial cells and pericytes, and can be considered as one of the most complex and 
pertinent BBB models to date. Since species differences exist in the expression and 
pharmacokinetic parameters of transporters at the BBB, human models are valuable and 
important research tools. For this reason we also used the human brain endothelial cell line 
hCMEC/D3 in our experiments. Importantly, the reliability of this model was tested against 
primary cultures and similar data were obtained on both models. Further progress is expected in 
several areas of BBB modelling to reach the goal of better modelling BBB functions. Human 
models and human data are very important for further development. A simple, cost-effective, 
validated human BBB culture model is not yet available. We can predict that in long term the cell 
culture based models will be replaced by human models for drug testing, but rodent models will 
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continue to be valuable tools in primary BBB research. The BBB culture models enabled us to 
test the effect of two major pathological factors, Aβ42 and methylglyoxal involved in AD. Our 
observations further support the toxic effects of amyloid peptides and methylglyoxal on brain 
endothelial cells and strengthen the link between AD and carbonyl stress. Oxidative stress was 
found as a common pathway induced by both toxic agents in brain endothelial cells, similarly to 
previous observations on other cellular systems. As a consequence, the BBB is considered as 
therapeutic target in AD, and anti-inflammatory molecules are among the possible protective 
pharmacons.  
The prospect of reducing the risk of AD by preventive strategies such as diet or lifestyle 
modification is highly favorable. Several epidemiological studies and growing experimental data 
has shown that dietary DHA may improve neuronal development, restore and enhance cognitive 
functions and increase neuronal resistance to amyloid-induced oxidative stress. DHA may be a 
potent agent to prevent Aβ-induced damages on the cells of the neurovascular unit acting via 
multiple ways. Based on our new observations DHA might exert a protective effect not only on 
neurons but also on the BBB and its functions, and this effect may be beneficial in the prevention 
of AD. Pentosan and edaravone can represent a new type of drugs to protect brain endothelial 
cells in pathological conditions, including Aβ toxicity, and carbonyl stress. As a new application 
these drugs may contribute to the maintenance of BBB functions, brain homeostasis and 
prevention of neuronal loss in AD. The presented results provide compelling evidence for barrier 
protective effect of DHA, pentosan and edaravone in cultured brain endothelium. Data from our 
studies could have therapeutical implication for disorders and diseases that are associated with 
carbonyl stress and AD.  
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5. SUMMARY 
 
The role of cerebral endothelial cells forming the blood-brain barrier to protect the brain in 
pathological conditions is increasingly emphasized in the literature. We have tested amyloid-β 1-
42 (Aβ42) and methylglyoxal, two major pathological factors, involved in Alzheimer’s disease 
and carbonyl stress. The hallmarks of Alzheimer’s disease are perivascular deposits and senile 
plaques of Aβ peptides in the brain.
 
The formation of these aggregates is enhanced by dicarbonyl 
compounds such as methylglyoxal. To study potential protective molecules, primary rat and 
human (hCMEC/D3 cell line) blood-brain barrier models were used. The effect of treatments was 
tested on cell viability and barrier functions. Aβ42 and methylglyoxal induced concentration- and 
time dependent toxicity and dramatically changed cell morphology. In Aβ42-treated brain 
endothelial cells cytoplasmic vacuolization, disruption of the structure of cytoplasmic organelles 
and tight junctions were visible. Additionally, methylglyoxal treatment caused detachment of 
endothelial cells. Further damage of barrier function was demonstrated by decreased resistance 
and increased para- and transcellular permeability of the endothelial monolayers. The production 
of reactive oxygen species in brain endothelial cells was also elevated. Pentosan polysulfate, a 
drug of plant origin, and the polyunsaturated fatty acid docosahexaenoic acid could attenuate the 
toxic effects of Aβ42 peptides. Co-treatment of the cells with Aβ42 and the protective agents 
prevented the morphological changes and cell cultures integrity resembled to the control ones. 
Furthermore, pentosan and docosahexaenoic acid could significantly protect the barrier from 
damaging actions of peptides. The barrier function of endothelial monolayers, mirrored by low 
permeability and high resistance, was restored. At molecular level, pentosan modified the size 
and decreased the number of amyloid aggregates demonstrated by atomic force microscopy. 
Docosahexaenoic acid had a different molecular mechanism, it decreased the elevated reactive 
oxygen species level and restored P-glycoprotein efflux pump activity. These results indicate for 
the first time that pentosan and docosahexaenoic acid can protect the blood-brain barrier from the 
toxic effects of Aβ42 and these protective molecules may be beneficial in Alzheimer’s disease. 
Edaravone, the active substance of a Japanese medicine, was effective against methylglyoxal 
induced damages. Co-administration of edaravone restored cell viability, barrier integrity and 
functions of brain endothelial cells. Edaravone prevented the methylglyoxal-induced cell 
detachment. The production of reactive oxygen species in human endothelial cells and protein-
modification were also blocked. We demonstrated that edaravone is protective in oxidative and 
carbonyl stress induced barrier damages. Our observations further support the toxic effects of 
amyloid peptides and methylglyoxal, and show for the first time the protective effect of pentosan, 
docosahexaenoic acid and edaravone on brain endothelial cells. The present data may contribute 
to the development of compounds protecting the blood-brain barrier in carbonyl stress related 
diseases, especially in Alzheimer’s disease. 
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Abstract. Endothelial cells of brain capillaries forming the blood-brain barrier play an important role in the pathogenesis and
therapy of Alzheimer’s disease. Amyloid-β (Aβ) peptides are key pathological elements in the development of the disease.
A blood-brain barrier model, based on primary rat brain endothelial cells was used in which the barrier properties were
induced by glial cells. The effects of amyloid peptides have been tested on cell viability and barrier functions. Aβ showed
toxic effects on primary rat brain endothelial cells measured by MTT dye conversion and the lactate dehydrogenase release.
Morphologically cytoplasmic vacuolization, disruption of the structure of cytoplasmic organelles and tight junctions could be
observed in brain endothelial cells. Treatment with Aβ1−42 decreased the electrical resistance, and increased the permeability
of brain endothelial cell monolayers for both fluorescein and albumin. Serum amyloid P component which stabilizes Aβ
fibrils in cortical amyloid plaques and cerebrovascular amyloid deposits significantly potentiated the barrier-weakening effect of
Aβ1−42. Sulfated polysaccharide pentosan could decrease the toxic effects of Aβ peptides in brain endothelial cells. It could
also significantly protect the barrier integrity of monolayers from damaging actions of peptides. Pentosan modified the size, and
significantly decreased the number of amyloid aggregates demonstrated by atomic force microscopy. The present data further
support the toxic effects of amyloid peptides on brain endothelial cells, and can contribute to the development of molecules
protecting the blood-brain barrier in Alzheimer’s disease.
Keywords: Amyloid-β, blood-brain barrier, brain endothelial cells, glia, pentosan polysulfate, permeability, rat, serum amyloid
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INTRODUCTION
Alzheimer’s disease (AD) is the most widespread
form of dementias. In the European Union, 50–70%
of dementias are diagnosed as AD and the number of
patients is over 7 million [1]. Despite intense research
efforts there is still no effective therapy for AD.
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Recent findings indicate that neurovascular mecha-
nisms contribute to cognitive decline and neurodegen-
eration in AD [2–6]. Decreased clearance of amyloid-
β (Aβ) across the blood-brain barrier (BBB), damaged
angiogenesis, dysfunction of the cerebrovascular sys-
tem all contribute to neurovascular uncoupling, brain
hypoperfusion, and neurovascular inflammation [4,5,
7]. The BBB is indispensable for creating and main-
taining the homeostasis of the central nervous system
(CNS), therefore BBB dysfunction leads to disturbed
homeostasis, neuronal dysfunction, and secondary neu-
ronal loss [4,5,8]. It has also become clear that even
subtle functional changes at the BBB without morpho-
logical alterations can lead to severe and lasting neuro-
logical dysfunction [3,5].
The BBB is increasingly considered as a target of
new therapeutical approaches in neurodegenerativedis-
orders, especially in AD [5,8]. In addition to produc-
tion of the peptide, transport of Aβ across the BBB is
essential in controlling Aβ levels in the brain [9]. En-
hancing Aβ clearance across the BBB, as well as pro-
tection of the BBB from injury are among the proposed
new strategies for the therapy of AD.
Aβ1−40 and Aβ1−42 peptides, cleaved from amyloid-
β protein precursor by secretases, are the main protein
components of neuritic plaques and cerebral amyloid
deposits and are considered as important factors in the
pathogenesis of Alzheimer’s disease [10]. Aβ pep-
tides can form soluble monomers, dimers, oligomers,
protofibrils and insoluble fibrils [11]. Amyloid pep-
tides have high affinity for serum amyloid P compo-
nent (SAP) that stabilizes the aggregates [12]. Direct
infusion of Aβ1−42 into the carotid artery increased the
permeability of the BBB to albumin in rats [13]. In
Tg2576 mice, an AD model, a higher BBB permeabil-
ity for albumin was measured in cerebral cortex, which
preceded senile plaque formation [14].
Experimental data support the direct toxicity of Aβ
peptides on cultured endothelial cells. Treatments with
Aβ1−40, Aβ1−42, and Aβ25−35 peptides resulted in de-
creased viability in cultured peripheral [15], as well as
brain endothelial cells [16,17]. Monolayer integrity of
cerebral endothelial cells is also affected by Aβ pep-
tides. Increased permeability for paracellular mark-
ers induced by Aβ25−35 and Aβ1−40 was detected in
rat [18], bovine [19], and human brain microvascular
endothelial cells [20].
Few protective molecules against the toxic effect of
Aβ peptides in cerebral endothelial cells were iden-
tified so far. In our previous studies we found that
pentosan polysulfate (PPS), a semisynthetic highly sul-
fated polysaccharide can favorably regulate BBB phe-
notype [21], and protect against prion peptide [22,23]
and lipopolysaccharide-induced toxicity [24] in brain
endothelial cells. Although pentosan can inhibit the
binding of endogenous glycosaminoglycans to Aβ and
this effect was suggested as a potentially effective ther-
apeutical approach to prevent or slow the amyloido-
genesis in AD [25], pentosan was not tested on brain
endothelial cells treated with Aβ peptides.
The aim of the study was to investigate the effect
of pentosan on Aβ peptide-induced changes in cell
viability and BBB functions in a relevant in vitro BBB
model. Primary rat brain endothelial cells were co-
cultured with rat glial cells to induce barrier properties.
The modulatory effects of serum amyloid P component
(SAP) in BBB dysfunction induced by Aβ were also
studied.
MATERIALS AND METHODS
All reagents were purchased from Sigma, Hungary,
unless otherwise indicated.
Peptides
Peptides Aβ1−40 and Aβ1−42 were synthesized at
the Department of Medical Chemistry, University of
Szeged, as it was previously described [26,27]. Prior
to measurements the purified peptide was dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma) and
incubated overnight at room temparature in order to de-
stroy the pre-formed aggregates. Aliquots were trans-
ferred into Eppendorf tubes and HFIP was evaporated
in vacuo. Dried peptide films were stored at −80◦C
until use. Oligomers were prepared by resuspending
the film in phosphate buffered saline (PBS). Oligomer-
ization of the peptide was checked by TEM. Sampling
for TEM and image preparation was done by following
a standard protocol [28,29]. According to the TEM
investigations, samples contained globulomers with a
diameter of 5–7 nm either alone or in chain-like or an-
nular assemblies, but not classical protofibrillar aggre-
gates, which are 50–200 nm long (Fig. 1).
Cell culture
Primary cultures of cerebral endothelial cells were
prepared from 2-week-old rats as described earlier in
detail [24]. Forebrains were collected in ice cold sterile
PBS; meninges were removed, gray matter was minced
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Fig. 1. TEM image of Aβ1−42 peptide dissolved in physiological
salt solution to a concentration of 75 µM, containing a mixture of
oligomers and small protofibrillar structures.
by scalpels to 1 mm3 pieces and digested with 1 mg/ml
collagenase CLS2 (Worthington, USA) in Dulbecco’s
modified Eagle medium (DME) for 1.5 h at 37◦C. Mi-
crovessels were separated by centrifugation in 20%
bovine serum albumin (BSA)-DME (1000×g, 20 min)
from myelin containing elements, and further digest-
ed with 1 mg/ml collagenase-dispase (Roche) in DME
for 1 h. Microvascular endothelial cell clusters were
separated on a 33% continuous Percoll gradient (1000
×g, 10 min), collected, and washed twice in DME be-
fore plating on collagen type IV and fibronectin coated
dishes, multiwell plates (Falcon, Becton Dickinson) or
cell culture inserts (Transwell clear, 1 cm2; pore size,
0.4 µm, Costar). Cultures were maintained in DME
supplemented with 5 µg/ml gentamicin, 20% plasma-
derived bovine serum (First Link, UK), 1 ng/ml basic fi-
broblast growth factor (Roche) and 100 µg/ml heparin.
In the first 2 days, culture medium contained puromycin
(4 µg/ml) to selectively remove P-glycoprotein nega-
tive contaminating cells [30].
Cultures reached confluency within a week and were
used for experiments. To induce BBB characteris-
tics, brain endothelial cells were treated with glia-
conditioned medium or co-cultured with rat cerebral
glial cells [18,24]. Primary cultures of glial cells were
prepared from newborn Wistar rats. Meninges were
removed, and cortical pieces were mechanically disso-
ciated in DME containing 5 µg/ml gentamicin and 10%
fetal bovine serum and plated in poly-L-lysin coated
12-well dishes and kept for minimum 3 weeks before
use. In confluent glia cultures 90% of cells were im-
munopositive for the astroglia cell marker glial fibril-
lary acidic protein, while the remaining 10% was im-
munopositive for CD11b, a marker of microglia. For
co-culture brain endothelial cells in cell culture inserts
were placed into multiwells containing astroglia at the
bottom of the wells with endothelial culture medium
in both compartments. When brain endothelial cells
became almost confluent 550 nM hydrocortisone was
added to the culture medium [18]. Before experiments
the cells were treated with CPT-cAMP (250 µM) and
RO 201724 (17.5 µM; Roche) for 24 h to tighten junc-
tions and elevate resistance [18,30].
Treatments
In case of viability assays the cells were treated with
glia-conditioned medium, whereas for all other studies
where the culture insert system made it possible co-
culture was done before treatments. Glia-conditioned
medium or glial cells were not present during peptide
treatments and experiments.
Peptides were tested at 0–200 µg/ml concentration
for 0–48 h treatment period in brain endothelial cells.
The doses of PPS (Cartrophen, Biopharm Australia Pty
Ltd.) varied between 1 and 100 µg/ml, as described
in previous studies [21,23,24]. The concentration of
human SAP (Merck, Germany) was 40 µg/ml. In cell
viability experiments done in 96-well format, where the
abluminal surface was not available the cultures were
treated only luminally. In all other experiments where
endothelial cells were cultured on the membrane of the
inserts Aβ1−42 was added both luminally and ablumi-
nally. Incubations of brain endothelial cells with the
peptides were performed in endothelial culture medi-
um.
Electron microscopy
Cells grown on the membrane were fixed with 3%
paraformaldehyde in cacodylate buffer (pH 7.5) for
30 min at 4◦C. After washing with cacodylate buffer
several times, the membranes of the culture inserts with
the cells on the two sides were removed from their sup-
port and placed into 24-well chamber slide and were
postfixed in 1 % OsO4 for 30 min. Following washing
with distilled water, the cells on the membrane were
dehydrated in graded ethanol, block-stained with 2%
uranyl acetate in 70% ethanol for 1 h and embedded in
Taab 812 (Taab; Aldermaston, Berks, UK). Ultrathin
sections were cut perpendicularly for the membrane
using a Leica UCT ultramicrotome (Leica Microsys-
tems, Milton Keynes, UK) and examined using a Hi-
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tachi 7100 transmission electron microscope (Hitachi
Ltd., Tokyo, Japan). Electron micrographs were made
by Megaview II (lower resolution, Soft Imaging Sys-
tem, Munster, Germany). Brightness and contrast were
adjusted if necessary using Adobe Photoshop CS3 (San
Jose, CA, USA).
Cell cytotoxicity assays
Living cells convert the yellow dye 3-(4,5-dimethyl-
tiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma M5655) to purple, insoluble formazan crystals.
For MTT reduction assay the rat brain endothelial cells
were cultured in 96 well plates. After treatments the
cells were incubated with 0.5 mg/ml MTT solution for
3 h in CO2 incubator. The amount of formazan crystals
was dissolved in dimethyl-sulfoxide and determined by
measuring absorbance at 570 nm with microplate read-
er (Multiskan Ascent, Thermo Electron Corp., MA,
USA).
To determine lactate dehydrogenase (LDH) from cul-
ture supernatant a commercially available kit (Cytotox-
icity detection kit LDH, Roche) was used. For LDH
release assay rat brain endothelial cells were cultured in
96 well plates. After treatments 50µl samples from cul-
ture supernatants were incubated with equal amounts of
reaction mixture for 15 min. The enzymic reaction was
stopped by 0.1 M HCl. Absorbance was measured at a
wavelength of 492 nm with a microplate reader (Multi-
skan Ascent, Thermo Electron Corp., MA, USA). Cy-
totoxicity is calculated as percentage of the total LDH
release from cells treated by 1% Triton X-100 deter-
gent.
Evaluation of the barrier integrity
Transendothelial electrical resistance (TEER), rep-
resenting the permeability of tight junctions for sodi-
um ions, was measured by an EVOM resistance meter
(World Precision Instruments Inc., USA) using STX-2
electrodes, and it was expressed relative to the surface
area of endothelial monolayer (Ω× cm2). TEER values
of cell-free inserts (90–100 Ω× cm2) were subtracted
from the measured data. The TEER of rat primary
brain endothelial monolayers in co-culture varied be-
tween 250 and 700 Ω× cm2, with an average of 358±
41 Ω× cm2, (mean ± S.D., n = 84, experiments from
6 separate isolations).
The flux of sodium fluorescein and Evans blue-
labeled albumin across endothelial monolayers was de-
termined as previously described [24,31]. Cell cul-
ture inserts, following treatment and measurement of
TEER, were transferred to 12-well plates containing
1.5 ml Ringer–Hepes solution (118 mM NaCl, 4.8 mM
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 5.5 mM D-
glucose, 20 mM Hepes, pH 7.4) in the basolateral com-
partments. In apical chambers culture medium was re-
placed by 500 µl Ringer–Hepes containing 10 µg/ml
sodium fluorescein (mw: 376 Da) and 165µg/ml Evans
blue bound to 0.1% BSA (mw: 67 kDa). The inserts
were transferred at 20, 40, and 60 min to a new well
containing Ringer–Hepes solution. The concentrations
of the marker molecules in samples from the upper
and lower compartments were determined. Evans blue
concentration was measured by a Labsystems Multi-
skan plate reader (absorbency: 620 nm), and fluores-
cein levels by a Polarstar Galaxy fluorescent plate read-
er (BMG Labtechnologies; emission: 525 nm, excita-
tion: 440 nm). Flux across cell-free inserts was also
measured.
Transport was expressed as µl of donor (luminal)
compartment volume from which the tracer is com-
pletely cleared. Transendothelial permeability coeffi-
cient (Pe) was calculated as previously described [18,
24]. Cleared volume was calculated from the concen-
tration (C) of the tracer in the abluminal and luminal
compartments and the volume (V) of the abluminal
compartment (0.5 ml) by the following equation:
Cleared volume(µl) = Cabluminal × Vabluminal
Cluminal
The average cleared volume was plotted vs. time, and
permeability× surface area product value for endothe-
lial monolayer (PSe) was calculated by the following
formula:
1
PSendothelial
=
1
PStotal
−
1
PSinsert
PSe divided by the surface area (1 cm2 for Transwell-
12) generated the endothelial permability coefficient
(Pe; in 10−3 cm/min).
Immunohistochemistry
Brain endothelial cell monolayers cultured on
fibronectin- and collagen-coated glass coverslips and
treated with Aβ peptides and/or PPS were stained for
ZO-1, occludin and claudin-5 junctional proteins. The
cultures were washed in PBS and fixed with ethanol
(95 vol.%)–acetic acid (5 vol.%) for 10 min at −20◦C
(ZO-1), with ethanol for 30 min at 4◦C (claudin-5)
with 4% paraformaldehyde for 30 min at 4◦C (oc-
cludin). Cells were blocked with 3% BSA and incubat-
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ed with primary antibodies anti-ZO-1 (Zymed, USA),
anti-claudin-5 (Zymed, USA), anti-occludin (Zymed,
USA), for 1 h 30 min. Incubation with secondary
antibody Cy3-labelled anti-rabbit IgG (Sigma, Hun-
gary) lasted for 1 h. Between incubations cells were
washed three times with PBS. Coverslips were mount-
ed in Gel Mount (Biomeda, USA) and staining was ex-
amined by a NikonEclipse TE2000 fluorescent micro-
scope (Nikon, Japan) and photographed by a Spot RT
digital camera (Diagnostic Instruments, USA).
Preparation of laser-grated surfaces and atomic force
microscopy
Master grating based two-beam interference (TBI)
arrangement was applied to generate sub-micrometer
periodic intensity modulation in the beam irradiating
the samples [32]. The fourth harmonic of a Nd:YAG
laser (lFH = 266 nm, t = 10 ns, f = 10 Hz) impinged
on a diffraction grating (PUV 1200, Spectrogon), and
the first order diffracted beams were recombined at the
sample plane, after propagation trough a fused silica
block. The samples were NBK7 substrates evaporated
by gold – silver bimetallic layers, and spin-coated by
polycarbonate. Samples were treated by s-polarized
beams, to produce linear gratings as described earli-
er [32]. The laser treated surfaces were investigated
by atomic force microscopy (AFM) operating in digital
pulsed force mode (DPFM, Witec GmbH, Germany).
The advantage of this scanning mode is the possibility
to map the micromechanical properties of the surface
with high resolution. We applied standard PFM tips
(NSC 18/NoA1, 2.5 N/m) and collected pictures about
the topography and adhesion. The purpose of these
measurements was to compare the adhesion distribu-
tion on structures produced by different laser-treatment
methods.
To examine biomolecules the samples with laser-
grated surfaces were completely immersed in fresh PBS
solutions containing Aβ1−42 peptide at a concentration
of 10 µg/ml (2.2µM), with or without PPS at a concen-
tration of 100 µg/ml. This dose of Aβ1−42 was deter-
mined in a preliminary experiment to optimize the pep-
tide amount for AFM measurement and particle count-
ing. Incubation of the samples in the solutions lasted
for 1 h at 37◦C, then all samples were washed three
times in sterile distilled water on a horizontal shaker
and finally allowed to dry overnight at room temper-
ature. A PSIA AFM operating in tapping-mode was
applied to detect the attached biomolecules using NT-
MDT tips (NSG11, 5.5 N/m, 150 kHz). The AFM pic-
tures were analyzed by Spot Advance software (Diag-
nostic Instruments Inc., Sterling Heights, MI, USA) to
obtain the number and size of the attached biomolecule
particles on the laser-grated surface of the samples.
Particles were counted on 25 fields of 1 µ m2 size from
3 different samples from each treatment groups from 2
separate experiments.
Statistical analysis
All data presented in Results section are means ±
S.E.M. The values were compared using the analysis of
variance followed by Dunnett, Bonferroni or Newman-
Keuls posthoc tests using GraphPad Prism 5.0 soft-
ware. Changes were considered statistically significant
at p < 0.05. All experiments were repeated at least
three times, the number of parallel wells or inserts for
each treatment and time point varied between 3 and 8.
RESULTS
The effect of Aβ peptide fragments on the morphology
of rat brain endothelial cells
In physiological solutions the Aβ1−42 peptide can
easily aggregate into oligomers, protofibrils and fibrils.
The size distribution of the aggregates is highly depen-
dent on the experimental conditions. In our experi-
ments the amyloid peptides were applied in oligomeric
form, as it is represented in Fig. 1. Under the circum-
stances we applied, Aβ1−42 formed globular specii (5–
7 nm), which were arranged occassionally into annular
or beaded chain-like assemblies with a maximum size
of 15–20 nm. In the course of Aβ1−42 treatment, the
oligomers were diluted directly to the cell culture medi-
um to the required concentration. In the solution phase,
these oligomers are assumed to remain stable for an
elongated time, as their molecular environment is very
similar to that of the so-called ’Amyloid Derived Dif-
fusible Ligands’ (ADDLs), which possessed the same
structural characteristics, i.e., globular oligomers in cell
culture medium and kept their stability in the course of
the biological experiments [33]. In-depth examination
of the ADDL population revealed, that it contains fairly
stable subpopulations of amyloid oligomers of different
size [34]. Therefore, upon application of such prepara-
tions, one has to consider that the observed effect was
exerted by a heterogeneous oligomeric population.
Furthermore, the amyloid aggregates can be accu-
mulated on the membrane surfaces, as it was observed
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Fig. 2. The effect of Aβ peptide fragments on the morphology of rat brain endothelial cells. Phase contrast (A-B) and transmission electron
microscopy (C-D) images of brain endothelial cells grown on the filter membrane of Transwell inserts. Typical details of control (A,C) and Aβ
1-42 peptide treated (B,D) endothelial cells. Bar for phase contrast microscopy (A-B): 100 µm; Bar for electron microscopy (C-D): 400 nm.
Asterisks show cytoplasmic vacuoles. N: nucleus, M: mitochondria.
in our experiments as well. Large assemblies of the
oligomers were found to adhere to the surface of the
endothelial cells from the culture medium therefore
the shape of cells could hardly be seen in light mi-
croscopy (Fig. 2B). A remarkable vacualisation could
be observed around the nucleus in the cell cytoplasm
induced by the peptide treatment (Fig. 2B). In the cyto-
plasm of control cells every cell organelle is bordered
by clearly visibly membrane (Fig. 2C). In control cells
well-developed Golgi, mitochondria, a small part of
the nucleus, and small dots of ribosomes are visible
(Fig. 2C), while the cytoplasm of the Aβ-treated en-
dothelial cell is more dense than the control one and sev-
eral mitochondria can be seen (Fig. 2D). The structure
of mitochondria in Aβ peptide-treated cells shows less
space between the outer and inner membranes but there
is some separation from the cytoplasm. In Aβ1−42-
treated cells less, if any, well preserved Golgi, more
vacuoles and organelles unidentifiable by morphology
were found compared with the control ones.
In control conditions endothelial cells show smooth
oval nuclei with uneven distribution of chromatin sub-
stance and several caveolae and caveolae-like invagi-
nations on the luminal side (Fig. 3A). Ribosomes are
clearly visible. The shape of nuclei of the Aβ1−42
peptide-treated endothelial cells are less regular, the
chromatin substance is more uniform. No caveolae-
like invaginations but vacuoles can be observed. The
cytoplasm is dense and ribosomes are indistinguish-
able (Fig. 3C). In untreated cells elaborate intercellular
junctions could be seen. A long overlapping part of two
endothelial cell processes is shown on Fig. 4A, “kiss-
ing points” are indicated by arrows. The dense mate-
rial at the kissing points demonstrates tight intercellu-
lar junctions. In contrast, the connection between two
Aβ1−42-treated endothelial cells (Fig. 4C) is not tight,
the processes do not lie on each other but one process
is circled by the other one. Pale kissing points (arrows)
can be observed. The process on the left hand side is
full with vacuoles. Although some regular tight junc-
tions (TJs) can be found in the Aβ1−42-treated cells
too, the irregular contacts, junctions with less kissing
points were more typical. Vacuolisation of processes
and cell bodies and decreased number of caveolae were
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Fig. 3. The effect of Aβ peptide fragments on the morphology of rat brain endothelial cells by transmission electron microscopy. Brain endothelial
cells were grown on filter membranes of Transwell inserts. Typical details of control (A), pentosan (B), Aβ1−42 peptide (C), Aβ1−42 and
pentosan (D) treated endothelial cells. Bar for electron microscopy: 400 nm. Asterisks show cytoplasmic vacuoles. N: nucleus, M: mitochondria.
common (shown by asterisks on Figs 2–4). PPS treat-
ment did not change the morphology of brain endothe-
lial cells as compared to control (Figs 3B and 4B) and
could ameliorate the ultrastructural changes induced by
Aβ1−42 (Figs 3D and 4D).
The effect of Aβ peptide fragments on rat brain
endothelial cells: toxicity assays
The direct effect of Aβ peptid fragments on brain
endothelial cell viability was examined in two toxicity
assays. The yellow MTT dye was efficiently converted
to purple formazan crystals by non-treated and scram-
bled peptide treated endothelial cells as demonstrat-
ed by the high absorbance values (Fig. 5A). Aβ1−42
peptide-treatment in concentrations higher than 10 µM
for 48 h significantly decreased the MTT reduction. A
similar effect was seen for Aβ1−40 peptide at 50 µM
dose. In the LDH release assay the 100 µM and 200
µM concentrations of Aβ1−42 peptide produced signif-
icant enzyme leakage from the brain endothelial cells
indicating membrane damage (Fig. 5B). The calculated
cytotoxicity based on LDH release was 9.2% at 100µM
and 19.5% at 200 µM Aβ1−42 peptide concentrations.
Lower doses of Aβ1−40 and Aβ1−42 peptides did not
exert toxic effect on brain endothelial cells in this test.
Modulating effect of SAP on Aβ1−42 peptide-induced
changes in endothelial barrier integrity
In preliminary functional studies 25µM Aβ1−42 was
found to be optimal to reproducibly induce damage to
BBB integrity and to examine protective effects. The
selected 25 µM dose of Aβ for the permeability exper-
iments is in good agreement with the treatment doses
of Aβ for brain endothelial cells in the literature [15,
16,35,36].
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Fig. 4. The effect of Aβ peptide fragments on the morphology of intercellular junctions of rat brain endothelial cells by transmission electron
microscopy. Brain endothelial cells were grown on filter membranes of Transwell inserts. Typical details of control (A), pentosan (B), Aβ1−42
peptide (C), Aβ1−42 and pentosan (D) treated endothelial cells. Bar for electron microscopy: 400 nm. The squares indicate the starting and the
ending point, arrows the kissing points of the interendothelial junctions. Asterisks show cytoplasmic vacuoles.
Fig. 5. The effect of Aβ peptide fragments on rat brain endothelial cells after 48 h treatment in MTT reduction assay (A) and LDH release assay
(B). All values presented are means ± S.E.M., n = 8, p < 0.05.
Treatment of monolayers with Aβ1−42 reduced the
TEER significantly after 24 h and the values further de-
creased at the 48 h timepoint (Fig. 6A). In Aβ1−42 pep-
tide treated monolayers the flux of fluorescein increased
as compared to the control (Fig. 6B). The Pe values
for permeability marker albumin were lower with one
order of magnitude than the values for fluorescein, a
paracellular marker, in agreement with literature da-
ta [18,37] and our previous results [24,31]. The per-
meability for albumin was also significantly elevated in
monolayers treated with Aβ1−42 (Fig. 6C).
When Aβ1−42 was co-administered with physiolog-
ical concentration of SAP (40 µg/ml) significantly re-
duced TEER values were measured at 24 h and 48 h
timepoints as compared to control or Aβ1−42 peptide-
treated monolayers (Fig. 6A). The Aβ1−42 peptide-
induced elevations in both fluorescein (Fig. 6B) and
albumin (Fig. 6C) permeability were siginificantly fur-
ther increased by the presence of SAP. SAP treatment
alone had no effect on the resistance or permeability of
the endothelial monolayers (Fig. 6).
The effect of PPS on Aβ1−42 peptide-induced changes
in rat brain endothelial cell morphology and function
In the viability assays pentosan could only slightly
inhibit the Aβ1−42 peptide-induced decrease in MTT
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Fig. 6. Changes in transendothelial electrical resistance (TEER) (A), and in transendothelial permeability (Pe) for permeability markers sodium
fluorescein (B) and Evans blue labelled albumin (C) in rat brain endothelial cell monolayers treated with Aβ1−42 peptide (25 µM) and serum
amyloid P component (SAP, 40 µg/ml). All values presented are means ± S.E.M., n = 8, p < 0.05.
reduction at the highest, 100 µg/ml dose (Fig. 7A).
Lower concentrations of PPS (0.1–10 µg/ml) had no
effect. Pentosan alone did not change MTT reduction
in the cells not even at high concentrations. PPS at 100
µg/ml dose could effectively block the LDH release
after amyloid exposure (Fig. 7B).
The same dose of PPS effective in the toxicity as-
says had protective effect against the Aβ1−42 peptide-
induced TEER decrease in brain endothelial cells at
24 h and 48 h timepoints (Fig. 8A). Pentosan alone had
no significant effect on barrier integrity. The Aβ1−42
treatment-induced increases in the BBB permeability
for markers (Figs 8B and 8C) were significantly de-
creased by PPS, however PPS alone did not change the
permeability of monolayers.
Effect of Aβ1−42 peptide on immunostaining for
junctional proteins in rat brain endothelial cells
To further investigate the effect of Aβ1−42 on the
morphology of interendothelial junctions of the brain
endothelial cells immunostainings for junctional pro-
teins were also performed. In control monolayers ZO-
1, occludin and claudin-5 staining localized to the cell
border and the tightly apposed, elongated endothelial
cells were well delineated (Fig. 9). The pattern of
the staining has been dramatically changed in Aβ1−42-
treated (25 µM, 48 h) cells. Treatment with Aβ pep-
tide resulted in decreased immunostaining intensity,
fragmentation or loss of the continuous cortical stain-
ing pattern, and appearance of intercellular gaps in rat
brain endothelial cells (shown by arrows on Fig. 9).
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Fig. 7. The effect of PPS on rat brain endothelial cells induced toxicity of Aβ1−42 peptide in MTT reduction assay (A) and LDH release assay
(B). All values presented are means ± S.E.M., n = 8, p < 0.05.
Fig. 8. Changes in transendothelial eletrical resistance (TEER) (A), and in transendothelial permeability (Pe) for permeability markers sodium
fluorescein (B) and Evans blue labelled albumin (C) in rat brain endothelial cell monolayers treated with Aβ1−42 peptide (25 µM) and pentosan
polysulfate (PPS, 100 µg/ml) for 24 or 48 h. All values presented are means ± S.E.M., n = 4, p < 0.05.
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Fig. 9. Effect of Aβ1−42 peptide (25 µM) and pentosan polysulfate (PPS, 100 µg/ml) for 48 h on immunostaining for junctional proteins ZO-1,
occludin, and claudin-5 in rat brain endothelial cells. Arrows show holes formed between endothelial cells, fragmentation or loss of junctional
immunostaining. Bar: 25 µm.
Co-administration of PPS inhibited these changes, the
monolayer integrity was better preserved and the im-
munostaining pattern resembled to the control ones.
The visualization of Aβ1−42 peptide aggregates at-
tached to the cells as cloudy patches by the anti-claudin-
5 antibody (Fig. 9) is most probably due to non-specific
binding of the antibody to the aggregates.
Atomic force microscopy measurement
To investigate the interaction between Aβ1−42 pep-
tide and pentosan, the biomolecules were attached
to linear-grated laser-sculpted surfaces and examined
by tapping-mode AFM to reveal the topography (not
shown) and adhesion (Fig. 10A). The AFM pictures
of the samples demonstrate that Aβ1−42 peptide ag-
gregates attached to the surface quite evenly, with a
high density and had an average diameter less than
33 nm (100.30 ± 6.59 particles/µm2 for aggregates
with largest diameter below 33 nm, and 17.44 ± 1.02
particles/µm2 for aggregates with largest diameter be-
tween 33 and 66 nm; Fig. 10B). PPS molecules gave a
small number of very characteristical large, oval aggre-
gates on the samples with a largest diameter of 200-320
nm and attached to the “hills” of the gratings (Fig. 10A).
The majority of PPS particles was in the size range of
260–290 nm. There was no overlap between the size
distribution of PPS as compared to Aβ particles from
Aβ or Aβ+PPS treatment groups. The AFM investi-
gation has shown that the number of the Aβ1−42 ag-
gregates in the presence of PPS was significantly re-
duced and the size of attached peptide aggregates be-
came larger (0 particle/µm2 for aggregates below 33
nm; 1.42 ± 0.44 particles/µm2 for 33–66 nm aggre-
gates; Fig. 10B). The size of the highest number of at-
tached particles was below 33 nm for Aβ1−42 treatment
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Fig. 10. Atomic force microscopy pictures about the phase of biomolecule aggregates attached to laser-grated polycarbonate surfaces (A). AFM
pictures show attachment of pentosan (PPS), amyloid β1−42 peptide (Aβ1−42), and both Aβ1−42 peptide and PPS to the linearly grated surfaces.
Concentration of the incubation solutions were 10 µg/ml for Aβ1−42 peptide and 100 µg/ml for PPS. Analysis of the size (largest diameter) and
density of the Aβ1−42 peptide aggregates (B) on laser grated surfaces in the absence and presence of pentosan (100 µg/ml) measured by atomic
force microscopy (mean ± S.E.M., two-way ANOVA followed by Bonferroni test, significant p < 0.001 differences were found between the two
groups).
and 66–99 nm for Aβ1−42 and PPS treatments (8.46±
0.69 particles/µm2).
Grating coupled surface plasmon resonance in-
vestigation was performed on biomolecule-covered
polymer-bimetal interfacial gratings in a separate ex-
periment [32]. The forward shift of the secondary res-
onance minima detected on samples treated by Aβ1−42
and PPS was smaller than the shift measured after pure
Aβ1−42 attachment. Since the resonance minima shifts
are proportional to changes in dielectric layer thick-
ness, the smaller shift indicates that the PPS therapeu-
tic molecules prevent the adherence of large amount of
Aβ1−42 to the examined surfaces. The analyses of the
results have shown that in presence of PPS the aver-
age thickness of the adhered biomolecule layer is re-
duced from 4.5 nm to 3.8 nm. The difference between
M.A. Deli et al. / Pentosan Protects Blood-Brain Barrier from Aβ 789
the layer thickness enhancements is significantly larger
than the change caused when PPS was applied solely
(−0.2 nm). Both AFM and plasmon resonance experi-
ments prove that PPS can directly interact with Aβ1−42
resulting in decreased adherence.
DISCUSSION
Changes in blood-brain barrier function and
morphology in AD
Recent clinical data indicate that vascular changes
play an important role early in AD pathogenesis. Cere-
bral blood flow (CBF) and cerebral glucose uptake re-
ductions were demonstrated in the early stages of AD
and both low CBF and reduced brain glucose uptake
may precede neurodegeneration and contribute to the
progression of dementia prior to cerebral atrophy [7].
Positive links and overlap exist between cerebrovascu-
lar disorders and AD. Severe atherosclerosis increases
threefold the risk of developing AD or vascular demen-
tia [38].
Pathological Aβ fibrils are deposited both in brain
parenchyma and around brain vessels in AD [2,4]. The
cerebrovascular amyloidosis or cerebral amyloid an-
giopathy is a hallmark of the disease, it is present in
more than 80% of AD patients, and is causally involved
in the development of neurodegeneration in AD [2,
7]. Accumulation of Aβ in the wall of cerebral blood
vessels and in the brain parenchyma in AD is due to
imbalances between its production and clearance from
the brain [4]. Several transporters were identified to
participate in the transport of Aβ across the BBB, in-
cluding receptor for advanced glycation end products
(RAGE) [39,40], low-density lipoprotein receptor re-
lated protein 1 [41,42] and 2 [43], P-glycoprotein [44],
and breast cancer resistance protein (BCRP) [5].
Morphological abnormalities in the cerebral mi-
crovasculature in AD include atrophy and irregulari-
ties of arterioles and capillaries, swelling and increased
number of pinocytic vesicles in endothelial cells, in-
crease in collagen IV, heparan sulfate proteoglycans
and laminin deposition in the basement membrane, dis-
ruption of the basement membrane, reduced total mi-
crovascular density and occasional swelling of astro-
cytic end feets [7]. An extensive degeneration of brain
microvascular endothelium was also demonstrated dur-
ing the disease progression in AD [45].
The morphological changes are accompanied by
functional alterations, microvascular segments directly
surrounded by amyloid plaques or representing cere-
bral amyloid angiopathy show increased permeability
to endogenous albumin [46]. The degree of AD can
influence these changes: in mild dementia the integri-
ty of the BBB can be well preserved, while it is dis-
turbed in a graded manner according to the progression
of dementia [47]. When Aβ1−42 is directly infused in-
to the carotid artery, it increased permeability to albu-
min in rats [13]. Using the AD model Tg2576 mice a
higher BBB permeability for albumin was measured in
cerebral cortex, which preceded senile plaque forma-
tion [14]. Even if extensive BBB damage or substantial
increases in BBB permeability in AD can not be found
in some animal studies [48] or clinical evaluations [49],
considering all available data focal and transient loss
of integrity of the BBB in AD seems probable [50].
Studies with Aβ on culture-based BBB models
BBB changes in AD were confirmed by experimental
data showing the effects of Aβ on cultured endothelial
cells. Aβ peptides inhibited the proliferation of brain
endothelial cells [2]. In addition, Aβ peptides exerted
toxic effects on both peripheral and cerebral microves-
sel endothelial cells. Aβ1−40 and Aβ25−35 peptide
treatments resulted in apoptosis in cultured pulmonary
endothelial cells, and elevated the monolayers’ albumin
permeability [15]. A similar toxicity was described in
RBE4 rat brain endothelial cell line [16]. Aβ1−40 and
Aβ1−42 peptides derived from rat and human amyloid,
alone or complexed with aluminum, decreased cell vi-
ability in rat brain endothelial cells between passage
3–4 [17,51]. Aggregates of Aβ1−40, and its muta-
tion Aβ1−40 E22Q (Dutch), as well as of Aβ1−42 and
Aβ25−35 were toxic to cultured human cerebrovascular
endothelial cells obtained from the brain of a victim
of AD [52]. The toxic effect of the Dutch Aβ pep-
tides on BBB is further supported by an in vivo study
showing that these mutant peptides are not cleared from
CSF [53]. The Akt [54], and protein kinase C [55]
signalling pathways, the RAGE [56] and the activa-
tion of caspase-8 [57] can participate in the decrease of
cell viability and apoptotic cascade induced by Aβ in
endothelial cells.
In our study, Aβ1−42 peptide induced remarkable ul-
trastructural alterations in primary rat brain endothelial
cells, which have not been described in the literature
earlier. In agreement with amyloid-induced changes
in brain microvessel morphology in pathological sam-
ples and animal studies [7,45] degeneration of the cells,
namely, dark cytoplasm, pronounced vacuolization, de-
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creased number of caveolae and Golgi, and shrunk-
en mitochondria could be observed after peptide treat-
ment. Irregular interendothelial contacts and junctions
with less kissing points were especially notable, indi-
cating an increased paracellular pathway. Cytoplasmic
vacuolization could be seen by both electron and phase
contrast microscopy. These toxic effects were also con-
firmed by reduced MTT dye reduction, and increased
LDH release indicating plasma membrane damage. In
the Aβ dose-range used in our experiments (10–200
µM) endothelial cell death did not exceed 20%. Both
Aβ1−40 and Aβ1−42 peptides exerted a similar toxic
effect to primary rat brain endothelial cells.
Aβ-induced permeability changes have been studied
only for Aβ1−40 and only in not co-cultured brain en-
dothelial cells so far and no data have been published on
pertinent co-culture in vitro BBB model yet. Aβ1−40 at
doses exceeding 5 µM increased the paracellular per-
meability in bovine brain endothelial cells [19]. It also
induced a marked elevation in the permeability for the
paracellular tracer 70 kDa FITC-dextran in an immor-
talized human brain endothelial cell line, hCMEC/D3
cells [58] and for the transcellular marker albumin in
human brain microvascular endothelial monolayers be-
tween passages 4–8 [20].
We have studied the effect of Aβ on several aspects
of the barrier function in BBB model of rat primary
brain endothelial cells, in which barrier properties were
induced by glial cells. Aβ1−42 decreased the resis-
tance and increased the permeability for markers flu-
orescein and albumin. The modulating effect of SAP
on Aβ in a BBB model was also demonstrated for the
first time. SAP, a serum protein belonging to the pen-
traxin protein family, participates in the regulation of
chromatin-induced autoimmunity and the immune de-
fense against bacterial infections due to its ability to
bind chromatin and bacterial lipopolysaccharides [59].
SAP treatment alone did not change brain endothelial
paracellular permeability or morphology. In a previous
in vivo study, when mice were injected with human
SAP no deleterious effect on paracellular permeability
was noticed [60]. Based on these observations, SAP
in physiological concentrations has no effect on brain
endothelial TJs. SAP avidly binds amyloid fibrils and
can be found in all types of amyloid depositions either
in the periphery or in the CNS [61]. While SAP is ab-
sent from the brain tissue in physiological conditions,
it is present in amyloid plaques and depositions around
brain vessels in AD and contributes to the stabilization
of Aβ fibrils [62]. In our experiments, SAP signifi-
cantly increased the damaging effect of Aβ on barrier
integrity of brain endothelial cells.
Since the paracellular barrier at the BBB is regulated
by TJ proteins [5,8,63,64] immunostaining for TJ pro-
teins was also investigated after Aβ treatment in brain
endothelial cells. Aβ led to fragmentation and loss
of junctional immunostaining for occludin, claudin-5
and ZO-1 in our model. These data are in agreement
with previous observations, where Aβ1−42 altered oc-
cludin, claudin-5 and ZO-2 TJ protein distribution and
expression [35], and Aβ1−40 resulted in relocalization
of ZO-1 [20] in rat and human brain endothelial cells,
respectively. Interestingly, a specific decrease of oc-
cludin but not of claudin-5 and ZO-1 was described in
an immortalized human brain endothelial cell line [58].
Our data indicate that Aβ1−40 and Aβ1−42 peptides
exerted a direct damaging effect on the morphology
and barrier integrity of brain endothelial cells which
could be aggravated by SAP. Using the same BBB
model we have recently confirmed the effect of hu-
man truncated tau protein, another pathological factor
in AD [65]. Truncated tau also impaired the barri-
er integrity, but this effect was indirect. Tau-induced
BBB damage was mediated by pro-inflammatory cy-
tokine tumor necrosis factor-α and chemokine mono-
cyte chemotactic protein-1 released from activated mi-
croglial cells. These observations indicate that while
both Aβ and truncated tau damage the BBB, the under-
lying mechanisms may be different [65].
Protection of BBB as a New Therapeutical Approach
in AD
AD, the most common form of degenerative demen-
tia, represents a huge unmet medical need. Although
AD had already been described about 100 years ago, at
present only few symptomatic treatment options exist
for the more than 25 million patients worldwide despite
continuous research efforts. Only two classes of medi-
cations have been approved by the US Food and Drug
Administration for the treatment of AD: cholinesterase
inhibitors for mild to moderate AD, and the noncom-
petitive NMDA receptor antagonist memantine for the
moderate to severe stages of AD [66].
BBB breakdown, due to disruption of the TJs, altered
transport of molecules at the BBB, aberrant angiogene-
sis, vessel regression, brain hypoperfusion, and inflam-
matory responses initiate and contribute to a “vicious
circle” of the disease process, resulting in progressive
synaptic and neuronal dysfunction and loss in AD [5,
67]. This current understanding places the neurovas-
cular unit at the epicenter of AD pathophysiology and
recognizes brain endothelial cells as new therapeuti-
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cal targets in AD [5,6]. Since previous therapeutical
attempts were focused on the prevention of neuronal
death there are a great number of experimental data on
the protection of neurons against the toxic effects of
Aβ [68]. In contrast, only few studies examined pro-
tective molecules in brain endothelial cells. Partial pro-
tection against Aβ25−35 peptide-induced cell damage
by carnosine, an endogenous antiglycating dipeptide
with free radical scavenging activity, homocarnosine
and β-alanine was described on a rat brain endothe-
lial cell line [16]. Simvastatin effectively blocked the
proinflammatory reactions induced by Aβ1−40 peptide
in a human brain endothelial cell line [69]. Taurour-
sodeoxycholic acid, an antiapoptotic endogenous bile
acid inhibited the apoptosis of human brain cerebral
endothelial cells triggered by the vasculotropic Aβ1−40
E22Q mutant peptide [70]. While apolipoprotein-E4
increased, apolipoprotein-E2 decreased the cytotoxic
effect of Aβ1−40 and Aβ1−42 pepides [71]. Recent-
ly, the JNK-AP1 signaling pathway [72], transcription
factors mesenchyme homebox gene 2 (MEOX-2) [5,
72], and serum response factor and myocardin [73]
have been identified as potential therapeutical targets
in brain endothelial cells in AD.
PPS, a drug of plant origin used clinically for a
long time, protected primary mouse cerebral endothe-
lial cells against prion peptide toxicity [3,22,23] and
attenuated both the permeability barrier impairment
and inhibition of P-glycoprotein in lipopolysaccharide-
exposed primary rat brain endothelial cells [24] in our
previous experiments.
PPS is excessively sulphated, has a high negative
charge density and a rod-like conformation; therefore
it competes more effectively with endogenous gly-
cosaminoglycans than most of the polyanions [74].
Since glycosaminoglycans are important regulators in
many biologically diverse processes, PPS has a wide
range of pharmacological effects [74,75]. It has long
been used in clinical practice as an anticoagulant [75],
and it is effective in the treatment of interstitial cysti-
tis [76], and osteoarthritis [77]. Experimental and clin-
ical data suggest that PPS may also have a therapeutic
efficacy in prion disease [78]. Because PPS does not
cross the BBB [79], endothelial cells of blood-nerve
and blood-brain barriers may be among the cellular
targets of PPS in the prevention of prion diseases in
vivo [22,23].
In our present and previous studies we demonstrated
for the first time that PPS did not change BBB param-
eters TEER, permeability or fluid phase endocytosis or
morphology in cultured brain endothelial cells [18,21,
23], but successfully attenuated the toxic effects of Aβ.
PPS also protected the barrier integrity of endothelial
monolayers treated with Aβ. The exact mode of action
of PPS at the BBB has not been elucidated yet.
In other cell types PPS inhibits a wide range of en-
zymes and biological modulators, like protein kinase
A, protein kinase C, tyrosine protein kinase in smooth
muscle cells [75], serine proteases, matrix metallopro-
teinases, lysosomal enzymes, coagulation factors, com-
plement factors and cytokines in chondrocytes [74]. In
peripheral endothelial cells PPS stimulates the release
of tissue-type plasminogen activator, superoxide dis-
mutase and lipase contributing to its efficacy in arthri-
tis [74]. The inhibition of serine proteases, matrix met-
alloproteinases and cytokines or increased levels of su-
peroxide dismutase could also contribute to the protec-
tion of the BBB; however other actions of PPS could
also be important.
Our previous and present surface plasmon resonance
and AFM data indicate for the first time that PPS can
directly interact with Aβ, and may have a physico-
chemical effect resulting in fewer adherences to the ex-
amined surfaces. This is in agreement with the only
study that examined the effect of PPS on the binding of
heparan sulfate glycosaminoglycans to Aβ [25]. PPS
was the most effective to displace heparan sulfate gly-
cosaminoglycans bound to Aβ. Since heparan sulfate
glycosaminoglycans are involved in Aβ aggregation
in vivo, sulfated polyanions, like PPS, can be useful
against amyloid deposition in AD brain [25].
Pentosan may exert multiple effects; some of these
could be cellular while others could be related to its
direct interaction with Aβ. The present results support
this dual mode of action and the endothelial protective
properties of PPS. Further experiments are needed to
fully map the mode of action of pentosan on brain
endothelial cells and on its direct interaction with Aβ.
In conclusion, pentosan can represent a new type of
molecule to protect brain endothelial cells in pathologi-
cal conditions, including Aβ toxicity, and to contribute
to the maintenance of brain homeostasis and prevention
of neuronal loss.
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Abstract: The blood-brain barrier (BBB) is a regulatory interface between the circulation and the central nervous system 
(CNS). Therapy of neurological diseases is limited due to restricted penetration of pharmacons across the BBB. Models 
for screening the brain penetration of drug candidates are needed early in drug discovery. Culture-based models are useful 
tools for both basic research on BBB, and testing the permeability of new therapeutical molecules. This review focuses on 
patented in vitro BBB models and their potential application in CNS drug discovery. Cell culture models using primary 
and immortalized brain endothelial cells of non-human and human origin, in co-culture or mono-culture setting, in static 
or dynamic conditions are discussed, as well as methods to induce BBB properties in such in vitro models. The aim of 
these models is to reproduce as many aspects as possible of the in vivo BBB. All models should show some elements of 
general endothelial and specific BBB properties, like physiologically realistic cell architecture, restrictive paracellular 
pathway, and functional expression of transport mechanisms. Though no “ideal in vitro BBB model” has been constructed 
yet, the currently available models provide valuable information on BBB permeability and are useful tools in CNS drug 
discovery. 
Keywords: Blood-brain barrier, brain endothelial cell, co-culture, in vitro blood-brain barrier model, model for CNS drug 
testing, prediction model for CNS permeability. 
INTRODUCTION 
 Endothelial cells lining the microvessels of the central 
nervous system (CNS) differ fundamentally from peripheral 
vascular endothelium both in their morphological and 
functional features including the regulation of the exchange 
of molecules and cells between the blood and the neural 
parenchyma. The blood-brain barrier (BBB) is constituted by 
brain capillaries, which possess specialized structural and 
functional characteristics. In humans, the estimated total 
length of cerebral capillaries is about 650 km and the total 
surface area is about 20 m2 [1, 2]. 
 Cerebral endothelial cells form the anatomical basis of 
the BBB. There is a dynamic interaction between brain 
endothelial and other neighboring cells, such as astroglia, 
pericytes, perivascular microglia, and neurons as depicted on 
Fig. (1). The cross-talk between these cells induce a unique 
BBB phenotype in endothelial cells including (i) a mor-
phological barrier based on interendothelial tight junctions 
(TJ) that markedly limit paracellular permeability, (ii) a 
unique pattern of receptors, transporters and drug efflux 
pumps, and (iii) enzymatic and metabolic barriers [3]. The 
three major functions of the BBB are the creation and 
maintenance of ionic homeostasis for neuronal functions, 
supply of the CNS with nutrients, and protection from toxic 
insults [4]. 
 
*Address correspondence to this author at the Laboratory of Molecular 
Neurobiology, Institute of Biophysics, Biological Research Centre of the 
Hungarian Academy of Sciences, Temesvári krt. 62, H-6726 Szeged, 
Hungary; Tel: +36 62 599602; Fax: +36 62 433133; E-mail: deli@brc.hu 
 By separating the brain from systemic circulation the 
BBB is the major entry gate for therapeutic compounds to 
the CNS. The low level of paracellular flux and transen-
dothelial vesicular trafficking results in a transport barrier for 
drugs which are hydrophilic and have a molecular mass 
bigger than 400 Da. Efflux pumps at the luminal membrane 
of brain endothelial cells limit the brain penetration of 
lipophilic xenobiotics and drugs [5]. These properties of the 
BBB and other factors contributing to the rate and extent of 
drug disposition within the brain prevent 98% of potential 
neuropharmaceuticals, especially new biopharmacons, 
nucleic acids, peptide or protein drugs, to reach therapeutical 
levels in the CNS [1, 6]. Despite efforts to increase drug 
delivery to brain through strategies to overcome the 
junctional or efflux barriers, to exploit BBB transport 
mechanisms or to circumvent the BBB [7], still the majority 
of newly developed neuropharmaceuticals fail due to poor 
CNS pharmacokinetics [2]. Therefore, the early screening of 
potential drug candidate molecules for brain penetration is a 
very important task in drug discovery and development. 
 BBB models have been widely used in pharmaceutical 
industry for testing the permeability of cerebral capillaries 
and investigating brain penetration. Cell culture-based 
models proved to be one of the most versatile tools in basic 
BBB research and also in testing CNS drug penetration [8]. 
In drug development, several sequential and parallel steps for 
screening BBB permeability are suggested [9]. Computa-
tional approaches to predict drug penetrability can be used to 
screen big compound libraries with the advantages of being 
quick and high throughput. Non-cell based in vitro models of 
permeability can further refine and specify penetration 
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properties. Epithelial cell line models offer better estimation 
of efflux transport of drug candidates, while brain endo-
thelial cell culture models mimic best BBB properties and 
complexity [2, 9]. Our main aim is to present a short over-
view on in vitro BBB models and to review patented BBB 
models that can be used as screening tools in CNS drug 
discovery. 
OVERVIEW OF IN VITRO BLOOD-BRAIN BARRIER 
MODELS 
 Viable cerebral microvessels isolated 40 years ago by 
Ferenc Joó and his co-workers can be considered as the first 
in vitro model of the BBB [10]. Studies on brain micro-
vessels opened a new era in BBB research and provided 
important data on cerebral endothelial receptors, transporters 
and signaling mechanisms [11,12]. Cerebral microvessels 
were also used to reveal the transcriptome and proteome of 
the BBB [13,14]. Despite of their versatility, isolated 
microvessels are not suitable for transcellular transport 
studies and cannot be recommended for drug screening [15]. 
 Just five years after the first isolation of cerebral 
microvessels, Panula and his colleagues observed endothelial 
cells growing out of brain capillaries in culture conditions 
[16]. Following this observation, several culture methods 
have been developed resulting in an increasing number of 
different BBB models, for review see [17,18]. The use of 
puromycin to selectively enrich brain endothelial cells and 
kill contaminating cell types in primary brain microvessel 
cultures was an important step to develop better BBB models 
[19, 20]. 
 Primary brain microvessel endothelial cells have been 
isolated from many species, including dog, cat, and gerbil, 
but well-characterized BBB models suitable for permeability 
experiments are prepared from bovine, human, mouse, 
porcine and rat endothelial cells as reviewed in [8, 17, 18, 
21]. The advantages of the bovine [22] and porcine [23] 
BBB models are the high yield of brain endothelial cells, 
tight paracellular barrier and good cost-effectiveness [18]. 
Human BBB models would be the best to screen drugs 
developed for human therapy. However, access to human 
brain tissue is difficult, the yield of cells from surgical 
samples is low, and available human models show weaker 
barrier properties than bovine or porcine models [18, 21]. It 
is also questionable whether brain tissue samples from auto-
psy or surgery could be considered suitable for physiological 
BBB models. Advantages of rat and mouse culture BBB 
models include the easy preparation of syngenic co-cultures, 
good comparison with data obtained by in vivo experiments, 
and the availability of transgenic and gene-targeted animals, 
and a wide range of antibodies [17, 18]. In case of rodent, 
especially of mouse, BBB models the cell yield is low, 
therefore they are mainly used in basic research [17, 18]. 
 Early studies applied monocultures of primary cerebral 
endothelial cells [16,24-27], but it turned out, that long-term 
cultivation and passages lead to the loss of barrier properties. 
The interaction between the cells of the neurovascular unit, 
brain endothelial cells, astroglia, pericytes and neurons Fig. 
(1) is crucial for the formation and maintenance of a 
functional BBB [4, 28]. The introduction of cell culture 
insert with porous membranes enabled the use of brain 
endothelial cells in co-culture with other cell types and thus 
the construction of the next generation of in vitro BBB 
models [12].  
 Astrocytes were the first to be recognized as regulators of 
brain endothelial characteristics and functions, for review see 
[4, 29]. Astrocytic endfeet covering the surface of brain 
capillaries allow both cross-talk between the two cell types 
and transport between blood and the neural tissue as it is 
shown on Fig. (1) [29]. It has been demonstrated that glial 
cells induce the development of TJs and barrier properties in 
cerebral endothelial cells, and both purified type-1 astrocytes 
and primary mixed glial cultures are efficient in the induc-
tion of BBB properties [21, 30, 31]. These results further 
supported the use of the co-culture of brain endothelial cells 
and astroglia, which became the most widespread type of 
 in vitro BBB model. In some models cells from different 
spe-cies are used, like the co-culture of bovine brain 
endothelial cells with rat glial cells [22]. Syngenic models 
were also developed using microvascular endothelial cells 
and astroglia from rat [19, 32], mouse [33], or human [34] 
brain. 
 A well-characterized bovine BBB model has been estab-
lished [22] and it was successfully used in the last 20 years 
as a permeability screen for CNS drugs [2]. The model, co-
culture of cloned and passaged bovine brain capillary 
endothelial cells with rat glia, shows good barrier properties 
 
 
 
 
 
 
 
Fig. (1). Drawing on the structure of the neurovascular unit. Brain endothelial cells and the tight junctions (TJ) between them constitute the 
anatomical basis of the blood-brain barrier. 
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and has been used for several permeability studies [22, 35, 
36]. Good correlations were obtained when the model was 
compared to other BBB models or in vivo data [37, 38]. A 
new version of the model uses 24-well format and a special 
inducing medium [39]. The largest number of data for 
compound permeability was published on this bovine BBB 
model [2, 18]. This model was not patented, and is used for 
pharmacological and toxicological evaluation of compounds 
by Cellial Technologies (Lens, France).  
 While the role of glial cells in the development of BBB 
properties has been extensively studied, for review see [21, 
29, 31], few data are available on the effect of neurons on the 
induction of BBB characteristics. Co-culture of a brain 
endothelial cell line with primary neurons induced BBB 
differentiation [40] and a similar effect was seen in the case 
of a brain slice culture [41]. Co-culture of endothelial cells in 
the presence of both neuronal and glial cells induced BBB 
characteristics in a brain endothelial cell line in a static 
model [42, 43] and in endothelial cells under dynamic 
conditions [44, 45].  
 Pericytes are the nearest neighbours of endothelial cells, 
and the two cell types share a common basal membrane in 
cerebral capillaries [46]. They participate in the develop-
ment, maintenance, and regulation of the BBB and have 
fundamental role in stabilizing brain capillary structure  
in vivo [28, 47, 48]. Pericytes are also able to tighten the 
paracellular barrier in cultured brain endothelial cells and to 
increase their BBB properties similarly to astrocytes [49, 
50].  
 Since primary cultures are expensive, time-consuming 
and need expertise, immortalized brain endothelial cell lines 
have been generated in growing number to overcome these 
difficulties and to establish easy, reproducible, and suffi-
ciently tight in vitro BBB models. Currently bovine, human, 
mouse, porcine and rat cell lines are available [18]. There are 
efforts to establish an ideal immortalized BBB model which 
could be applicable to high-throughput screening systems to 
estimate drug permeability across the BBB. Several brain 
endothelial cell lines were developed from human tissue, but 
only few of them were tested in permeability studies. Human 
brain endothelial cell lines are widely applied in basic 
research, mostly in infectological studies with human patho-
gens [8, 21]. The paracellular barrier properties of mono-
layers from these human cell lines are rather weak, even 
compared to cell lines from other species [18, 21]. 
 The pharmaceutical industry needs simple, reliable,  
in vitro BBB models for predicting the brain penetrability of 
CNS drugs. A model to serve as a permeability screen should 
display (i) a physiologically realistic cell architecture, (ii) a 
restrictive paracellular pathway, (iii) functional expression of 
transporter mechanisms and (iv) ease of culture to facilitate 
drug screening [51]. The aim of any model is to reproduce as 
many aspects as possible of the in vivo BBB.  
 All models should show some elements of general 
endothelial and specific BBB properties [18]. The adjacent 
cells should possess endothelial morphology, like growing in 
monolayer and having tight interendothelial junctions bet-
ween overlapping plasmamembranes. Expression and typical 
pericellular localization of integral membrane TJ proteins, 
such as occludin, junctional adherent molecules (JAM), 
endothelial cell-specific adhesion molecule (ESAM), and 
claudin-3, -5 contribute to the maintenance of the restrictive 
paracellular pathway of the BBB. Absence of fenestration 
and low number of pinocytotic vesicles are also important 
elements of the physiological barrier [52]. 
 The tightness of the paracellular barrier is a fundamental 
property of BBB, which prevents hydrophilic molecules and 
even ions and water to enter freely the CNS [28]. One of the 
most direct methods to determine the tightness of a model is 
the measurement of transendothelial electrical resistance 
(TEER) [21]. The TEER of brain parenchymal microvessels 
in vivo exceeds 1000 ? [53]. Commercially available Volt-
Ohm resistance meters (World Precision Instruments, 
Millipore) and custom devices with “chopstick”, chamber 
type or needle electrodes can be used as TEER measurement 
systems, which give different background resistance values 
and enable repeated measurements or continuous monitoring 
[21]. Special culture conditions, like in the case of the 
dynamic BBB model, need custom TEER measurement 
systems [54], but it is difficult to compare results obtained 
by different devices [21]. BBB models should reach a tight-
ness of at least 150-200 ??cm2 to study the permeability or 
transport of molecules [8, 18, 21, 55]. Another way to assess 
the integrity of the paracellular barrier is the measurement of 
passive flux of small hydrophilic tracers across monolayers. 
The endothelial or apparent permeability coefficients (Pe or 
Papp) are important parameters of the quality of BBB models 
[18, 21]. The in vivo Papp of sucrose, a marker of passive 
permeability, is 3?10-7 cm/s [37]. The barrier properties of 
different BBB models can be compared by TEER and Pe 
values, which in case of the best in vitro models can 
approach the values measured in vivo [18, 21]. 
 The polarized expression of transporters, receptors and 
enzymes at either the luminal or abluminal cell surface is a 
crucial aspect of models used for drug screening. Saturable, 
bi-directional transport systems exist for nutrients, vitamins 
and minerals at the BBB [28, 52, 56]. About 40 members of 
the solute carrier (SLC) transporter family were identified in 
brain microvessels [13]. Efflux pumps protect the brain from 
xenobiotics, but they are also responsible for restricting the 
penetration of many therapeutical molecules to brain. The 
primary efflux pumps at the BBB belong to the ATP-binding 
cassette (ABC) transporter family [5]. The presence of the 
most important carriers supplying the CNS with glucose, 
ketons or amino acids, like glucose transporter 1 (GLUT1), 
monocarboxylic acid transporter 1 (MCT1), large neutral 
amino acid transporter (LAT1), and the primary efflux 
pumps, e.g. P-glycoprotein (ABCB1), breast cancer resis-
tance protein (ABCG2) and multidrug resistance proteins 
(ABCC family) should be verified in BBB models [56]. In 
addition, elements of the metabolic barrier, such as alkaline 
phosphatase, ?-glutamyl transpeptidase, monoamine oxi-
dases or cytochrome P450 enzymes should be also expressed 
on BBB models. 
 Furthermore, an ideal in vitro model should not only 
show BBB characteristics, it also needs to be simple to use, 
reproducible, cost-effective and applicable for medium or 
high throughput screening. Unfortunately, none of the 
available model fulfills all the above mentioned criteria, but 
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models expressing the most critical features of the BBB can 
provide valuable information on BBB permeability and be 
useful tools in CNS drug discovery. 
PATENTED IN VITRO BLOOD-BRAIN BARRIER 
MODELS 
 Eight in vitro BBB models patented between 1990 and 
2010 and their important features are summarized in Table 1 
[57-64]. The characteristics, advantage, disadvantage and 
application of these models will be discussed. 
1. PRIMARY CULTURE BASED BBB MODELS 
1.1. Brain Endothelial Cells in Co-culture with 
Astrocytes 
 The BBB model patented by Rubin et al. [57] is based on 
the culture of an essentially confluent monolayer of brain 
microvascular endothelial cells from any vertebrate species 
on porous solid support in the presence of endothelial- or 
astrocyte-derived conditioned medium, or the co-culture of 
these monolayers on porous solid support, which enables the 
communication with the astrocytes at the lower compartment 
Fig. (2) [57, 65, 66]. The major novelty of the patent is that 
endothelial cells are grown in contact with agents elevating 
cyclic AMP (cAMP) concentration in these cells leading to 
increased barrier function. This aspect of the model will be 
discussed in section 3.1. 
 
 
 
 
 
 
 
 
 
 
Fig. (2). BBB model based on co-culture of brain endothelial and 
astroglial cells or cell lines using inserts with porous membrane. 
1.2. Brain Endothelial Cells in Triple Culture with 
Astrocytes and Pericytes  
 In the triple culture model described in the patent by 
Niwa et al. [58] endothelial cells are grown in the presence 
of both astrocytes and pericytes Fig. (3), so a synergetic 
effect on the induction of BBB properties can be observed. 
The model closely mimics the anatomical position of the 
cells at the BBB in vivo. Primary cultured rat brain micro-
vascular endothelial cells are seeded onto the upper surface 
of the filter while pericytes grow on the opposite surface of 
the filter sharing a common membrane as in vivo. Primary 
astrocytes are placed at the bottom of the well Fig. (3). The 
permeable membrane of the inserts enables a bidirectional 
communication between the cells by exchanging soluble 
factors in both directions leading to the induction of good  
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). BBB model based on co-culture of brain endothelial, brain 
pericyte and astroglial cells using inserts with porous membrane. 
The triple co-culture model mimics the in vivo anatomical structure 
of the BBB. 
 
BBB properties. In the presence of both pericytes and 
astrocytes rat brain endothelial cells expressed enhanced 
levels of TJ proteins occludin, claudin-5 and ZO-1 [50]. The 
barrier function of the monolayers was elevated as measured 
by higher TEER and lower Pe for marker molecules [49, 50]. 
Brain endothelial cells in this new model expressed glucose 
transporter-1, efflux transporters P-glycoprotein and multi-
drug resistance protein-1, and showed a polarized transport 
of rhodamine 123, a ligand for P-glycoprotein. Drug permea-
bility assays were performed using a set of 19 compounds 
with known in vivo BBB permeability and good correlation 
(R2=0.89) was found between in vitro Pe values obtained 
from measurements on the BBB model and in vivo BBB 
permeability data [50]. 
 This BBB model is intended to provide a screening 
system for centrally acting drugs transported across the BBB, 
drugs acting on brain endothelial cells, and peripheral acting 
drugs to exclude brain penetration and potential side effects. 
Furthermore, the model is suitable to study BBB pathology 
in neurological diseases by testing pathogenetic factors/ 
conditions, and cellular changes and drug transport in 
pathological conditions.  
 The advantages of the model are that it is made from 
primary cultures, has good barrier properties, and mimicks 
the anatomical situation in vivo. The model is used for 
primary research in different laboratories, for example the 
effect of oxygen-glucose deprivation was tested on ectonuc-
leotidase activity in the cells of the BBB [67]. However, 
development of such a complex model in a laboratory can be 
time-consuming and needs expertise. To solve these 
problems a patented frozen ready-to-use kit version of the 
model [68] was prepared by PharmaCo-Cell Co. Ltd. 
(Nagasaki, Japan) which is commercially available. The 
three types of cells are seeded in the appropriate compart-
ments and surfaces of the porous inserts and the culture plate 
Fig. (3), and are frozen in situ using a cryoprotecting 
medium. After storage and delivery of the frozen model, 
cells are thawed and after four days in culture the model is 
ready for experiments [68]. The BBB kit has been success-
fully used in drug discovery to measure the permeability of 
different alkaloids in vitro [69]. 
In Vitro Blood-Brain Barrier Models Recent Patents on CNS Drug Discovery, 2011, Vol. 6, No. 2    111 
 Recently, a monkey triple co-culture BBB model was 
developed by the same group, in which brain microvascular 
endothelial cells from Macaca irus are cultured together with 
rat pericytes and astrocytes [70]. The model shows 
morphological and functional characteristics similar to the 
patented rat BBB model, and there is a good correlation 
between permeability data obtained on the two BBB models. 
1.3. Brain Endothelial Cells in Co-culture with Neural 
Progenitor Cells 
 During the embryogenesis angiogenic vessels invade the 
immature neural environment and begin establishing BBB 
characteristics well in advance of the onset of gliogenesis 
[71, 72]. The BBB development begins prenatally and is 
followed by a gradual maturation to full BBB function in 
which the influence of both neuronal precursors and glial 
cells takes part. In direct contact culture condition, endo-
thelial cells regulate neuronal precursor cell differentiation, 
proliferation, and quiescence showing mutual influence 
between them [73, 74]. Differentiating embryonic neural 
progenitor cells were shown to be able to induce BBB 
properties [75, 76]. 
 Based on this knowledge a BBB model using co-culture 
of primary brain microvascular endothelial cells or 
embryonic stem cell-derived endothelial cells with neural 
progenitor cells (NPC) Fig. (4) was disclosed [59]. After a 
few days the cultured NPC differentiate into mixtures of 
astrocytes, neurons, and oligodendrocytes and a multicellular 
BBB model is created, where barrier properties are enhanced 
in endothelial cells [75]. The inventors claim that the model 
more accurately predicts in vivo behavior than current 
models, it is reproducible and reliable and less labor inten-
sive. Because embryonic NPCs are easily isolated and 
expand rapidly, a large relatively homogeneous cell stock 
can be obtained. NPCs survive cryopreservation, making 
possible multiple uses of the same NPC stock over a long 
period of time. The relative percentages of neurons and 
astrocytes differentiated from NPCs can be controlled to 
create designer mixtures of brain cells that can be co-
cultured with the brain endothelial cells [59]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). BBB model based on co-culture of brain endothelial cells 
grown on inserts with porous membrane and neural progenitor cells 
that can differentiate into a mixture of astroglia, neurons and 
oligodendroglia. 
 The model is described to be suitable for testing potential 
drug candidates in a multicellular environment with the 
contribution of perivascular non-endothelial cells in the local 
microenvironment. However, since the recent publication of 
the patent no further application of the model for CNS drug 
testing is known. 
2. CELL LINE BASED BBB MODELS 
 Immortalized cell lines could serve as simple and non-
expensive tools for CNS drug delivery and discovery 
research. 
2.1 Bovine Cell Line 
 The only patented bovine cell line, TBMEC P11, was 
made by transfecting the cells with a vector containing the 
entire coding region of virus middle-T antigen gene [60]. 
According to the inventor this cell line shows substantial 
impermeability to small substances imparted by their ability 
to form confluent monolayers. It is claimed that TBMEC 
P11 cell line was tested for 39 low molecular weight hydro-
philic and lipophilic pharmaceuticals and other chemicals 
and according to the permeability data this cell line is 
appropriate for drug permeability tests.  
 The general disadvantage of immortalized endothelial 
cells, the low paracellular permeability, can be seen in the 
case of this cell line, too. The permeability for sucrose, a 
paracellular marker is ten times higher than for primary cell 
based BBB models Table 1. There are no scientific publi-
cations on the model and no commercial or other application 
of the model for CNS drug testing is known. 
2.2 Rat Cell Line 
 Several immortalized rat cerebral endothelial cell lines 
were prepared but only few of them were tested in 
permeability assays. One of the cell lines applicable for drug 
screening is the conditionally immortalized BBB model 
prepared by cocultivating cerebral capillary endothelial cell 
line TR-BBB and astrocyte cell line originating from a 
transgenic rat transfected by large T antigen gene from the 
temperature-sensitive mutant SV 40 tsA58 [61]. The cells 
acquire immortalized characteristics if they are cultured at 
33°C because the temperature-sensitive SV40 large T-
antigen gene product is activated only at this temperature. 
However shifting the culture temperature to 37°C the SV40 
large T-antigen is inactivated and the cell growth is repressed 
or arrested. Therefore, these cells are conditionally immortal 
which is one of the biggest advantages of the model. As 
large T-antigen interacts with many kinds of protein, 
including Rb protein and p53, these interactions would affect 
cell functions by drug effect screening studies without the 
inactivation facilities [77, 78]. The conditionally immor-
talized endothelial cells express several BBB transporters 
and give a good correlation with in vivo permeability data for 
six selected compounds although they do not form rigid TJs 
[79, 80]. The expression of TJ proteins, such as claudin-5, 
occludin and junctional adhesion molecule [79, 80], might be 
down-regulated in this cell line due to the transfection.  
 In summary, the conditionally immortalized BBB model 
is suitable to investigate regulation of BBB functions, 
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especially transporter functions and can help to understand 
drug distribution under pathophysiologic conditions, such as 
brain edema and inflammation [81]. The TR-BBB cell line is 
mainly used in primary research, and nineteen scientific 
studies have been published since 2001, but application of 
the model for CNS drug testing or screening is not known. 
2.3 Human Cell Line 
 The first stable, well characterized human brain 
endothelial cell line, hCMEC/D3 was patented in 2006 [62]. 
It shows several endothelial and BBB characteristics, 
including chemokine receptors, TJ proteins and drug efflux 
mechanisms [82]. It is claimed that the cell line retains many 
of the morphological and functional characteristics of brain 
endothelial cells, and expresses the major BBB efflux pumps 
[83-85] and several carriers from the SLC transporter family 
[86]. hCMEC/D3 cell layers in mono-culture show moderate 
paracellular barrier properties, see Table 1 [82]. When 
hCMEC/D3 cells were maintained in a dynamic system, the 
paracellular barrier properties were significantly improved 
and a high TEER value exceeding 1000 ??cm2 was 
achieved [54]. It should be noted, that these TEER values 
were measured by a newly developed device (Flocel Inc., 
Cleveland, USA), which allows for real-time measurements 
in the cell culture cartridges of the dynamic model [54]. The 
permeability of the cell line was tested for 5 drugs and 
markers in static condition [82, 83] and for two antiepileptic 
drugs in dynamic condition [54].  
 The two main advantages of hCMEC/D3 cell line are that 
it is a human cell line and has become the most widely used 
brain endothelial cell line in BBB research since 2005. The 
published data demonstrate that hCMEC/D3 cell line 
constitutes a valuable in vitro BBB model, which mimics the 
restricted permeability of brain endothelium for a wide 
variety of compounds, except for small hydrophilic mole-
cules (< 300 Da) and ions. Permeability of centrally acting 
drugs, liposomes and solid lipid nanoparticles was also tested 
on the model [87-90]. Commercial application of the cell 
line for drug testing is not known.  
3. FACTORS AND CULTURE CONDITIONS 
INCREASING BBB PROPERTIES OF IN VITRO 
MODELS 
 The unique BBB phenotype of brain endothelial cells is 
the result of continuous influence from the surrounding 
nervous tissue, although the details of this induction and the 
exact signalling mechanisms are still unclear [21, 28]. 
Besides co-culture with different cell types, several other 
culture conditions and factors, like sera, and serum compo-
nents, hormones and growth factors, lipids, lipid mediators 
and lipoproteins have been tested to induce complex BBB 
Table 1. Patented In Vitro BBB Models and Their Parameters. 
Patent Number Major Novelty Cell Types BBB Quality Parameters Ref. 
WO9105038 
(1991) 
BBB model tightened by cAMP 
signaling 
2 Cell types: primary brain endothelial cells and 
astrocytes  
TEER > 200 ?xcm2 [57] 
WO2007072953 
(2007) 
Triple co-culture, mimicking the 
anatomical structure of the BBB 
3 Cell types: primary brain endothelial cells, 
astrocytes, and brain pericytes 
TEER = 350-600 ?xcm2 
Pe sucrose = 1.14x10-6 cm/s 
Pe fluorescein = 2.48x10-6 cm/s 
[58] 
US2008044847 
(2008) 
Multicellular BBB model 
2 Cell types: primary brain or embryonic stem 
cell derived endothelial cells and neural 
progenitor cells 
TEER = 100-250 ?xcm2 [59] 
WO0031240 
(2000) 
Immortalized brain endothelial 
line 
Monolayer of immortalized bovine brain 
endothelial cell line (TBMEC) 
Pe sucrose = 26x10-6 cm/s [60] 
WO0164849 
(2001) 
Co-culture of conditionally 
immortalized cell lines 
2 Cell types: temperature sensitive immortalized 
rat brain endothelial cell line, temperature 
sensitive immortalized rat astrocyte cell line 
(TR-BBB) 
TEER = 106 ?xcm2 [61] 
WO2006056879 
(2006) 
Human BBB model 
Monolayer of human brain endothelial cell line 
(hCMEC/D3) 
TEER = 40 ?xcm2 
Pe sucrose = 27.57x10-6 cm/s 
Pe fluorescein = 6x10-6 cm/s 
[62] 
WO2010014622 
(2010) 
BBB model tightened by Wnt/?-
catenin signaling 
Monolayer of mouse primary or immortalized 
endothelial cells (H5V) 
ND [63] 
WO03025206 
(2003) 
Dynamic BBB model 
2 Cell types: co-culture of brain endothelial 
cells and astrocytes under luminal flow 
condition 
ND [64] 
Abbreviations: ND, no data; TEER, transendothelial electrical resistance; Pe, endothelial permeability coefficient 
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phenotype and tighten paracellular barrier in BBB models 
[21]. Three of these treatment modalities were patented. 
3.1. Cyclic AMP Pathway 
 Although previous studies were performed with second 
messenger systems to regulate BBB transport using in vivo 
and isolated brain capillary models, for review see Joó [12], 
Rubin et al. [57, 65] were the first to describe the effect of 
intracellular cAMP elevation on the barrier function of 
cultured brain endothelial cells. Increased cAMP in bovine 
brain endothelial cells either in co-culture with astrocytes or 
treated with astrocyte-conditioned medium resulted in a 
barrier tightening measured by 7-fold higher TEER. In the 
patent, agents which can increase intraendothelial cAMP, 
namely cAMP analogs, compounds that stimulate endo-
genous adenylate cyclase activity, or compounds that inhibit 
the activity of cAMP phosphodiesterase (PDE) thereby 
inhibiting cAMP degradation were examined on cultures of 
endothelial cells [57]. The cAMP analog 8-(4-chlorophenyl-
thio) cAMP (CPT-cAMP), forskolin, a cell-permeable 
adenylate cyclase activator, the PDE inhibitor 4-(3-butoxy-4-
methoxybenzyl)-2-imidazolidinone (RO-20-1724), and 
isoproterenol, a selective ?-adrenergic agonist that stimulates 
adenylate cyclase activity and activates mitogen-activated 
protein (MAP) kinases all raised brain endothelial TEER [57, 
65, 66]. The effect of forskolin on brain endothelial cells was 
also confirmed by other studies [91, 92]. Calcitonin gene-
related peptide and parathyroid hormone [65] and 
adrenomedullin [32, 93] also clearly demonstrated a cAMP-
like effect. The permeability decreasing effect of cAMP 
analogs was more pronounced in the presence of PDE 
inhibitors theophylline, methylisobutylxanthine, rolipram, or 
RO-20-1724 [57]. Elevated intracellular cAMP levels 
resulted in barrier tightening and decreased paracellular flux 
in all BBB models tested, for review see [21]. 
 The inventors claimed that the mode of action of cAMP 
analogs is the activation of protein kinases and protein 
phosphorylation Fig. (5A), and that the effects of cAMP are 
reversed by phosphoprotein phosphatases [57]. This finding 
is also supported by the quick effect of cAMP on brain 
endothelial permeability [94]. The integral membrane TJ 
proteins [95] were discovered after the issue of the patent, 
therefore they could not have been investigated at that time. 
Since then a protein kinase A independent cAMP-induced 
pathway has been identified to increase claudin-5 expression, 
the most important occluding TJ protein at the BBB [93, 96]. 
The freeze fracture electron microscopy results of Wolburg 
et al. [97] confirmed that an increased TJ strand formation 
between brain endothelial cells contribute to the effect of 
cAMP on paracellular permeability. 
 Importantly, the other regulatory cyclic nucleotide, cyclic 
GMP (cGMP) has an opposite effect than cAMP [57]. It has 
been discovered that increasing cGMP concentrations in 
brain endothelial cells lead to a decrease in resistance, and 
thus to an increase in TJ permeability [65, 98]. 
 The application of cAMP elevation to induce barrier 
properties in BBB models became a widely used method in 
primary research [17, 19, 20]. However, such a model 
presents a problem in the screening of drugs that may 
influence intracellular cyclic nucleotides. 
3.2. Wnt/?-catenin Signaling Pathway  
 One of the major pathways regulating brain development 
is the wingless (Wnt) pathway, acting via ?-catenin 
stabilization [99]. This favors translocation of ?-catenin to 
the nucleus, binding to transcription factors of the lymphoid 
enhancer factor/T-cell factor (Lef/TCF) family and modu-
lating gene transcription [100]. Dejana, Liebner and co-
workers have found that endothelial Wnt/?-catenin signaling 
regulates induction and maintenance of BBB characteristics 
during brain angiogenesis and postnatal vascular maturation 
[63, 101]. This signaling pathway can upregulate BBB-
related genes, like TJ protein claudin-3 and barrier-related 
transporters, in endothelial cells Fig. (5B), whereas permea-
bility-related genes, such as plasmalemma vesicle-associated 
protein (Plvap1), are down regulated [102]. Loss of ?-catenin 
or inhibition of its signaling abrogates this effect causing 
down-regulation of claudin-3, an increase in Plvap1 and 
BBB breakdown [101]. 
 Based on this knowledge, Dejana and Liebner have 
patented the method to tighten TJ between cultured brain 
endothelial cells via the Wnt/?-catenin signaling [63]. 
Stabilization of ?-catenin in primary or in H5V immortalized 
mouse brain endothelial cells increases claudin-3 expression, 
TJ formation and a gene signature characteristic to BBB. 
Agents that stabilize ?-catenin or inhibit its degradation 
activate Wnt/?-catenin signaling. Such an agent can be a 
Wnt protein (Wntl, Wnt3, Wnt3a, and Wnt7a), or an agonist 
specific for Wnt/?-catenin signaling, or an inhibitor of 
glycogen synthase kinase 3 (GSK3), such as lithium [63]. 
 The Wnt/?-catenin signaling pathway is a novel method 
to increase barrier functions in BBB models and shows a 
great potential [103]. However, further experiments and 
results are needed to reveal its applicability for models to test 
CNS drugs. A potential disadvantage of the method could be 
that it might not be suitable to screen neuropharmacon 
candidates interfering with the Wnt/?-catenin signaling 
pathway. 
3.3. Fluid-induced Shear Stress 
 In contrast to the static environment in standard culture 
conditions, blood vessels are exposed to fluid-induced shear 
and circumferential stresses in vivo. While all the above-
mentioned in vitro BBB models are static, a new dynamic 
BBB model has been developed by the group of Janigro [64, 
104-107]. This model has a 3-dimensional tube structure 
with a continuous flow of culture medium mimicking the 
physiological shear stress in blood vessels Fig. (6). The 
dynamic BBB model was prepared by using different types 
of mono- and co-cultures, e.g. rat brain endothelial cells and 
rat astrocytes [45, 106, 107], human brain endothelial cells 
[108], and hCMEC/D3 immortalized human brain 
endothelial cell line [54] and the barrier and permeability 
properties were characterized. In the dynamic BBB model 
flow upregulated the barrier functions in all endothelial cell 
types [17]. 
 A device to prepare such a dynamic BBB model was 
patented in 2003 [64]. The goal of the model is to better 
reproduce the physiological conditions found in vivo and to 
reintroduce important BBB properties in brain endothelial 
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cells. The aim of the invention was to address the limitations 
of a commercially available cell culture device not desig-
nated for BBB application and add functionality, modularity, 
and expandability of the experimental configuration. The 
dynamic model is monitored by a TEER measurement 
system (Flocel Inc., Cleveland, USA). Four electrodes are 
positioned in the culture cartridges, one pair in the luminal 
and one pair in the abluminal compartments that connect to a 
computerized monitoring system [54]. 
 The major advantage of the arrangement is that it is more 
similar to in vivo conditions than static models. Due to the 
complexity of dynamic model, however, static models 
remain much more widespread both in primary and in 
applied research. The model is used by Flocel Inc., a 
company that does business in the field of cerebrovascular 
and BBB research. 
CURRENT & FUTURE DEVELOPMENTS 
 The increasing prevalence of CNS disorders and the 
introduction of new centrally active pharmacons and 
biomolecules need the prediction of brain penetration and 
BBB permeability. There is a demand for efficient and inex-
pensive in vitro BBB models to screen novel drug candidates 
that can be adapted as high throughput systems. The present 
BBB models will be further refined to achieve this goal.  
 Due to the requirement that a reliable model should 
present anatomically and physiologically realistic cell 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Signaling pathways that lead to the tightening of the intercellular tight junctions (TJ) of brain endothelial cells. (A) Signaling 
pathways of cyclic AMP (cAMP) increase the tightness of brain endothelial cell monolayers via the activated expression of the claudin-5 
gene in a protein kinase A (PKA)-independent manner and the cAMP-induced phosphorylation of claudin-5 and myosin light chain through a 
PKA-dependent way. (B) The activation of the Wnt pathway leads to the stabilization of ?-catenin via the inhibition of glycogen synthase 
kinase 3 (GSK3). Translocation of ?-catenin to the nucleus results in the activation of T-cell factor (TCF) dependent gene transcription of 
claudins, which in turn enhance the barrier function. Abbreviations: AJ, adherens junction; FZD, Wnt ligand receptor Frizzled; H-89, 
inhibitor of PKA; JAM, junctional adhesion molecule; LRP5/6, Wnt ligand receptor LDL receptor related protein 5/6. Figure modified from 
Refs. [95] and [102]. 
 
 
 
 
 
 
 
 
Fig. (6). A dynamic BBB model based on co-culture of brain endothelial and astroglial cells or cell lines using a device with porous 
membrane and flow condition to induce physiological BBB properties by shear stress. 
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architecture, non-brain endothelial models will be replaced 
by systems using brain endothelial cells in co-culture with 
other elements of the neurovascular unit.  
 The introduction of new miniaturized microfluidic bio-
chips in endothelial research will certainly enter the field of 
BBB models, too. Other important advances in cell culture 
based research are the optical and impedance-based real-time 
label-free measurements of cell changes, which could be 
combined with the present in vitro BBB systems in the 
future. Such future models may provide real-time tracking of 
TEER, optical monitoring of cell morphology with parallel 
measurement of permeability. 
 CNS penetration is multifaceted and is determined by 
three major parameters of drug delivery to brain, the 
permeability clearance to brain, the concentration ratio of 
unbound drug in brain to blood and the intra-brain 
distribution [6]. To estimate the rate and extent of drug 
disposition within the CNS an integrated approach is needed, 
where additional factors, such as plasma and brain tissue 
binding, brain interstitial fluid dynamics and plasma profile 
are also taken into account [6, 8]. Therefore, a combination 
of different in vivo and in vitro methods, including the 
presented in vitro BBB models is suggested for estimating 
brain drug delivery. 
 Since species differences exist in the transport proteins of 
the BBB [109] and in pharmacokinetic parameters [110], 
monkey and human models are valuable and important for 
further development. Despite research efforts a simple, cost-
effective, validated human BBB cell culture model is not yet 
available for drug screening. The use of human pluripotent 
stem cells may provide breakthrough in this field. Our 
present knowledge on the permeability of the human BBB 
for different drugs is very limited and is mostly based on 
studies using positron emission tomography (PET) and 
single photon emission computed tomography. There are 
only a few papers with correlations between permeability 
data obtained on human in vitro BBB models and by PET 
imaging [111]. Novel techniques like near infrared optical 
tomography will lead to the accumulation of data on human 
BBB and will permit better and more relevant correlations 
between clinical data and in vitro models. It is expected, that 
in vitro models with parameters more closely matching the in 
vivo BBB will be developed in the near future that can 
provide more accurate and valuable data for CNS drug 
discovery than the present ones. 
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Abstract. Alzheimer’s disease (AD) is characterized by the accumulation of amyloid- peptides (A) as perivascular deposits
and senile plaques in the brain. The intake of the polyunsaturated fatty acid docosahexaenoic acid (DHA) has been associated
with decreased amyloid deposition and reduced risk in AD in several epidemiological trials; however the exact underlying
molecular mechanism remains to be elucidated. The aim of the study was to test whether DHA can exert a direct protective
effect on the elements of the neurovascular unit, such as neurons, glial cells, brain endothelial cells, and pericytes, treated with
A42 (15M). A dose-dependent high cellular toxicity was found in viability assays in all cell types and on acute hippocampal
slices after treatment with A42 small oligomers prepared in situ from an isopeptide precursor. The cell morphology also
changed dramatically in all cell types. In brain endothelial cells, damaged barrier function and increased para- and transcellular
permeability were observed after peptide treatment. The production of reactive oxygen species was elevated in pericytes and
endothelial and glial cells. DHA (30M) significantly decreased the A42-induced toxic effects in all cell types measured by
viability assays, and protected the barrier integrity and functions of brain endothelial cells. DHA also decreased the elevated
rhodamine 123 accumulation in brain endothelial cells pre-treated with A42 indicating an effect on efflux pump activity. These
results indicate for the first time that DHA can protect not only neurons but also the other elements of the neurovascular unit
from the toxic effects of A42 and this effect may be beneficial in AD.
Keywords: Alzheimer’s disease, amyloid-, blood-brain barrier, brain endothelial cells, docosahexaenoic acid, glia, neuron,
neurovascular unit, pericyte, P-glycoprotein
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INTRODUCTION
Neurons and their associated glial cells interacting
with endothelial cells and pericytes of brain microves-
sels are organized into well-structured neurovascular
units. The proper function of this unit is responsible
not only for the neuronal activity dependent oxy-
gen and nutrient supply of the brain, but also for
ISSN 1387-2877/13/$27.50 © 2013 – IOS Press and the authors. All rights reserved
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neuro-hemodynamic coupling, neuro-angiogenic cou-
pling, and neuro-trophic coupling [1]. Neurovascular
mechanisms play a crucial role in cognitive decline and
neurodegeneration in Alzheimer’s disease (AD) [2–6].
Cerebral amyloid angiopathy and senile plaques are
two of the pathological hallmarks in brains of patients
with AD. The major component of amyloid deposition
is the amyloid- peptide (A), cleaved from amyloid-
 protein precursor by secretases. The dysfunction of
the cerebral circulation induces decreased clearance
of A across the blood-brain barrier (BBB) formed by
brain microvascular endothelial cells and pericytes. In
addition to production of the peptide, transport of A
across the BBB is essential in controlling A levels
in the brain [7, 8]. The dysfunction of the cerebrovas-
cular system leads to disturbed homeostasis, neuronal
dysfunction, and secondary neuronal loss [2, 4, 6]. Pro-
tection of the neurovascular unit from injury is among
the proposed new strategies for the therapy of AD
[1].
Epidemiological observations suggest that high
unsaturated fatty acid intake has been associated with
decreased risk of dementia [9–12]. In particular long-
chain polyunsaturated -3 fatty acids (n-3 PUFAs)
found in marine fish have become of major interest.
Docosahexaenoic acid (DHA), the end product of n-3
PUFA synthesis, is essential for brain maturation and as
an important membrane component it plays a primary
role in neurotransmission. DHA is responsible for the
neuroprotective action on developing cholinergic neu-
rons against glutamate cytotoxicity [13]. A reduced
level of DHA was found in AD patients [14] and in AD
postmortem brains [15] compared with age-matched
healthy controls. DHA reduces A42 peptide produc-
tion in animal models of AD [16, 17] and chronic
DHA treatment improves cognition in 3xTG-AD mice
[18]. However clinical studies found no effect or only
minor effects of DHA on the improvement of cognitive
functions in the very early stage of the disease [19–22].
Based on these data, DHA can be potentially impor-
tant in the prevention of AD, however there are no
data on its effect on the cells of the neurovascular unit,
except neurons [23–25], and its mechanism of action
against A42 peptide toxicity. Therefore the aim of the
present study was to test the effect of DHA not only
on neurons, but also on other important elements of
neurovascular unit, such as glial cells, brain endothe-
lial cells, and pericytes. In addition, BBB functions
and reactive oxygen species (ROS) production were
also tested on a relevant in vitro BBB model made
from primary rat brain endothelial cells, glial cells, and
pericytes [26, 27].
MATERIALS AND METHODS
All reagents were purchased from Sigma-Aldrich,
Hungary, unless otherwise indicated.
Synthesis of ‘iso-Aβ42’ and characterization of
oligomers
The synthesis of ‘iso-A42’ was discussed in details
by Bozso et al. [28]. Briefly the peptide was syn-
thesized using Boc-chemistry on a Boc-Ala-PAM
resin. Acylation of the -amino groups was done
by activating threefold excess of N - Boc protected
amino acids (or 2-Cl-Z-Ser(OtBu)-OH for position
26) with DCC/1-hydroxybenzotriazole in DCM/DMF
(dichloromethane-dimethyl formamide, 1 : 1) and the
peptide resin was reacted with this mixture for 2 h.
If incomplete acylation was detected by the qual-
itative ninhydrin test, the coupling was repeated
with DCC/1-hydroxy-7-azabenzotriazole activation.
Boc and tBu groups were removed by treat-
ing the resin with 50% triflouroacetic acid/DCM
mixture twice (5 + 25 min). Neutralization was per-
formed with 5% N,N-diisopropylethylamine/DCM
(2 × 1 min). Esterification of the hydroxyl group
of Ser26 with Boc-Gly-OH was performed by
treating the peptide-resin with Fmoc-Gly/DCC/N-
methylimidazole (10-fold excess) in DCM/DMF (3 : 1)
for 2 × 4 h. The peptide was cleaved from the resin with
a mixture containing hydrogen fluoride (10 mL), anisol
(0.2 mL), dimethyl sulfide (0.8 mL), and dithiothre-
itol (0.1 g) at 0◦C for 45 min. The crude product was
precipitated and washed with diethyl-ether, dissolved
in 50% acetic acid/water, lyophilized, and purified by
HPLC. At physiological conditions (37◦C and pH 7.4),
iso-A42 in situ forms oligomeric A42 via an O-N
acyl-transfer reaction. The aggregates were visualized
by transmission electron microscopy. Iso-A42 forms
round shaped oligomers, which can be characterized
with a bimodal size-distribution: the small aggre-
gates have an average diameter of 5.3 ± 1.0 nm, while
the large spherical aggregates have 7.9 ± 3.3 nm. The
oligomers applied in 15M concentration aggregate
slowly in vitro after 24 h of incubation. Protofibrillar
assemblies having a length of 30–100 nm with an aver-
age diameter of 8.4 ± 2.1 nm are present together with
spherical oligomers.
Cell culture
Primary neuronal cultures were prepared from Wis-
tar rat forebrains at embryonic day 16 by mechanical
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dissociation using fire-polished Pasteur pipettes as
described previously [29]. The cell suspension was
filtered through a nylon mesh with a pore diame-
ter of 45m to obtain single cells. The cells were
seeded onto poly-L-lysine coated 96-well plates or
glass coverslips with a density of 2.5 × 105 cell/cm2 in
Eagle’s Minimum Essential Medium (MEM) supple-
mented with 4 mM glutamine, 40g/ml gentamycin,
and 5% fetal calf serum (FCS; PAA, Austria). The
medium was changed to defined medium (MEM-F12
supplemented with insulin, transferrin, and sodium
selenite) 24 h after plating. The cultures were main-
tained in humidified air atmosphere containing 5%
CO2, at 37◦C. The obtained primary cultures has been
extensively studied and characterized and the number
of neurons was above 80–90% of total cell number
[29].
Primary cultures of cerebral endothelial cells were
prepared from 2-week-old rats as described ear-
lier in detail [30–32]. Forebrains were collected
in ice-cold sterile phosphate buffered saline (PBS);
meninges were removed, gray matter was minced
by scalpels to 1 mm3 pieces and digested with
1 mg/ml collagenase CLS2 (Worthington, USA) in
Dulbecco’s modified Eagle medium (DMEM) for 1.5 h
at 37◦C. Microvessels were separated by centrifuga-
tion in 20% bovine serum albumin (BSA)-DMEM
(1000×g, 20 min) from myelin containing elements,
and further digested with 1 mg/ml collagenase-dispase
(Roche) in DMEM for 1 h. Microvascular endothelial
cell clusters were separated on a 33% continu-
ous Percoll gradient (1000×g, 10 min), collected,
and washed twice in DMEM before plating on
collagen type IV and fibronectin coated dishes (Fal-
con, Becton Dickinson). Cultures were maintained
in DMEM/F12 supplemented with 50g/ml gen-
tamicin, 15% plasma-derived bovine serum (First
Link, UK), 1 ng/ml basic fibroblast growth fac-
tor (Roche), insulin (5g/ml), transferrin (5g/ml),
sodium selenite (5 ng/ml) (insulin-transferrin-sodium
selenite media supplement), and 100g/ml heparin. In
the first 3 days, culture medium contained puromycin
(4g/ml) to selectively remove P-glycoprotein neg-
ative contaminating cells [33]. The endothelial cell
cultures were immunopositive for von Willebrand
factor and negative for the astroglia cell marker
glial fibrillary acidic protein (GFAP) and -smooth
muscle actin (-SMA) in accordance with earlier pub-
lished results [33, 34]. When the cultures reached
80% confluency (fourth day in vitro), the puri-
fied endothelial cells were passaged to multiwell
plates or Transwell filter inserts by a brief treat-
ment with trypsin (0.05% wt/vol)-EDTA (0.02%
wt/vol) solution, and used for experiments. To induce
BBB characteristics, brain endothelial cells were
treated with glia/pericyte-conditioned medium or co-
cultured with rat cerebral glial cells and rat pericytes
[26].
Primary cultures of glial cells were prepared from
newborn Wistar rats [31, 32]. Meninges were removed,
and cortical pieces were mechanically dissociated in
DMEM containing 50g/ml gentamicin and 10% FBS
and plated in poly-L-lysin coated 12-well dishes and
kept for minimum 3 weeks before use. In confluent
glia cultures, 90% of cells were immunopositive for
GFAP, while the remaining 10% were immunopositive
for CD11b, a marker of microglia. For co-culture, brain
endothelial cells in cell culture inserts were placed into
multiwells containing astroglia at the bottom of the
wells with endothelial culture medium in both com-
partments.
Pure cultures of rat cerebral pericytes were obtained
by a prolonged, 2-week culture of isolated rat brain
microvessel fragments that contain pericytes beside
endothelial cells. The same preparations yield primary
brain endothelial cells except puromycin-treatment.
Pericyte survival and proliferation were favored by
selective culture conditions, using uncoated dishes,
and DMEM supplemented with 10% FBS and antibi-
otics. Culture medium was changed every 3 days. As
described in our previous papers [34, 35], cultured
brain microvascular pericytes show typical morphol-
ogy of large, flat multipolar cells with several branches
in accordance with literature data [36] and look simi-
lar to the pericyte cultures described by Vandenhaute
et al. [37]. Pericyte cultures are regularly checked
and positive for -SMA (97% positivity) and NG2
(94% positivity) and completely negative for GFAP
and vWF immunostaining as shown by Nakagawa
et al. [34]. Therefore we can exclude the glial and
endothelial contamination of the pericyte cultures.
Since the cultures are made from brain microvessel
fractions where pericytes are more numerous than
smooth muscle cells, we assume that the number
of smooth muscle cells in our preparations is mini-
mal.
To construct the three cell-type BBB model, Tran-
swell cell culture inserts were placed into multiwell
plates containing astroglia at the bottom of the wells,
pericytes were seeded on the bottom side of the inserts,
and finally endothelial cells were passaged to the upper
side of the inserts coated with fibronectin and colla-
gen type IV with endothelial culture medium in both
compartments [26].
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Preparation and treatment of acute hippocampal
slices
A slightly modified version of the method reported
by Datki et al. [38, 39] was used in our slice
viability experiments. After anesthesia with chloral
hydrate (0.4 g/kg), 10 ± 1 week-old male Wistar rats
were decapitated and the whole heads (without scalp-
leather) were put in ice cold distillated water for
1 min. The brains were quickly removed and immersed
in H-ACSF/1 (preparation solution substituted with
HEPES) with very low Ca2+ and with elevated Mg2+
concentration at 4ºC. The composition of this prepa-
ration solution (in mM) was the following: NaCl 122,
KCl 3, CaCl2 0.3, MgCl2 3.7, NaHCO3 25, HEPES
5, D-glucose 10, pH = 7.4. Brain slices (thickness was
400m) were prepared from the hippocampus with a
McIlwain tissue chopper at 4ºC. After the preparation
of the slices in ice-cold H-ACSF/1 solution, we took
photos of them (to measure the slice area). The slices
(with an area of approximately 9 mm2) were quickly
transferred into the ExViS mini-chamber (maximum
5 slices in 1 ml) for conditioning (30 min) in the car-
boxygenated (95/5%: O2/CO2) preparation solution at
room temperature (24ºC).
After resting (30 min) in the carboxygenated H-
ACSF/1 solution at room temperature, the transduction
of the brain slices from the mini-chamber into the
plastic Petri dish was executed with cut-off pipettes
(type 200l) and was left to rest in glucose- and
carboxygenated-free (glucose-oxygen deprivation) H-
ACSF/2 (4 ml/Petri dish) for 1 h. The composition
of this H-ACSF/2 (in mM) was the following: NaCl
132, KCl 3, CaCl2 2, MgCl2 2, NaHCO3 25, HEPES
5, pH = 7.4. The Petri dish was continuously being
stirred at 370 rpm (modified BIOSAN TS-100 thermo
shaker). After resting being treated in glucose- and
oxygen-free H-ACSF/2, the content (supernatant) of
the Petri dish was changed to the H-ACSF/3 solution
(3 ml/Petri dish). The composition of this prepara-
tion solution (in mM) was the following: NaCl 120,
KCl 3, CaCl2 2, MgCl2 2, NaHCO3 25, HEPES 5,
D-glucose 12, pH = 7.4 (with normal calcium, mag-
nesium, and glucose levels). The slices were quickly
transferred into the ExViS mini-chambers (maximum
5 slices in 1 ml) for treating with actual A42 pep-
tide (50l stock solution was added into 950l
H-ACSF/3 per chamber; 20M A42 in final con-
centration). Before each slice viability assay, the
stock solution of A42 peptide (0.4 mM) was freshly
prepared (and stored for maximum 10 min) in dis-
tilled water (pH = 5). The foaming was inhibited by
a floating plastic ball (diameter: 5 mm) in mini tube
chambers.
Aβ42 treatment and cell toxicity assays in cell
culture
Living cells convert the yellow dye 3-(4,5-
dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma M5655) to purple, insoluble formazan
crystals. For MTT reduction assay the neurons, rat
brain endothelial cells, glial cells, or pericytes were
cultured in 96-well plates. The 75M stock solu-
tion of A42 was freshly prepared in phosphate buffer
and the further dilutions were in cell culture medium.
DHA was diluted in culture medium from a 300 mM
stock solution prepared in ethanol. Control condi-
tions were similar to other treatment conditions except
they did not contain peptide or DHA. The medium
for the controls was also diluted with the vehicle
(PBS) in the appropriate proportion. All stock solu-
tions were prepared freshly and separately, and added
to the cells consecutively. After treatments of A42
(24 h; 0.1–30M) or DHA (24 h; 1–300M in cul-
ture medium) endothelial cells were incubated with
0.5 mg/ml MTT solution for 3 h in CO2 incubator.
The amount of formazan crystals was dissolved in
dimethyl-sulfoxide (DMSO) and determined by mea-
suring absorbance at 595 nm with microplate reader
(Fluostar Optima, BMG Labtechnologies, Germany).
Cell viability assay on acute hippocampal slices
After treating the slices with 20M A42 (or with
30 or 50M DHA) for 4 h, we changed the super-
natant to H-ASCF/3 and we added 0.1 ml MTT (stock
solution 5 mg/ml MTT dye in H-ACSF) to the wells in
which they were left to rest for 15 min without carboxy-
genation (the H-ACSF/3 solution was saturated with
carboxygen before using). To block the reduction of
the MTT to formazan crystals, we changed the super-
natant on the slices from H-ACSF/3 to pure DMSO and
left the slices rest for 30 min in a 96-well plate (Costar
3595; 100l DMSO/slice/well). After dissolving the
formazan, we transferred 70l DMSO from each slice
(well) into another 96-well plate (Costar 3695). The
optical density (OD) of the dissolved formazan was
measured at 550 and 620 nm. To synchronize the data,
we used the following formula: [(OD550 – OD620)/area
of slice (mm2)] = 100% in control (A42 untreated
slices).
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Evaluation of the barrier integrity
Transendothelial electrical resistance (TEER), rep-
resenting the permeability of tight junctions for sodium
ions, was measured by an EVOM resistance meter
(World Precision Instruments Inc., USA) using STX-2
electrodes, and it was expressed relative to the surface
area of endothelial monolayer (× cm2). TEER values
of cell-free inserts (90–100 × cm2) were subtracted
from the measured data. The TEER of rat primary brain
endothelial monolayers in co-culture varied between
650 and 780 × cm2, with an average of 723 ± 41
× cm2 (mean ± S.D., n = 12).
The flux of sodium fluorescein and Evans blue-
labeled albumin across endothelial monolayers was
determined as previously described [31, 32]. Cell cul-
ture inserts, following treatment of A42 (24 h, 15M)
and/or DHA (24 h, 30M) and measurement of TEER,
were transferred to 12-well plates containing 1.5 ml
Ringer–Hepes solution (118 mM NaCl, 4.8 mM KCl,
2.5 mM CaCl2, 1.2 mM MgSO4, 5.5 mM D-glucose,
20 mM Hepes, pH 7.4) in the basolateral compart-
ments. In apical chambers, culture medium was
replaced by 500l Ringer–Hepes containing 10g/ml
sodium fluorescein (mw: 376 Da) and 165g/ml Evans
blue bound to 0.1% BSA (mw: 67 kDa). The inserts
were transferred at 20, 40, and 60 min to a new well
containing Ringer–Hepes solution. The concentrations
of the marker molecules in samples from the upper
and lower compartments were determined. Evans blue
(excitation: 584 nm, emission: 680 nm) and fluorescein
(excitation: 485 nm, emission: 520 nm) concentrations
were measured by a Fluostar Optima (BMG Labtech-
nologies, Germany) plate reader.
Transport was expressed as l of donor (lumi-
nal) compartment volume from which the tracer
is completely cleared. Transendothelial permeability
coefficient (Pe) was calculated as previously described
[32, 40]. Cleared volume was calculated from the con-
centration (C) of the tracer in the abluminal and luminal
compartments and the volume (V) of the abluminal
compartment (0.5 ml) by the following equation:
Cleared volume (l) = Cabluminal × Vabluminal
Cluminal
The average cleared volume was plotted versus time,
and permeability × surface area product value for
endothelial monolayer (PSe) was calculated by the fol-
lowing formula:
1
PSendothelial
= 1
PStotal
− 1
PSinsert
PSe divided by the surface area (1 cm2 for Transwell-
12) generated the endothelial permeability coefficient
(Pe; in 10−3 cm/min).
Functional assay for P-glycoprotein
Efflux pump activity was determined by the mea-
surement of cellular accumulation of rhodamine 123
[41]. While rhodamine 123 is also a substrate of
breast cancer resistance protein (BCRP or ABCG2),
it is widely used as a P-glycoprotein (ABCB1) ligand
[26, 32, 37, 41, 42]. In brief, endothelial monolayers
pretreated with A42 (15M) and/or DHA (30M)
for 24 h in 24-well plates were washed, and incu-
bated with Ringer–Hepes buffer containing 10M
rhodamine 123 for 1 h at 37◦C. The solution was
quickly removed; endothelial cells were washed three
times with ice-cold PBS, and solubilized in 0.2 M
NaOH. Rhodamine 123 content was determined by
Fluostar Optima (BMG Labtechnologies, Germany)
plate reader with excitation at 485 nm, emission at
520 nm. Verapamil (2 mM, 30 min preincubation) was
used as a reference P-glycoprotein inhibitor.
Western blot
After amyloid and DHA treatment brain endothe-
lial cells were washed in ice-cold PBS and scraped
into 8 M urea/PBS containing 0.1% Triton-X, 1g/ml
leupeptin, 10 ng/ml aprotinin, 100M phenylmethyl-
sulphonyl fluoride (PMSF), 100M dithiothreitol,
200M sodium orthovanadate, and 1 mM sodium
fluoride. Cells were lysed with three cycles of snap-
freezing and thawing. The extracts were centrifuged
at 12,000g for 20 min and protein concentration in
the supernatant was determined using the method
described by Lowry et al. [43]. For Western blot-
ting, 25g protein samples were loaded on 7.5%
Tris-glycine gel (PAGEr® Gold Precast Gel, Lonza,
Rockland, ME, USA) and blotted onto polyvinylidene
difluoride membrane (BioRad Laboratories, Hercules,
CA, USA). Blots were probed overnight at 4◦C
with primary rabbit polyclonal anti-P-glycoprotein
antibody (H-241, 1 : 200, Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA), or for loading
control with primary rabbit anti-actin polyclonal
antibody (1 : 200, Sigma-Aldrich, St. Louis, MO,
USA) for 1 h at room temperature. Then, sec-
ondary antibody (goat anti-rabbit HRP-conjugated
IgG antibody 1 : 3000, Bio-Rad) were added for 1 h
at room temperature. Chemoluminescence method
(SuperSignal West Pico Chemiluminescent Substrate,
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Thermo scientific Rockford, IL, USA) was applied
for detection of P-glycoprotein. For loading control,
3,3′-diaminobenzidine (Sigma-Aldrich) was used.
Detection of reactive oxygen species
To measure ROS, we used a fluorometric detection
probe from Molecular Probes [32]. Chloromethyl-
dichloro-dihydro-fluorescein diacetate (DCFDA) indi-
cator penetrates the cells by diffusion and becomes
deacetylated by intracellular esterases. Oxidation
of CM-H2DCFDA by ROS yields a fluorescent
molecule. Confluent rat primary pericyte, glial, and
brain endothelial cell layers cultured in 96-well
plates were pretreated with A42 (15M) and/or
DHA (30M) for 24 h, then washed, and incu-
bated with Ringer–Hepes buffer containing 1 mM
CM-H2DCFDA for 1 h at 37◦C. Hydrogen peroxide
pretreatment (100M, 15 min) served as a positive
control in the ROS assay. The plates were measured
by Fluostar Optima fluorescent plate reader (BMG
Labtechnologies, Germany) with excitation at 485 nm,
emission at 520 nm.
Statistical analysis
All data presented are means ± S.E.M. The values
were compared using the analysis of variance followed
by Dunnett, Bonferroni or Newman-Keuls posthoc
tests using GraphPad Prism 5.0 software (Graph-
Pad Software Inc., San Diego, CA, USA). Changes
were considered statistically significant at p < 0.05 or
p < 0.001. All experiments were repeated at least three
times, the number of parallel wells or inserts for each
treatment and time point varied between 3 and 16.
RESULTS
The effect of Aβ42 on the viability of the cells of
the neurovascular unit
The direct effect of oligomeric A42 peptide on
the viability of neurons, glial cells, brain endothelial
cells, and pericytes was examined by MTT cytotoxicity
assay. The yellow MTT dye was efficiently converted
to purple formazan crystals by non-treated cells, but in
the A42 treated groups a dose-dependent decrease in
viability could be observed in all four cell types. The
different cell types had different sensitivity for the pep-
tide treatment (Fig. 1). The most sensitive cells were
the neurons and the brain endothelial cells (Fig. 1A, C).
Oligomeric A42 peptide-treatment in concentrations
of 0.1M or higher for 24 h significantly decreased
the viability of both cells. In contrast, only 5M or
higher doses exerted significant effects in glial cells
and pericytes (Fig. 1B, D).
The effect of DHA on the viability of the elements
of the neurovascular unit
Before testing the potential protective effect of DHA
against oligomeric A42 toxicity, its direct effect on
cell viability was elucidated. Cells were incubated with
DHA in the 1–300M concentration range for 24 h,
than MTT assays were performed as shown in Fig. 2.
In neurons (Fig. 2A), glial cells (Fig. 2B), and brain
endothelial cells (Fig. 2C), the highest dose of DHA
(300M) significantly decreased the MTT conversion.
In pericytes, 10M DHA and higher doses signif-
icantly decreased the cellular viability and only the
1M concentration of DHA was found to be safe and
non-toxic (Fig. 2D). In the most sensitive cell type,
brain pericytes, these results were also supported by
elevated lactate dehydrogenase release by 10M and
higher concentrations of DHA (data not shown) indi-
cating membrane perturbance.
The effect of DHA on Aβ42-induced damages:
toxicity tests
Based on the results of the toxicity assay (Fig. 1), the
15M concentration of oligomeric A42 was selected
to be optimal to reproducibly induce damages to the
cell cultures. The 30M dose of DHA was chosen to
be tested as a protective agent against A42 toxicity in
neurons and endothelial and glial cells. In the case of
pericytes, the previously determined non-toxic 1M
dose of DHA was selected (Fig. 3). DHA significantly
decreased the A42-induced toxic effects in all cells of
the neurovascular unit, neurons, glial cells, endothelial
cells, and pericytes measured by MTT viability assays
(Fig. 3). The DHA (30M) administration was most
effective in brain endothelial cells (Fig. 3C). The pro-
tective effect of DHA was confirmed not only in cell
cultures but also in experiments using acute hippocam-
pal slices (Fig. 4). A42 treatment induced significant
decrease in the viability of the hippocampal cells that
was dose-dependently inhibited by DHA.
The effect of DHA on Aβ42-induced damages:
morphological changes
In the primary culture of neurons, the cells have
small and rounded cell bodies connected with long
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Fig. 1. Dose-dependent toxic effect of oligomeric amyloid- 1-42 (A42) in neuronal (A), glial (B), brain endothelial (C), and pericyte (D)
primary cell cultures measured by MTT assay. Values presented are means ± S.E.M., n = 8. Statistically significant differences (p < 0.05) between
the controls and A treated groups (*) are indicated.
neurites (Fig. 5 control). Oligomeric A42 peptide
treatment (15M for 24 h) induced cell death in neu-
ronal cultures; apoptotic cells and loss of cellular
processes were observed. The co-administration of
DHA (30M) with A42 attenuated the level of the
damage in neurons; the network of the neurites was
preserved (Fig. 5). In our culture conditions, glial
cells showed a mature, differentiated phenotype with
astroglia showing multiple, long and thin processes.
After A42 treatment, glial cells underwent cellular
hypertrophy, and fewer and thicker cell processes and
increased number of apoptotic cells were observed. In
the presence of DHA, more glial cell processes and
less damaged cells could be seen. Brain endothelial
cells formed confluent monolayers (Fig. 5) and the cel-
lular morphology was typical for primary cultures as
described earlier [32]. Treatment with A42 resulted
in big intercellular gaps in the monolayers and floating
apoptotic cells in the culture medium. At higher magni-
fication, cytoplasmic vacuolization could be observed,
as in our previous study earlier [44]. DHA inhib-
ited these changes; the monolayer integrity was better
preserved and resembled to the control ones. Brain
microvascular pericytes in cell culture may form mul-
tiple cell layers. These cells are multipolar, large and
flat with irregular projections. Even by phase contrast
microscopy, the cytoskeletal fibers are visible (Fig. 5).
After peptide treatment, the cytoplasmic fibers in peri-
cytes were diminished and some rounded cells full with
vacuoles could be observed. DHA (1M) was able to
ameliorate the phenotypic changes in pericytes (Fig. 5).
Effect of DHA on Aβ42-induced changes in barrier
integrity of brain endothelial cells
Treatment of endothelial cell monolayers with
oligomeric A42 (15M) reduced the TEER by 70%
of the control after 24 h (data not shown). In A42
treated monolayers, the flux of the paracellular marker
of fluorescein was 4.6 fold higher as compared to the
control group (Fig. 6A). The Pe values for transcel-
lular permeability marker albumin were lower with
one order of magnitude than the values for fluores-
cein, in agreement with literature data [40] and our
previous results [31, 32, 40]. The permeability for
albumin was elevated by 5.9 fold in monolayers treated
AU
TH
OR
 C
OP
Y
494 S. Veszelka et al. / DHA Protects the Neurovascular Unit from Aβ
Fig. 2. Dose-dependent effect of docosahexaenoic acid (DHA) in neuronal (A), glial (B), brain endothelial (C), and pericyte (D) primary cell
cultures measured by MTT assay. Values presented are means ± S.E.M., n = 8. Statistically significant differences (p < 0.05) between the controls
and DHA treated groups (*) are indicated.
with A42 (Fig. 6B). Co-administration of DHA could
significantly decrease the flux of permeability mark-
ers through endothelial monolayers (Fig. 6B). DHA
alone had no effect on permeability of brain endothelial
monolayers.
Effect of DHA on Aβ42-induced changes in efﬂux
pump activity and P-glycoprotein expression of
brain endothelial cells
Brain endothelial cells expressed a functional P-
glycoprotein efflux pump (Fig. 7B) similar to our
previous studies [32, 34] and as demonstrated by
the robust effect of verapamil, an inhibitor of P-
glycoprotein used as a reference blocker in this
rhodamine 123 uptake assay (Fig. 7A). Administration
of oligomeric A42 (15M for 24 h) as a pre-treatment
significantly decreased efflux pump activity of brain
endothelial cells in the absence of the peptide as indi-
cated by the high level of rhodamine 123 accumulation
(Fig. 7A). The administration of DHA decreased the
rhodamine 123 accumulation in brain endothelial cells
pre-treated with A42 for 24 h (Fig. 7A). There was
no significant difference in the protein level of P-
glycoprotein in the treated groups as compared to the
control group (Fig. 7B).
Effect of DHA on Aβ42-induced reactive oxygen
species production in brain endothelial cells
The ROS production in cultured pericytes, glial, and
brain endothelial cells measured by DCFDA assay was
significantly enhanced by oligomeric A42 treatment
(15M, 24 h) compared to that in control cells (1.71
fold in glial cells, 1.4 fold in endothelial cells, 1.67 fold
in pericytes compared to control group) (Fig. 8). DHA
in 30 and 1M concentrations, which had no effect
alone, effectively inhibited the A -induced change in
ROS production in brain endothelial and glial cells, and
pericytes, respectively. Hydrogen peroxide treatment
(100M, 15 min), a positive control in the ROS assay,
elevated by 3.4 fold the amount of ROS measured in
brain endothelial cells and 2.5 fold in glial cells and
pericytes.
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Fig. 3. The effect of docosahexaenoic acid (DHA, 1M on pericytes and 30M on the other three cell types) on oligomeric amyloid- 1-42
(A42, 15M) induced toxicity in neurons (A), glial cells (B), brain endothelial (C), and pericyte primary cell cultures (D). Values presented
are means ± S.E.M., n = 8. Statistically significant differences (p < 0.05) between the control and treated groups (*), A42 and A42 + DHA
treated groups (#) are indicated.
Fig. 4. The effect of docosahexaenoic acid (DHA) on oligomeric
amyloid- 1-42 (A42, 20M) induced toxicity on acute hip-
pocampal slices measured by MTT assay. Values presented
are means ± S.E.M., n = 16. Statistically significant differences
(p < 0.05) between the controls and treated groups (*), A42 and
A42 + DHA treated groups (#) are indicated.
DISCUSSION
The toxicity of Aβ42 on the cells of the
neurovascular unit
The direct toxic effect of different A42 peptides
on cultured neurons and glial cells have been exten-
sively investigated and established [39, 45, 46]. The
present results confirm the toxicity of oligomeric A42
not only on cultured neurons but also on acute hip-
pocampal slices. Brain endothelial cells are much less
studied, despite their importance in the transport and
clearance of A42 peptides and the pathological cere-
brovascular changes in AD [2, 4, 7]. Studies on cultured
brain endothelial cells demonstrate that A42 peptides
are directly toxic to these cells [47, 44], disturb the
barrier integrity, and increase the permeability of brain
endothelial cell monolayers as presented in our pre-
vious study [44]. Cultured brain pericytes have been
examined so far only by the group of Verbeek et al.
[48, 49] and were found to be also sensitive to A42
toxicity. Our results are in agreement with these data.
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Fig. 5. The effect of docosahexaenoic acid (DHA, 1M on pericytes and 30M on the other three cell types) on oligomeric amyloid- 1-42
(A42, 15M) induced toxicity on the morphology of neuronal, glial, brain endothelial, and pericyte primary cell cultures examined by phase
contrast microscopy. Arrows show processes of neurons or glial cells, arrow heads point to apoptotic cells, asterisks show holes of in endothelial
monolayers, cross signs show cytoplasmic fibers inside pericytes. The pericyte encircled by dotted line has cytoplasmic vacuolization.
Fig. 6. Effect of docosahexaenoic acid (DHA, 30M) on oligomeric amyloid- 1-42 (A42, 15M) induced changes in the permeability of
primary brain endothelial cells for fluorescein (A) and Evans blue labeled albumin (B) Values presented are means ± S.E.M., n = 6. Statistically
significant differences (p < 0.05) between the controls and treated groups (*), A42 and A42 + DHA treated groups (#) are indicated.
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Fig. 7. Effect of docosahexaenoic acid (DHA, 30M) on oligomeric amyloid- 1-42 (A42, 15M) induced changes in efflux pump activity
of primary brain endothelial cells measured by rhodamine 123 accumulation (A). Changes of expression level of P-glycoprotein measured by
Western blot analyses (B). Values presented are means ± S.E.M., n = 5. Statistically significant differences (p < 0.05) between the control and
treated groups (*), A42 and A42 + DHA treated groups (#) are indicated.
It is important to note that the cellular toxicity of
oligomeric A42 on the four types of cells was tested
using the same assay conditions, therefore a compari-
son on their sensitivity can be made for the first time.
The highest and similar level of toxicity was observed
in the case of neurons and brain endothelial cells, while
both glial cells and pericytes were more resistant to
the damaging effect of oligomeric A42. This novel
observation on cultured cells is in agreement with AD
pathology, where the two hallmarks of the disease are
the cerebrovascular damages and neuronal loss [50]. A
possible explanation for the higher sensitivity of neu-
rons and brain endothelial cells to oligomeric A42
as compared to glia and perictyes could be the higher
expression level of receptors and transporters related
to A42 efflux, uptake, or transport, but further com-
parative analysis is needed to prove this hypothesis.
Protection of the cells of the neurovascular unit
against Aβ42 by DHA
BBB dysfunction initiates and contributes to the
disease process in AD [4]; therefore in addition to
neurons, brain endothelial cells and other elements of
the neurovascular unit are increasingly recognized as
therapeutic targets in AD [1, 3]. There is little data
on the protection of BBB and brain endothelial cells
against the toxic effects of A42. Partial protection
was described against A25–35 peptide induced cell
damage by carnosine, an endogenous antiglycating
dipeptide, homocarnosine and -alanine on a rat brain
endothelial cell line [51] and by simvastatin on a human
brain endothelial cell line [47]. In a recent study on a
human brain endothelial cell line, A42 cytotoxicity
was reversed by administration of exogenous antioxi-
dants, NADPH oxidase-2 inhibitors, and by blocking
receptor for advanced glycation end products (RAGE)
[52]. In our previous study, pentosan, a clinically used
sulfated polysaccharide, protected rat brain endothelial
cells against A42 toxicity [44].
The prospect of reducing the risk of AD by preven-
tative strategies such as diet or lifestyle modification
is highly favorable. Several epidemiological studies
[9–12] and growing experimental data have shown that
dietary DHA may improve neuronal development [53],
restore and enhance cognitive functions [18, 54–56],
and increase neuronal resistance to amyloid-induced
oxidative stress [57–59]. Importantly, DHA readily
crosses the BBB by diffusion [60, 61] and can easily
reach glial cells and neurons.
Except for the highest tested dose, DHA was not
toxic for neurons or glial and brain endothelial cells.
Interestingly, pericytes showed an increased sensitiv-
ity to DHA treatment. The DHA content is high in
retina, brain tissue, isolated brain microvessels, and
cultured brain endothelial cells [62]. The high percent-
age of PUFAs in retinal microvessels was hypothesized
to contribute to oxidation products and be involved in
the pathogenic process of diabetic retinopathy [63].
Enrichment of cultured cells with DHA increases lipid
peroxidation [64]. Differences in antioxidant enzyme
activities, especially the higher level of superoxide
dismutase and glutathione peroxidase were observed
in retina endothelial cells as compared to retina per-
icytes, explaining their different behavior during the
pathogenesis of diabetic retinopathy, early cell death
of pericytes, and late endothelial cell proliferation [65].
No data on the ROS producing and antioxidant enzyme
capacities of brain endothelial cells as compared to per-
icytes is available, but the high ROS-tolerance of brain
endothelial cells was described recently [66]. We spec-
ulate that the lower level of ROS-scavenging capacity
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Fig. 8. Effect of docosahexaenoic acid (DHA, 30M) on oligomeric
amyloid- 1-42 (A42, 15M) induced changes in reactive oxy-
gen species production in glial (A), brain endothelial cells (B),
and pericyte (C) primary cell cultures measured by chloromethyl-
dichloro-dihydro-fluorescein diacetate (DCFDA). Values presented
are means ± S.E.M., n = 8. Statistically significant differences
(p < 0.05) between the control and treated groups (*), A42 and A42
+ DHA treated groups (#) are indicated.
of cultured brain pericytes, as compared to other neu-
rovascular cells, might explain the observed sensitivity
to DHA.
The beneficial effect of DHA was investigated in
several model of AD but they were focused on neurons
[17]. In neuroblastoma cells, DHA reduced amyloido-
genic APP processing and A42 production [23].
In the present study DHA was not only protective
against oligomeric A42 toxicity in primary neurons
but also on acute hippocampal slices, a more com-
plex, ex vivo model. Our main results indicate for the
first time that DHA can protect not only neurons but
also the other elements of the neurovascular unit (brain
endothelial cells, glial cells, and pericytes) from the
toxic effects of A42. DHA was effective in neuronal,
endothelial, glial, and pericyte cell cultures in toxicity
tests and improved the morphological changes in all
four cell types after oligomeric A42 treatment, indi-
cating a more extensive and diverse protective effect
than previously supposed. The permeability of cerebral
endothelial monolayers was increased by A42 simi-
larly to our previous study [44], which was attenuated
by DHA.
The mechanism of the DHA action is not fully under-
stood. While there are no data on how DHA may affect
RAGE, it was demonstrated recently in cultured brain
endothelial cells that A accumulation is lipid raft-
and caveolae-dependent and involves RAGE and the
caveolae-associated Ras signaling [67]. Disruption of
lipid rafts by pretreatment with -methyl-cyclodextrin
protected against A accumulation in this model. DHA
is a well-known inducer of membrane fluidity [68] and
by reducing cholesterol [23], it has a raft destabilizing
effect and decreases the docking of A [25], which
may influence RAGE activity and contribute to the
protective effect of DHA.
P-glycoprotein and BCRP are important efflux
pumps at the BBB limiting the flux of drugs and
xenobiotics to brain [69] and participating in A42
transport [70–72]. Beside changes in barrier func-
tion, A42 pretreatment inhibited the efflux activity
of brain endothelial cells, in agreement with data
from the literature [73, 74]. However, no change in
P-glycoprotein expression level was observed. There
could be several explanations for this observation: in
addition to protein levels, several other factors influ-
ence the activity efflux pumps, like plasma membrane
lipid composition, intracellular signaling pathways,
and also intracellular ATP levels; and other pumps may
also participate in rhodamine efflux.
The relevance of these results is emphasized by a
recent clinical observation providing the first direct evi-
dence that the P-glycoprotein transporter at the BBB
is compromised in sporadic AD [75]. Since decreased
P-glycoprotein function may be involved in the patho-
genesis of AD [72, 75], our novel finding that DHA can
prevent the decrease in P-glycoprotein activity induced
by A42 treatment strengthens the therapeutic poten-
tial of DHA.
In AD, the accumulation of A42 increases the
production of ROS resulting in increased lipid per-
oxidation in the brain [76]. Oxidative damage and
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formation of oxidized lipids and proteins have been
observed in the brains of patients with AD dur-
ing postmortem analysis [77]. Lipid peroxide levels
are significantly lower in DHA-administered rats
indicating that dietary DHA contributes to the antiox-
idant defense, decreases oxidative stress, and protects
against memory loss [12]. The levels of ROS in the
cerebral cortex and hippocampus increase significantly
after the infusion of A42 into the cerebral ventri-
cle of rats, but then decrease significantly after the
dietary administration of DHA [58]. In the present
study, ROS production was elevated by oligomeric
A42 in primary brain endothelial cells, in agreement
with data obtained on a brain endothelial cell line [52].
Similarly to cytotoxicity and BBB dysfunction, this
effect could be also inhibited by DHA. These obser-
vations suggest that DHA increases the antioxidant
defense in the brain including the BBB and its mode
of action may be related to direct scavenging of ROS
or to the induction of antioxidant enzymes. Additional
mechanisms cannot be excluded. Since the activation
of the Wnt/-catenin pathway increases BBB func-
tions [78] and the effect of A42 on P-glycoprotein is
mediated via Wnt/-catenin signaling [73], it is tempt-
ing to speculate that DHA may also act through this
pathway.
In conclusion, DHA may be a potent agent to pre-
vent A42 induced damages on the elements of the
neurovascular unit acting via multiple ways. Based on
these new observations, DHA might exert a protective
effect not only on neurons but also on the BBB and its
functions, and this effect may be beneficial in AD.
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Abstract  18 
 19 
Background: Elevated level of reactive carbonyl species, such as methylglyoxal, triggers carbonyl stress and 20 
activates a series of inflammatory responses leading to accelerated vascular damage. Edaravone is the active 21 
substance of a Japanese medicine, which aids neurological recovery following acute brain ischemia and 22 
subsequent cerebral infarction. Our aim was to test whether edaravone can exert a protective effect on the barrier 23 
properties of human brain endothelial cells (hCMEC/D3 cell line) treated with methylglyoxal. 24 
Methodology: Cell viability was monitored in real-time by impedance-based cell electronic sensing. The barrier 25 
function of the monolayer was characterized by measurement of resistance and flux of permeability markers, and 26 
visualized by immunohistochemistry for claudin-5 and β-catenin. Cell morphology was also examined by 27 
holographic phase imaging. 28 
Principle Findings: Methylglyoxal exerted a time- and dose-dependent toxicity on cultured human brain 29 
endothelial cells: a concentration of 600 µM resulted in about 50% toxicity, significantly reduced the integrity 30 
and increased the permeability of the barrier. The cell morphology also changed dramatically: the area of cells 31 
decreased, their optical height significantly increased. Edaravone (3 mM) provided a complete protection against 32 
the toxic effect of methylglyoxal. Co-administration of edaravone restored cell viability, barrier integrity and 33 
functions of brain endothelial cells. Similar protection was obtained by the well-known antiglycating molecule, 34 
aminoguanidine, our reference compound.  35 
Conclusion: These results indicate for the first time that edaravone is protective in carbonyl stress induced 36 
barrier damage. Our data may contribute to the development of compounds to treat brain endothelial dysfunction 37 
in carbonyl stress related diseases. 38 
 39 
Keywords: carbonyl stress, methylglyoxal, edaravone, aminoguanidine, human brain endothelial cells, 40 
hCMEC/D3, impedance, holographic phase contrast microscopy, permeability, reactive oxygen species, 41 
immunhistochemistry, β-catenin, claudin-5, resistance 42 
 43 
 44 
Introduction 45 
 46 
Increased serum levels of reactive carbonyl species, such as methylglyoxal, are present in several 47 
pathologies and cause complications in severe conditions and diseases, like diabetes mellitus [1,2], 48 
cardiovascular diseases [3,4], atherosclerosis [5], hypertension [6], metabolic syndrome [7], obesity [8], 49 
psoriasis [9], aging [10,11] Alzheimer’s disease [12] [13], dementias [14], and other neurobiological diseases 50 
[15]. Methylglyoxal is a highly reactive α-oxoaldehyde with strong oxidant and glycation properties [16]. Its 51 
immediate elimination by detoxification systems is crucial [17]. Accumulated methylglyoxal reacts with 52 
proteins, DNA and other biomolecules [18] causing inhibition of enzyme activity [19], transcriptional activation 53 
[20], apoptosis [21]. The end products of the reactions between methylgyoxal and free amino groups of 54 
molecules are insoluble protease-resistant polymers (advanced glycation end products AGE) [22]. 55 
Methylglyoxal triggers carbonyl [18] and oxidative stress [23,24] and activates a series of inflammatory 56 
responses leading to accelerated vascular endothelial damage [25-27]. 57 
Based on data obtained on peripheral endothelial cells, the effect of methylglyoxal on brain 58 
microvascular endothelium, which forms the blood-brain barrier was also investigated [25,28]. A concentration-59 
dependent cell toxicity and barrier dysfunction was recently described on a brain endothelial cell line [28]. This 60 
study reported methylglyoxal-induced glycation of the tight junction protein occludin in culture, as well as in 61 
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brain microvessels of diabetic rats, and a disturbed architectural organization of zonula occludens-1 protein. 1 
Similar to other cellular systems, methylglyoxal-treatment promoted carbonyl and oxidative stress in brain 2 
endothelial cells [28]. Methylglyoxal induced mitochondrial apoptotic signaling: decreased mitochondrial 3 
membrane potential, activated caspases and perturbed the cellular glutathione redox status [25]. These findings 4 
indicate that methylglyoxal-induced carbonyl and oxidative stress may play an important role in neurovascular 5 
pathology, and brain endothelium can be an early and significant target site of methylglyoxal. 6 
The prevention of methylglyoxal-induced injury is in the focus of current research [29]. 7 
Aminoguanidine was the first drug extensively studied, and attenuated the development of a range of diabetic 8 
vascular complications both in vitro and in vivo. However, due to toxic side effects at high doses, it failed in 9 
clinical trials. This compound is considered as a prototype for antiglycation agents and used as a reference 10 
molecule in experiments [30]. Recently, a new promising agent, edaravone is investigated for its beneficial 11 
effects on brain endothelial cells. Edaravone is a neuroprotective free radical scavenger. It is the active substance 12 
of a Japanese medicine, which helps neurological recovery following acute brain and subsequent cerebral infarct 13 
[31,32]. To further reveal the mechanism of protection, brain microvessels [33] and the blood-brain barrier [34] 14 
were investigated as potential pharmaceutical targets of edaravone in animal models of stroke. The effect of 15 
edaravone alone has been described on barrier function: it promoted tight junction formation via activation of 16 
sphingosin-1-phospate signaling pathway [35] and down-regulation of interleukin-1β induced monocyte 17 
chemoattractant protein-1 secretion [36] in human microvascular endothelial cells. In a recent study, 18 
methylglyoxal-induced decrease in cell viability and methylglyoxal enhanced cell injury by oxygen-glucose 19 
deprivation were alleviated by pretreatment with edaravone in brain endothelial cells [37]. However, it remained 20 
unanswered whether edaravone can also protect against methylglyoxal-induced barrier dysfunction of brain 21 
endothelial monolayers.  22 
The tight intercellular barrier maintaining low permeability is the fundamental characteristic of brain 23 
endothelial cells [38]. Therefore, this study aimed to clarify the effect of edaravone against methylglyoxal-24 
induced barrier and morphological damage. In the experiments the widely used human hCMEC/D3 brain 25 
endothelial cell line [39], and new investigation methods, such as impedance monitoring in multiwell plates and 26 
holographic phase contrast imaging were used in addition to viability assays, permeability tests and 27 
immunohistochemistry for junctional proteins. 28 
 29 
 30 
Materials and Methods 31 
 32 
Ethics statement 33 
All procedures involving experimental animals adhered to the law (No. 105) and notification (No. 6) of 34 
the Japanese Government, and were approved by the Laboratory Animal Care and Use Committee of Fukuoka 35 
University. The details of the isolation of primary brain endothelial cells from rats is described in Text S1. 36 
 37 
Materials 38 
All reagents were purchased from Sigma-Aldrich Ltd., Hungary, unless otherwise indicated. 39 
 40 
Cell Culture 41 
Human hCMEC/D3 brain endothelial cell line [39,40] at passage number ≤ 35 was used in the 42 
experiments. Cells were plated on rat tail collagen-coated culture dishes (Orange Scientific, Braine-l’Alleud, 43 
Belgium) or Transwell clear inserts (polyethylene membrane, 0.4 µm pore size, 1.2 cm2 surface area, Corning 44 
Life Sciences, Tewksbury, MA, USA) depending on the experiment and cultured at 37 ºC, 5 % CO2 in EBM-2 45 
medium (Lonza, Basel, Switzerland) containing 5 % fetal bovine serum, hydrocortisone (1.4 µM), 10 mM 46 
HEPES, gentamycin (50 µg/mL), acid ascorbic (5 µg/mL), 1 % chemically defined lipid concentrate, basic 47 
fibroblast growth factor (1 ng/mL) (Roche, Basel, Switzerland). Cells were seeded in culture dishes at a density 48 
of 2.5 × 104 cells/cm2 and the medium was changed every 3 days. At the first change of medium, the medium 49 
was supplemented with 10 mM lithium chloride [41]. When cells reached approximately 80-90 % of confluence 50 
in the dish, they were subcultured with 0.05 % trypsin-EDTA solution. For the cytotoxicity assays cells were 51 
cultured in 96-well culture plates (Orange Scientific, Braine-l’Alleud, Belgium). For real-time cell electronic 52 
sensing 96-well plates with gold electrodes (E-plate 96, ACEA Biosciences, San Diego, USA) were used. For 53 
permeability studies cells were cultured on Transwell inserts. 54 
 55 
Treatments 56 
Human brain endothelial cells were treated with methylglyoxal in the 100-1000 µM concentration range 57 
in EBM-2 medium containing 10 % fetal bovine serum, HEPES (10 mM) and gentamycin (50 µg/mL). 58 
Edaravone was used in the 600-3000 µM concentration range. Aminoguanidine, a well-known antiglycation 59 
agent, was tested at 600-2000 µM concentration and applied as a positive control [42]. Triton X-100 detergent 60 
was used at 10 mg/ml concentration in viability assays as a reference compound to cause cell death.  61 
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 1 
Real-Time Monitoring of Impedance 2 
Impedance-based cell electronic sensing is a label-free technique for dynamic monitoring of living 3 
cells. The RTCA-SP instrument (ACEA Biosciences, Inc., USA) utilizes an automatical and continuous 4 
impedance measurement to non-invasively quantify adherent cell proliferation and viability in real-time. This 5 
method has been succesfully used to measure number, adherence, growth and health of cells in control and 6 
treatment conditions [43-46]. E-plates were coated with rat tail collagen at room temperature and dried for 40 7 
min under UV and air-flow. Culture medium (50 µL) was added to each well for background readings, then 8 
50 µL of cell suspension was dispensed at the density of 1.6 × 104 cells/well. The cells were kept in incubator at 9 
37 °C for 5 days until reaching confluence. Impedance was monitored every 2 minutes. The cell index at each 10 
time point was defined as (Rn - Rb)/15, where Rn is the cell-electrode impedance of the well when it contains 11 
cells and Rb is the background impedance of the well with the medium alone.  12 
 13 
MTT Dye Reduction Cell Viability Assay 14 
Living cells convert the yellow dye 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide 15 
(MTT) to purple, insoluble formazan crystals. Decrease in dye conversation reflects cellular damage. Human 16 
endothelial hCEMC/D3 cells grown to confluency in 96-well culture plates were treated with methylglyoxal 17 
with or without protective agents for 8 hours. Then the treatment medium was removed from the wells and the 18 
cells were incubated with MTT solution (0.5 mg/mL) in Dulbecco’s modified Eagle’s medium for 3 hours in 19 
CO2 incubator. The amount of formazan crystals was dissolved in dimethyl-sulfoxide and determined by 20 
measuring absorbance at 570 nm wavelength with a microplate reader (Fluostar Optima, BMG Labtechnologies, 21 
Germany). Cells receiving treatment medium without methylglyoxal or protective agents, the control group, was 22 
considered as 100 % viable. 23 
 24 
Detection of Reactive Oxygen Species 25 
To measure reactive oxygen species (ROS) we used a fluorometric detection probe, chloromethyl-26 
dichloro-dihydro-fluorescein diacetate (DCFDA) (Molecular Probes, Life Technologies Corp., Carlsbad, USA). 27 
This indicator penetrates the cells by diffusion and becomes deacetylated by intracellular esterases. Oxidation of 28 
DCFDA by reactive oxygen species yields a fluorescent molecule. Confluent brain endothelial cell layers 29 
cultured in 96-well plates were pretreated with methylglyoxal (600 µM) and/or protective agents for 0-8 hours, 30 
then washed, and incubated with Ringer–Hepes buffer containing 2 µM DCFDA and 1.5 µM pluronic acid (Life 31 
Technologies, Molecular Probes, USA) for 1 hour at 37 °C. Hydrogen peroxide pretreatment (100 µM, 30 min) 32 
served as a positive control in the ROS assay. The plates were measured by Fluostar Optima fluorescent plate 33 
reader (BMG Labtechnologies, Germany) at 485 nm excitation and 520 nm emission wavelengths. The 34 
fluorescent values were presented as percent of the control group (cells receiving treatment medium without 35 
methylglyoxal or protective agents) after 1 hour incubation with DCFDA indicator.  36 
 37 
Measurement of Barrier Functions: Transendothelial Electrical Resistance 38 
Transendothelial electrical resistance (TEER) reflects the permeability of intercellular tight junctions 39 
for ions. TEER was measured by an EVOM resistance meter using STX-2 electrodes (World Precision 40 
Instruments Inc., Sarasota, FL, USA) and expressed relative to the surface area (Ω × cm2). TEER values of cell-41 
free inserts were subtracted from the measured data. The TEER of untreated human hCMEC/D3 brain 42 
endothelial cell monolayers was 43.3 ± 6.1 Ω × cm2 (mean ± SD; n=60) in agreement with literature data [40]. 43 
Resistance measurements were carried out before and after treatments to check the barrier integrity. The TEER 44 
values are presented as percent of non treated control groups. 45 
 46 
Measurement of Barrier Functions: Permeability Experiments 47 
To measure the flux of permeability marker molecules fluorescein isothiocyanate labeled dextran 48 
(FITC-dextran, mw: 4.4 kDa) and Evans blue-labeled albumin (mw: 67 kDa) across endothelial cell layers 49 
hCMEC/D3 cells were seeded onto Transwell inserts and grown for 5 days. Inserts with confluent layers were 50 
transferred to 12-well plates containing 1.5 mL Ringer–Hepes solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM 51 
CaCl2, 1.2 mM MgSO4, 5.5 mM D-glucose, 20 mM Hepes, pH 7.4), which was the abluminal (lower) 52 
compartment in the permeability experiments. In the upper chambers (luminal compartment) culture medium 53 
was replaced by 500 µL of Ringer-Hepes buffer containing 100 µg/mL FITC-dextran solution and 165 µg/mL 54 
Evans blue bound to 0.1 % BSA. The plates were kept in a 37 °C incubator with 5 % CO2 on a horizontal shaker 55 
(100 rpm) for 1 h. After incubation the concentrations of the marker molecules in samples from the luminal 56 
(upper) and abluminal (lower) compartments were determined by a fluorescent microplate reader (Fluostar 57 
Optima; emission wavelength: 485 nm, excitation wavelength: 520 nm). Flux across cell-free inserts was also 58 
measured.  59 
The apparent permeability coefficient (Papp) was calculated from the concentration difference of the 60 
tracer in the abluminal compartments (∆[C]A) after 1 hour and luminal compartments at 0 hour ([C]L), the 61 
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volume of the abluminal compartment (VA; 1.5 mL) and the surface area available for permeability (A; 1.1 cm2) 1 
by the following equation [47]. The Papp values were presented as percent of non treated control groups. 2 
 4 
 6 
 8 
Immunohistochemistry  9 
Cell-cell connections and morphology of hCMEC/D3 cells were confirmed by immunostaining for 10 
junctional proteins β-catenin and claudin-5. Cells cultured on rat tail collagen coated Transwell inserts were 11 
washed in phosphate buffered saline (PBS) and fixed with acetone-methanol (1:1) for β-catenin and with 12 
ethanol-acetic acid (95:5) for claudin-5 at -20 °C for 10 minutes. After rehydrating with PBS containing 1% fetal 13 
bovine serum and washing with PBS cells were blocked with 3 % BSA in PBS at room temperature for 30 14 
minutes. Samples were incubated overnight at 4 °C with anti-β-catenin or anti-claudin-5 primary antibodies 15 
(Invitrogen, Life Technologies Corp., Carlsbad, USA; 1:200). Incubation with Cy3-labeled or Alexa Fluoro 488-16 
labeled anti-rabbit IgG secondary antibodies and bis-benzimide (Hoechst dye 33342) to stain cell nuclei lasted 17 
for 1 hour. Between and after incubations cells were washed three times with PBS. Inserts were mounted in Gel 18 
Mount (Biomeda, USA) and staining was examined by Olympus Fluoview FV1000 and Leica SP5 confocal 19 
laser scanning microscopes (Leica Microsystems GmbH, Wetzlar, Germany). 20 
 21 
Holographic Phase Contrast Microscopy 22 
Digital holographic images were taken with a Holo-Monitor M3 instrument (Phase Holographic 23 
Imaging AB, Lund, Sweden). Endothelial cells were cultured on collagen coated culture dishes with borosilicate 24 
glass bottom (MatTek, Ashland, MA, USA). All treatments lasted for 4 hours. Holographic images of the same 25 
culture area were captured before and during treatments. Cell morphological changes were analysed by the 26 
Holostudio 2.4 software provided with the microscope (Phase Holographic Imaging AB, Lund, Sweden). Each 27 
point in the box plot reflects the data obtained on a single cell [48,49].  28 
 29 
Statistical Analysis 30 
All data presented are means ± SD or SEM as indicated in the text. The values were compared using the 31 
analysis of variance followed by Dunnett or Bonferroni posthoc tests using GraphPad Prism 5.0 software 32 
(GraphPad Software Inc., San Diego, CA, USA). Changes were considered statistically significant at p < 0.05. 33 
All experiments were repeated at least three times, the number of parallel wells or inserts for each treatment and 34 
time point varied between 3 and 16. 35 
 36 
 37 
Results 38 
 39 
Methylglyoxal-induced Time- and Dose-dependent Cellular Toxicity Measured by Real-Time 40 
Impedance Monitoring  41 
The direct effect of methylglyoxal on cellular changes and cell viability was investigated by real-time 42 
impedance monitoring with an RTCA-SP instrument. Methylglyoxal showed dose and time-dependent toxicity 43 
in hCMEC/D3 endothelial cells (Figure 1A). The highest concentrations of methylglyoxal (300-1000 µM) 44 
caused a very quick and significant decrease of cell index values compared to control. However, this initial 45 
impedance drop was compensated with time depending on the amount of methylglyoxal. In case of cells treated 46 
with 100-400 µM methylglyoxal no effect on cell index was measured from 3 to 24 hour. A significant toxicity 47 
of methylglyoxal was seen in concentrations of 500 µM and above. Irreversible cell damage was observed at 800 48 
and 1000 µM (Figure 1A).  49 
To validate our data, 600 µM methylglyoxal concentration was tested using the colorimetric end-point 50 
MTT assay at 8-hour time point. The cell viability values after methylglyoxal treatment measured by the MTT 51 
test decreased to 56.7 ± 4.6% (mean ± SD, n=50) in good agreement with the decrease of cell index at the same 52 
concentration of methylglyoxal at the same time point (58.2 ± 5.8%, mean ± SD, n=10). The 600 µM 53 
concentration of methylglyoxal causing approximately 50 % toxicity was selected for further tests. 54 
To support the relevance of our data on endothelial cell line, the effect of methylglyoxal was also tested 55 
on cultures of primary rat brain endothelial cells (for preparation of cultures see Text S1). The toxicity of 56 
methylglyoxal was investigated by the WST-8 colorimetric assay of cell metabolism and LDH release reflecting 57 
cell membrane damage. No effect on viability was measured in primary cells treated with 100-300 µM 58 
methylglyoxal compared to control. Toxic effect was seen at 500 µM: the cell viability values decreased to 68.0 59 
± 15.5% of the control (mean ± SEM, n=8) by WST-8 assay and 76.7 ± 5.9% (mean ± SEM, n=12) by LDH 60 
assay (Figure S2).  61 
 62 
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5 
Co-administration of Edaravone Protects against Methylglyoxal-Induced Toxicity Measured by Real-1 
Time Impedance Monitoring 2 
To investigate the protective effects of edaravone on methylglyoxal-induced cell injury, brain 3 
endothelial cells were co-treated with different concentrations of edaravone and with a fixed concentration of 4 
methylglyoxal (600 µM). Cell index decreased by half in the methylglyoxal group (Figure 1B). Edaravone 5 
protected cells at 1000-3000 µM concentrations and reversed or attenuated the drop in cell index caused by 6 
methylglyoxal in a dose and time-dependent way. In case of cells co-treated with 60-600 µM edaravone no 7 
effect on cell index was measured compared to the methylglyoxal group. Edaravone at 1 mM showed a short 8 
term (0.5-2 hour) but statistically significant effect. The 1.5 and 2 mM concentrations of edaravone could protect 9 
the endothelial cells till 6 and 8 hours post-treatment, respectively. Long lasting protection of hCMEC/D3 cells 10 
could be observed at 2.5 and 3 mM concentrations of edaravone. 11 
Our reference compound, aminoguanidine at 2 mM concentration showed a complete protection against 12 
methylglyoxal-induced cellular toxicity (Figure 1B). This result is in agreement with its effect determined by 13 
MTT test. Aminoguanidine at 2 mM concentration was found to be the most effective against methylglyoxal-14 
induced cell damage in the colorimetric assay: cell viability was 93.2 ± 0.6 % of control at 8 hour time point. To 15 
determine the effect of protective agents alone, cells were incubated with different concentrations of edaravone 16 
(600-3000 µM) and aminoguanidine (600-2000 µM). There was no statistically significant decrease in cell 17 
viability measured by MTT assay and impedance monitoring in cells treated with edaravone or aminoguanidine 18 
alone. (Figure S1). Edaravone at 3 mM concentration increased both the impedance of the endothelial layers and 19 
the metabolic activity measured by MTT assay (121.8 ± 5.9%, mean ± SD, n=4, p < 0.05). 20 
Based on these results, the 3 mM concentration of edaravone showing the best protection of brain 21 
endothelial cells was selected for other investigation. 22 
 23 
Methylglyoxal-induced Time-Dependent ROS Production 24 
As methylglyoxal generates not just carbonyl [18] but also oxidative stress [23,24], ROS production in 25 
cells treated with 600 µM methylglyoxal was investigated at different time points (Figure 2A). The fluorescence 26 
intensity in cultured human brain endothelial cells measured by DCFDA assay at 1 hour time point was 27 
considered as 100 % (1285.6 ± 105.2, fluorescence intensity in arbitrary units). ROS production was 28 
significantly enhanced (126.1 ± 12.0 %, p < 0.001) after one hour treatment by methylglyoxal as compared to 29 
control group, and remained elevated (114.7 ± 14.9 % and 114.4 ± 9.7 %) at 2 and 4 hours time points, 30 
respectively. ROS production in endothelial cells treated for 8 hours by methylglyoxal (109.7 ± 5.7%) did not 31 
differ significantly from non-treated group. Hydrogen peroxide treatment (100 µM, 15 min), a positive control in 32 
the ROS assay, elevated the amount of ROS measured in brain endothelial cells by 2 fold (199.4 ± 7.1 %; Figure 33 
2A). Based on these data and results from real-time monitoring, the 4 hours time point of 600 µM methylglyoxal 34 
treatment causing significantly elevated ROS production was chosen for further experiments. 35 
 36 
Co-administration of Edaravone Protects against Methylglyoxal-induced ROS Production 37 
Edaravone (3 mM) completely inhibited the methylglyoxal-induced increase in ROS production (120.9 38 
± 7.3 %,) bringing back to the level of control (97.2 ± 1.7 %, p < 0.001 as compared to the methylglyoxal treated 39 
group) at the 4 hours time point. Co-administration of aminoguanidine (2 mM) also decreased ROS production 40 
stimulated by methylglyoxal (89.1 ± 2.1 %). In contrast to edaravone, which had no effect alone (102.5 ± 1.7 %), 41 
treatment with aminoguanidine alone decreased the amount of ROS in endothelial cells below the level of the 42 
control group (87.4 ± 1.3 %; Figure 2B). 43 
Methylglyoxal-Induced Decrease of Resistance 44 
The direct effect of different concentrations of methylglyoxal on the ionic permeability of brain 45 
endothelial monolayers was determined by TEER measurement. The resistance of hCMEC/D3 control group 46 
was 37.5 ± 5.5 Ω × cm2 (mean ± SD; n=14). Methylglyoxal at 100 and 300 µM concentrations (4 hours) did not 47 
cause significant changes. Treatment of endothelial cell monolayers with methylglyoxal at 600 µM and 1 mM 48 
concentrations significantly impaired the barrier integrity and decreased TEER to 90.6 ± 2.5 % and 89.9 ± 2.7 % 49 
(p < 0.01 for both treatment groups) compared to control (Figure 3A). Treatment of primary brain endothelial 50 
cells with methylglyoxal at 300 and 500 µM concentrations also damaged the integrity of the barrier (Figure 51 
S3A). Methylglyoxal at 300 and 500 µM concentrations decreased the resistance (80.2 ± 4.9 % and 56.8 ± 4.6 52 
%, respectively) as compared to the control (96.1 ± 11.4 %; n=14). 53 
 54 
Co-administration of Edaravone Protects against Methylglyoxal-Induced Resistance Decrease 55 
Co-administration of the protective agents with methylglyoxal preserved the barrier tightness and 56 
elevated resistance values to the level of control (edaravone: 97.9 ± 0.8 %; aminoguanidine: 99.2 ± 2.1 %). 57 
There was no significant difference between the resistance value of control and the groups treated with 58 
edaravone (3 mM) or aminoguanidine (2 mM) alone (Figure 3B). 59 
 60 
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6 
Methylglyoxal-Induced Dose-dependent Permeability Increase 1 
Following the real-time impedance monitoring experiments, the direct effect of different methylglyoxal 2 
concentrations on the permeability of brain endothelial monolayers was measured using dextran (Figure 4A) and 3 
albumin (Figure 4B) as marker molecules. Cells were incubated with methylglyoxal (100-1000 µM, 4 hours), 4 
then permeability measurements were performed. Methylglyoxal at 100 and 300 µM concentrations did not 5 
cause barrier disruption. Treatment of hCMEC/D3 endothelial cell monolayers with methylglyoxal at 600 µM 6 
and 1 mM concentrations significantly impaired the barrier integrity and increased the permeability for both 7 
markers. The flux of the paracellular marker 4.4 kDa FITC-dextran was elevated by 1.5 fold (158.9 ± 5.8 %) in 8 
monolayers treated with 600 µM methylglyoxal and was doubled (196.4 ± 7.2 %) by 1 mM methylglyoxal 9 
treatment as compared to the control group (Figure 3A). The permeability coefficient values for transcellular 10 
permeability marker albumin (67 kDa) were one sixth of the values for FITC-dextran (4.4. kDa), 0.6 ± 0.03 x106 11 
cm/s and 3.6 ± 0.8 x106  cm/s, respectively, in agreement with literature data [39]. The permeability for albumin 12 
was doubled (221.8 ± 8.7 %) after incubation with 600 µM methylglyoxal and tripled (307.2 ± 8.1 %) in the case 13 
of 1 mM methylglyoxal treatment (Figure 4B). Treatment of primary brain endothelial cells with 500 µM 14 
methylglyoxal also increased the permeability of monolayers for fluorescein (209.69 ± 17.7 %) and albumin 15 
(168.9 ± 38.6%), but 100-300 µM concentrations had no effect (Figure S3B and S3C).  16 
These results, that low concentrations of methylglyoxal (100-300 µM) do not increase permeability, 17 
while higher concentrations significantly reduce barrier integrity are in agreement with our results from 18 
impedance measurements. In further permeability assays to test the effect of protective agents, human brain 19 
endothelial cells were treated with 600 µM concentration of methylglyoxal. 20 
 21 
Co-administration of Edaravone Protects against Methylglyoxal-Induced Permeability Increase 22 
Co-administration of edaravone at 3 mM concentration, selected previously by impedance 23 
measurement, could completely protect brain endothelial monolayers from the damaging effects of 24 
methylglyoxal (Figure 4C and 4D). Co-administration of edaravone shielded the cells from the damaging effect 25 
of methylglyoxal and kept the permeability for FITC-dextran at the control level (MG+E: 103.8 ± 4.9 % vs. MG: 26 
165.6 ± 6.0 %). The same effect was seen by the co-administration of aminoguanidine at 2 mM concentration, 27 
endothelial permeability stayed at the level of control group (100.6 ± 1.7 %) (Figure 4C). The increased 28 
permeability for albumin of brain endothelial cell layers treated with methylglyoxal (261.3 ± 12.2 %) was 29 
completely prevented by the co-administration of 3 mM edaravone (112.1 ± 2.8 %) or 2 mM aminoguanidine 30 
(113.0 ± 6.5 %) (Figure 4D). 31 
Aminoguanidine (2 mM) alone had no effect on the permeability of brain endothelial monolayers. 32 
Edaravone (3 mM) was able to tighten the barrier for both FITC-dextran (81.9 ± 2.0 %; Figure 4C) and albumin 33 
(56.5 ± 3.5 %; Figure 4D) as compared to the permeability of the control group.  34 
 35 
Co-administration of Edaravone Protects against Methylglyoxal-Induced Changes in Immunostaining 36 
The effect of methylglyoxal on cell-cell adhesion was investigated by immunostaining for β-catenin, a 37 
cytoplasmic adherens junction protein, and claudin-5, a transmembrane tight junction protein (Figure 5). In 38 
control monolayers β-catenin staining was localized to the cell border and the tightly apposed, elongated 39 
endothelial cells were well delineated (Figure 5A). Claudin-5 localization at the interendothelial junctions was 40 
less stringent than for β-catenin but clearly visible in part of the cell borders (Figure 5E) and resembled the 41 
immunostaining shown in the paper describing this cell line [39]. The pattern of the staining was dramatically 42 
changed in methylglyoxal (600 µM, 4 hours) treated cells. Treatment with methylglyoxal resulted in decreased 43 
immunostaining intensity, fragmentation or loss of the continuous cortical staining pattern, the appearance of 44 
intercellular gaps (Figure 5B and 5F) and apoptotic cells (Figure 5F). Co-administration of protective agents, 45 
edaravone (Figure 5C and 5G) and aminoguanidine (Figure 5D and 5H) attenuated these changes, the monolayer 46 
integrity was better preserved and the immunostaining pattern resembled to the control ones.  47 
 48 
Co-administration of Edaravone Protects against Methylglyoxal-Induced Morphological Changes 49 
Examined by Holographic Phase Contrast Microscopy 50 
Holographic phase contrast microscopic analysis was performed to visualize the morphological changes 51 
caused by methylglyoxal and the protective effect of edaravone (Figure 6). This novel technology enabled us to 52 
follow living cells in a label-free and non-invasive way. Morphological parameters of treated cells, such as 53 
surface area, optical thickness and cell volume could be measured. Holographic images were taken every 30 54 
minutes before and during the 4-hour treatment of hCMEC/D3 cells. Endothelial cells show a flat, elongated 55 
shape and grow next to each other. Treatment with methylglyoxal caused drastic changes in cell morphology: as 56 
indicated by the colour-scale, growth of cell height was especially prominent (Figure 6). In contrast, in 57 
endothelial cells co-treated with edaravone (3 mM) and methylglyoxal (600 µM) there was no change in cell 58 
morphology during the treatment period (Figure 6). Two short videos on the cell morphology in both treatment 59 
groups at all timepoints are shown as supplementary data (Video S1 and S2). The analysis of morphological data 60 
is shown on Figure 7. During treatment with methylglyoxal the area of the cells significantly decreased (63.1 ± 61 
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33.7%) and their optical thickness increased by 1.8 fold (176.2 ± 36.1%) compared to the values at the beginning 1 
of treatment. These data indicate that endothelial cells treated with methylglyoxal contracted and rounded up, 2 
which is also visible on Figures 6 and Video S1. The volume of the cells was unchanged. Meanwhile, no 3 
changes were observed in cells co-treated with edaravone and methylglyoxal (Figure 7) or in the control group 4 
which was treated with medium only. This is the first report on methylglyoxal-induced morphology changes in 5 
brain endothelial cells using holographic phase contrast imaging. 6 
 7 
 8 
Discussion 9 
 10 
Carbonyl stress and brain endothelial damage 11 
Higher incidence of stroke, dementia and Alzheimer’s disease is observed in diabetes mellitus [50,51]. 12 
Carbonyl stress induced by high level of methylglyoxal is responsible for the diabetes related vascular 13 
complications [52]. A direct toxic effect of methylglyoxal on brain microvessels was proposed in a recent study 14 
[28]. In the present study we further supported the fact that methylglyoxal alone could induce damage to brain 15 
endothelial cells. Methylglyoxal exerted a time- and dose-dependent toxicity on cultured human brain 16 
endothelial cells; it significantly reduced the integrity of the barrier measured by both functional and 17 
morphological experiments. This is the first study to provide kinetic data on the toxicity of methylglyoxal by 18 
impedance-based cell electronic sensing, a noninvasive label-free technique. The two different cell viability 19 
assays we used were in complete agreement on the direct cellular damaging effect of methylglyoxal, impedance 20 
data reflecting changes in cell adhesion, cell shape and number were confirmed by MTT tests measuring the 21 
metabolic activity of cells. Our data lend support to and expand previous findings on the effect of methylglyoxal 22 
on human brain endothelial cells [25,28,37,53]. We selected the human hCMEC/D3 cell line as a simplified 23 
model of the blood-brain barrier. This cell line is widely used in different experiments, including 24 
pharmacological and drug studies [40]. To support the relevance of our data on hCMEC/D3 endothelial cell line, 25 
the effect of methylglyoxal was also tested on primary cultures of rat brain endothelial cells. The observed 26 
effects were in agreement with our observations on the human cell line, indicating a similar sensitivity of 27 
primary endothelial cells and hCMEC/D3 endothelial cell line for the toxic effects of methylglyoxal. We found 28 
no data on primary brain endothelial cells related to methylglyoxal in the literature, therefore the present 29 
observation is the first study to include primary brain endothelial cells in this setting. The relevance of our 30 
findings on endothelial cells is limited by the use of high concentrations of methylglyoxal to induce barrier 31 
damage, a common concern in cell culture studies. However, in four recent and independent studies both the 32 
time needed to measure methylglyoxal-induced injury in cultured endothelial cells and the concentrations used 33 
were in similar range as in our study [25,28,37,53].  34 
Damage by methylglyoxal is mediated not only via carbonyl stress, but also by oxidative stress. [23,24]. 35 
Reactive oxygen species are generated as by-products of protein glycation [54]. Furthermore, methylglyoxal 36 
increases glycation of selected mitochondrial proteins resulting in increased formation of superoxide [55]. 37 
Elevated level of ROS weakens the barrier integrity [56], however the contribution of methylglyoxal-triggered 38 
ROS production in the increased endothelial permeability is controversial [28]. In the present study we 39 
confirmed that methylglyoxal treatment promotes oxidative stress in brain endothelial cells, similarly to previous 40 
studies on endothelial cells [28,53] and other cellular systems [57]. The kinetics of ROS production also helped 41 
to determine the optimal time point for protection assays and other experiments: a time point, where ROS 42 
formation was still elevated, was purposefully selected.  43 
In good agreement with the data from toxicity measurements methylglyoxal increased the permeability 44 
of human and rat brain endothelial monolayers. The effect was dose-dependent, with only high concentrations of 45 
methylglyoxal causing significant damage in barrier integrity. These data are in accordance with findings of a 46 
previous study showing that methylglyoxal induced permeability increase in brain endothelial cells [28]. In that 47 
study decreased transendothelial electrical resistance and increased dextran flux were coupled with glycation of 48 
occludin and disturbed localization of zonula occludens-1 tight junction proteins [28]. In the present study we 49 
found the redistribution of two other junctional proteins important for the regulation of brain endothelial 50 
permeability, namely the tight junction protein claudin-5 and adherens junctional protein β-catenin in 51 
methylglyoxal-treated brain endothelial cells. Claudin-5 is the most abundant integral membrane protein of the 52 
brain endothelial tight junctions and a major regulator of the blood-brain barrier permeability [59]. β-catenin 53 
binds the cytoplasmic tail of vascular endothelial cadherin (VE-cadherin) to the actin cytoskeleton [58]. Besides 54 
its role as a cytoskeletal linker, β-catenin is an important signaling and transcriptional factor at the blood-brain 55 
barrier regulating its tightness [59]. Delocalization/redistribution of β-catenin in brain endothelial cells is linked 56 
to permeability increase in many pathologies [60,61,62]. We demonstrated for the first time, that treatment with 57 
methylglyoxal resulted in fragmentation and loss of the continuous cortical pattern of β-catenin in brain 58 
endothelial cells, confirming the importance of β-catenin in barrier integrity.  59 
For the maintenance of the integrity of the blood-brain permeability barrier the attachment of 60 
endothelial cells to the basement membrane is crucial [63]. Damage to the basal lamina weakens microvascular 61 
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wall structures and results in increase of brain vessel permeability in vivo [64]. Our data confirmed these 1 
observations and visualized for the first time the kinetics of morphological changes caused by methylglyoxal 2 
using a novel technique, holographic phase contrast microscopy. This technology follows the morphology of 3 
living cells in a label-free and non-invasive way and detects only the effects of the tested compound [48,49]. In 4 
our study methylglyoxal changed drastically the shape of brain endothelial cells by time: the area of cells 5 
decreased, their optical height significantly increased indicating cell-cell and cell-basal lamina detachment. 6 
Similar observation was made in case of peripheral endothelial cells, where modification of basement membrane 7 
by methylglyoxal caused cell detachment, anoikis and inhibition of angiogensis [65].  8 
 9 
Protective effect of edaravone on methylglyoxal-injured brain endothelial cells 10 
Edaravone was reported to protect brain microvessels and the blood-brain barrier after ischemic stroke 11 
[33,34]. In a recent study, edaravone reduced cell injury in oxygen-glucose deprivation in vitro model. 12 
Edaravone pretreatment attenuated methylglyoxal-induced decrease in cell viability of brain endothelial cells 13 
[37]. In our study co-treatment with edaravone provided a complete protection against the toxic effect of 14 
methylglyoxal. We could see a dose- and time-dependent effect based on kinetic data from impedance 15 
measurements. Our data are in agreement with viability studies on the effect of edaravone pretreatment against 16 
methylglyoxal-induced toxicity [37]. Edaravone treatment alone increased the metabolic activity and impedance 17 
of the endothelial layers. A beneficial effect of edaravone on human endothelial cells was also found previously 18 
by resistance measurement and proteomic assay [35,36]. The edaravone concentrations used were in the 19 
millimolar range similarly to another independent work on cultured human brain endothelial cells. For long-20 
lasting protection suprapharmacological concentration of edaravone [66] was needed in our culture study. 21 
However, the applied methylglyoxal levels were also comparably high, as in other in vitro methylglyoxal studies 22 
[25,28,37,53]. Although we use higher concentrations in cultured cells, importantly, the ratio of the 23 
methylglyoxal to edaravone used in our study is the same as the ratio of the pathological plasma methylglyoxal 24 
concentrations [67] to clinical concentrations of edaravone [66].  25 
Originally, edaravone has been described as a drug to treat ischemic stroke by protecting against 26 
oxidative stress [31]. Its antioxidant effect was observed in our experiment, too. In a recent independent study 27 
edaravone suppressed methyglyoxal-induced ROS production in human brain endothelial cells by two possible 28 
mechanisms [37]. Pre-treatment with edaravone decreased methylglyoxal-induced AGE accumulation and 29 
activation of its receptor RAGE [37], and the subsequent production of ROS [68,69]. Furthermore, edaravone 30 
inhibited protein-glycation by methylglyoxal in a cell free system [37], therefore, it decreased ROS generated as 31 
by-products during protein glycation [54]. All these results together indicate that the antioxidant mechanisms 32 
induced by edaravone contribute to its protective effect against methylglyoxal-induced oxidative stress. 33 
Prior work described, that edaravone protects from methylglyoxal-induced injury by inhibiting 34 
AGEs/RAGE/oxidative stress in human brain microvascular endothelial cells [37]. However, it remained 35 
unanswered whether edaravone can also protect against methylglyoxal-induced barrier dysfunction in brain 36 
endothelial monolayers. Therefore, this study focused on the protective effect of edaravone against 37 
methylglyoxal-induced barrier damage. We found that co-treatment with edaravone restored barrier properties of 38 
endothelial cells and protected against methylglyoxal-induced decrease of resistance and increase in 39 
permeability for paracellular and transcellular markers. Moreover, we also demonstrated that edaravone 40 
treatment alone tightened the brain endothelial barrier. Our data expand and further support previous 41 
observations on barrier enhancing effect of edaravone [35,36].  42 
Increased endothelial permeability was coupled with disturbed localization of junctional proteins 43 
claudin-5 and β-catenin after incubation with methylglyoxal, while co-treatment with edaravone restored 44 
distribution of both proteins along the cell borders. Similar observation was made in a previous study, where 45 
edaravone treatment enhanced β-catenin at cell-cell contact area and the cortical arrangement for its linked 46 
protein, actin on half confluent endothelial monolayer [35]. Our holographic phase contrast microscopic data are 47 
in accordance with these observations: edaravone completely prevented methylglyoxal-induced changes in cell 48 
morphology, no sign of detachment and cellular morphological change was observed, indicating there was no 49 
cytoskeletal rearrangement.  50 
Our results have answered the question that edaravone can protect against methylglyoxal-induced 51 
barrier dysfunction in brain endothelial cells. However, the underlying signal transduction pathways during co-52 
treatment were not examined and further work is needed to elucidate the precise mechanism.  53 
 54 
 55 
Conclusion  56 
This is the first study to investigate the protection of cerebral endothelial cells by edaravone in co-57 
treatment with methylglyoxal. Our results provide compelling evidence for barrier protective effect of edaravone 58 
in cultured endothelium of brain microvasculature. Data from this study could have therapeutical implication for 59 
disorders and diseases that are associated with carbonyl stress.  60 
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Text S1 1 
 2 
Materials and Methods for supplementary figures S2 and S3 3 
All procedures involving experimental animals adhered to the law (No. 105) and notification (No. 6) of the 4 
Japanese Government, and were approved by the Laboratory Animal Care and Use Committee of Fukuoka 5 
University.  6 
 7 
Materials 8 
All reagents were purchased from Sigma-Aldrich Ltd., unless otherwise indicated. 9 
 10 
Isolation of primary rat brain endothelial cells 11 
Primary cultures of rat brain capillary endothelial cells (PRBECs) were prepared from 3 week-old Wistar rats 12 
CREA Japan, Inc. (Tokyo, Japan). The rats had free access to food and water and were maintained on a 12-h 13 
dark/light cycle in a room with controlled temperature (24-1ºC) and humidity (55-5%). After decapitation the 14 
meninges were carefully removed from the forebrains, and the gray matter was minced in DMEM cooled at 2ºC, 15 
and digested with collagenase type 2 (1 mg/mL, Worthington, Lakewood, NJ, USA) for 1.5 h at 37ºC. The pellet 16 
was separated by centrifugation in 20% bovine serum albumin (BSA)-DMEM (10006g, 20 min). The 17 
microvessels obtained in the pellet were further digested with collagenase/dispase (1 mg/mL, Roche, Mannheim, 18 
Germany) for 1 h at 37ºC. Microvessel clusters containing pericytes and endothelial cells were separated on a 19 
33% continuous Percoll (GE Healthcare, Buckinghamshire, UK) gradient, collected and washed twice with 20 
DMEM before plating on collagen type IV-fibronectin (both 0.1 mg/mL) coated dishes. Rat brain endothelial 21 
cell cultures were maintained in DMEM/F12 medium supplemented with 10% plasma derived sera, basic 22 
fibroblast growth factor (1.5 ng/mL, Roche), heparin (100 µg/mL), insulin (5 µg/mL), transferrin (5 mg/mL), 23 
sodium selenite (5 ng/mL; insulin-transferrin-sodium selenite media supplement) and gentamicin (50 µg/mL)] 24 
containing puromycin (4 µg/mL) at 37ºC in a humidified atmosphere of 5% CO2/95% air, for two days. To 25 
remove the puromycin, cells were washed three times with fresh medium and cultured for three days. On the 26 
fifth day, cell culture typically reached 80–90% confluency. 27 
 28 
Treatments 29 
Brain endothelial cells were treated with methylglyoxal in the 100-500 µM concentration range. Confluent 30 
primary rat brain endothelial cells were treated in DMEM/F12 medium supplemented with basic fibroblast 31 
growth factor (1.5 ng/mL, Roche), heparin (100 µg/mL), insulin (5 µg/mL), transferrin (5 mg/mL), sodium 32 
selenite (5 ng/mL; insulin-transferrin-sodium selenite media supplement) and gentamicin (50 µg/mL).  33 
 34 
Cell Viability Assays 35 
For endpoint viability assays brain endothelial cells were grown to confluency in 96-well culture plates and 36 
treated with methylglyoxal, with or without protective agents for 8 hours. In WST-8 assay (Cell Counting Kit, 37 
Dojindo, Kumamoto, Japan) similarly to MTT assay, living cells produce formazan by mitochondrial 38 
dehydrogenase. The absorbance of the highly water-soluble formazan dye (WST-8) was measured in each 39 
sample at wavelengths of 450 nm (test wavelength) and 700 nm (reference wavelength). Cells receiving 40 
treatment medium without methylglyoxal or protective agents, the control group, was considered as 100 % 41 
viable. 42 
Lactate dehydrogenase (LDH) release is the indicator of cell membrane damage. was determined from culture 43 
supernatants by a commercially available kit (Cytotoxicity detection kit LDH, Roche, Basel, Switzerland). After 44 
the treatment 50 µl samples from culture supernatants were removed and incubated with equal amounts of 45 
reaction mixture for 15 minutes. The enzyme reaction was stopped by 0.1 M HCl. Absorbance was measured at 46 
a wavelength of 492 nm with a microplate reader (Opsys MR, DYNEX Technologies, Chantilly, VA,USA). Cell 47 
death was calculated as percentage of the total LDH release from cells treated by 1 % (w/v) Triton X-100 48 
detergent.  49 
 50 
Measurement of Barrier Functions: Transendothelial Electrical Resistance 51 
Transendothelial electrical resistance (TEER) reflects the permeability of intercellular tight junctions for ions. 52 
TEER was measured an Epithelial-volt-ohm meter and Endohm-6 chamber electrodes (World Precision 53 
Instruments, Sarasota, FL, USA) and expressed relative to the surface area (Ω × cm2). TEER values of cell-free 54 
inserts were subtracted from the measured data. Resistance measurements were carried out before and after 55 
treatments to check the barrier integrity. The TEER values are presented as percent of non treated control 56 
groups. 57 
 58 
Measurement of Barrier Functions: Permeability Experiments 59 
Cell culture inserts were transferred to 24-well plates containing 0.6 ml permeability assay buffer (141 mM 60 
NaCl, 2.8 mM CaCl2, 1 mM MgSO4, 4 mM KCl, 1 mM NaH2PO4, 10 mM glucose and 10 mM Hepes, pH 7.4) 61 
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in the lower or abluminal compartments. In the inserts (luminal compartment), culture medium was replaced by 1 
0.1 ml buffer containing 100 µg/ml Na–Fluorescein (MW: 376 Da) and 4% bovine serum albumin mixed with 2 
0.67 mg/mL Evan’s blue dye (EBA; MW: 67,000 Da). Samples (400 µL) were removed from each side at 15, 3 
30, 45, 60, 120 and 180 min. To ensure mixing of the layers, we stirred the assay buffer in the receiver chamber, 4 
into which test compounds permeate, with a pipette before removing the buffer and immediately replacing with 5 
fresh permeability assay buffer. The concentrations of Na–Fluorescein were determined with a CytoFluor Series 6 
4000 fluorescence multiwall plate reader (PerSeptive Biosystems) using a fluorescein filter pair (Ex(λ) 485±10 7 
nm; Em(λ) 530±10 nm). The EBA concentration in the abluminal chamber was measured by determining the 8 
absorbance of samples at 630 nm with a microplate reader (Opsys MR, DYNEX Technologies, Chantilly, 9 
VA,USA). 10 
Transendothelial permeability coefficient (Pe) was calculated from the transport of donor (luminal) compartment 11 
volume from which the tracer is completely cleared. Cleared volume was calculated from the concentration (C) 12 
of the tracer in the abluminal and luminal compartments and the volume (V) of the abluminal compartment (0.5 13 
ml) by the following equation: 14 
luminal
abluminalabluminal
C
VC ×
=(µl) volumeCleared
 15 
The average cleared volume was plotted vs. time, and permeability × surface area product value for endothelial 16 
monolayer (PSe) was calculated by the following formula:  17 
inserttotallendothelia PSPSPS
111
−=
 18 
PSe divided by the surface area (1 cm2 for Transwell-12) generated the endothelial permability coefficient (Pe; in 19 
10-3 cm/min). The values were presented as percent of non treated control groups. 20 
 21 
Statistical Analysis 22 
Data are presented as means ± SEM. The values were compared using the analysis of variance followed by 23 
Dunnett or Bonferroni posthoc tests using GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, 24 
CA, USA). Changes were considered statistically significant at p < 0.05. All experiments were repeated at least 25 
three times, the number of parallel wells or inserts for each treatment and time point varied between 3 and 6. 26 
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Figures 1 
 2 
 3 
Figure 1. Effect of methylglyoxal and edaravone on cell viability  4 
Effect of methylglyoxal (100–1000 µM) on human hCMEC/D3 endothelial cells measured by real-time cell 5 
electronic sensing method (A). Effect of co-treament with 600 µM methylglyoxal and different concentrations of 6 
edaravone (MG + E; 600–3000 µM) or aminoguanidine (MG + AG; 2 mM) (B). Cell index is expressed as an 7 
arbitrary unit and calculated from impedance measurements between cells and sensors. Data are presented as 8 
means ± SD, n = 10. Triton X-100 was used at 10 mg/mL concentration. Statistical analysis: two-way ANOVA 9 
followed by Bonferroni test. Statistically significant differences (p < 0.05) from the control group (#) and from 10 
the methylglyoxal-treated group (*) are indicated.  11 
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Figure 2. Effect of methylglyoxal and edaravone on reactive oxygen species production  8 
Time-dependent effect of methylglyoxal (MG; 600 µM) on ROS production of human brain endothelial cells 9 
(hCMEC/D3) (A). Effect of co-treament with 600 µM methylglyoxal and 3 mM edaravone (MG + E) or 2 mM 10 
aminoguanidine (MG + AG) after 4 hours (B). Fluorescent intensity of ROS expressed as a percentage of control 11 
(C). Values presented are means ± SD, n = 9. Statistical analysis: ANOVA followed by Dunnett test. 12 
Statistically significant differences (p < 0.05) from the control group (#) and from the methylglyoxal-treated 13 
group (*) are indicated.  14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
  24 
 25 
 26 
Figure 3. Effect of methylglyoxal and edaravone on the resistance of human brain endothelial 27 
monolayers 28 
The effect of methylglyoxal on the resistance of human brain endothelial cells (hCMEC/D3) after 4-hours 29 
treatment (A). Protective effect of 3 mM edaravone (MG + E;) and 2 mM aminoguanidine (MG + AG) on 30 
methylglyoxal (MG, 600 µM) induced changes in the resistance of cell layers (4 hours co-treatment), and effect 31 
of 3 mM edaravone (E) and 2 mM aminoguanidine (AG) alone (B). TEER values are expressed as percentage of 32 
control (C). Values presented are means ± SD, n = 4. Statistical analysis: ANOVA followed by Dunnett test. 33 
Statistically significant differences (p < 0.05) from the control group (#) and from the methylglyoxal treated 34 
group (*) are indicated.  35 
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 1 
Figure 4. Effect of methylglyoxal and edaravone on the permeability of human brain endothelial 2 
monolayers  3 
Dose-dependent effect of methylglyoxal-induced changes in the permeability of human brain endothelial cells 4 
(hCMEC/D3) for FITC-dextran (4.4 kDa) (A) and Evans blue labelled albumin (65 kDa) after 4 hours treatment 5 
(B). Protective effect of 3 mM edaravone (MG + E;) and 2 mM aminoguanidine (MG + AG) on methylglyoxal-6 
induced (MG, 600 µM) changes in the permeability for FITC-dextran (4.4 kDa) (C) and Evans blue labelled 7 
albumin (D), when co-treated for 4 hours. Effect of 3 mM edaravone (E) and 2 mM aminoguanidine (AG) alone 8 
(C, D). Papp, apparent permeability coefficient expressed as a percentage of control (C). Values presented are 9 
means ± SD, n = 4. Statistical analysis: ANOVA followed by Dunnett test. Statistically significant differences (p 10 
< 0.05) from the control group (#) and from the methylglyoxal treated group (*) are indicated.  11 
 12 
 13 
 14 
Figure 5. Effect of methylglyoxal and edaravone on junctional morphology  15 
Immunostaining for adherens junction protein β-catenin (A-D) and integral tight junction membrane protein 16 
claudin-5 (E-H) in human hCMEC/D3 brain endothelial cells. Control (A and E), 4 hour treatment with 17 
methylglyoxal (600 µM; B and F), co-treatment with edaravone (3 mM; C and G) or aminoguanidine (2 mM; D 18 
and H). Blue color: bis-benzimide staining of cell nuclei; red color: immunostaining for β-catenin; green color: 19 
immunostaining for claudin-5. Bar = 20 µm. 20 
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Figure 6. Effect of methylglyoxal and edaravone on cellular morphology  2 
Holographic phase contrast images of morphological alterations induced in hCMEC/D3 human brain endothelial 3 
cells by treatment with methylglyoxal (MG; 600 µM) and co-treatment with 3 mM edaravone (MG + E) for 4 4 
hours. Color scale bar correspond to the height of single cells. Data were analysed by means of HoloStudio 2.4 5 
software. Red circles indicate cells with drastical changes in cell morphology. Yellow circles indicate cells 6 
without any morphological changes. Bar = 100 µm 7 
 8 
 9 
Figure 7. Effect of methylglyoxal and edaravone on area and thickness of adjacent cells 10 
Morphological alterations induced in human brain endothelial cells (hCMEC/D3) by treatment with 11 
methylglyoxal at 600 µM (A and B) and co-treatment with edaravone at 3 mM (C and D) for 4 hours. Surface 12 
area (A and C) and average optical thickness (B and D) were calculated before and during treatments. Box 13 
represents 25 and 75 percentiles. Horizontal line represent the median. Whiskers show minimum and maximum 14 
values. Statistical analysis: ANOVA followed by Dunnett test, n=12. Statistically significant differences (p < 15 
0.05) from 0 time point (*) are indicated.  16 
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Supporting Information Legends 1 
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Figure S1. Effect of edaravone and aminoguanidine on cell viability 11 
Effect of edaravone (E; 600 µM – 3 mM) and aminoguanidine (AG; 600 µM – 2 mM) on human hCMEC/D3 12 
endothelial cells measured by real-time cell electronic sensing (RTCA-SP) method (A) and by MTT metabolic 13 
assay at 8 hours timepoint (B). MTT assay and cell index data are expressed as percentage of control. Data are 14 
presented as means ± SD, n = 6. Triton X-100 was used at 10 mg/mL concentration. Statistical analysis: 15 
ANOVA followed by Dunnett or by Bonferroni test. Statistically significant differences (p < 0.001) from the 16 
control group (#) are indicated.  17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
  27 
 28 
 29 
Figure S2. Effect of methylglyoxal on the viability of primary brain endothelial cells  30 
Effect of methylglyoxal (100–1000 µM) on primary rat brain endothelial cells measured by WST-8 (A) and 31 
lactate dehydrogenase (LDH) release assay (B). Values are expressed as percentage of control. Data are 32 
presented as means ± SEM, n = 20. Statistical analysis: one-way ANOVA followed by Dunett test. Statistically 33 
significant differences (p < 0.05) from the control (C) group (#) are indicated.  34 
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Figure S3. Effect of methylglyoxal on the barrier properties of primary brain endothelial monolayers 4 
Dose-dependent effect of methylglyoxal-induced changes in the resistance (A) and the permeability of primary 5 
rat brain endothelial cells for sodium-fluorescein (B) and Evans blue labeled albumin (B). Transendothelial 6 
electrical resistance (TEER) and endothelial permeability coefficient (Pe) are expressed as a percentage of 7 
control (C). Data presented are means ± SEM, n = 16-24. Statistical analysis: ANOVA followed by Dunnett test. 8 
Statistically significant differences (p < 0.05) from the control group (#) and from the methylglyoxal treated 9 
group (*) are indicated.  10 
 11 
 12 
 13 
 14 
 15 
Video S1 and S2. Effect of methylglyoxal on cellular morphology 16 
Videos were made from holographic phase contrast images on morphological alterations induced in hCMEC/D3 17 
human brain endothelial cells by treatment with 600 µM methylglyoxal (Video S1) and co-treatment with 3 mM 18 
edaravone (Video S2). Pictures were taken every 30 min until 4 hours. Color scale bar correspond to the height 19 
of single cells. Data were analysed by means of HoloStudio 2.4 software.  20 
 21 
